Asymmetric tibial components for a knee prosthesis

Information

  • Patent Grant
  • 11224519
  • Patent Number
    11,224,519
  • Date Filed
    Tuesday, October 8, 2019
    5 years ago
  • Date Issued
    Tuesday, January 18, 2022
    2 years ago
Abstract
An orthopaedic tibial prosthesis includes a tibial baseplate with an asymmetric periphery which promotes proper positioning and orientation on a resected tibia, while also facilitating enhanced kinematics, soft-tissue interaction, and long-term fixation of the complete knee prosthesis. The asymmetric baseplate periphery is sized and shaped to substantially match portions of the periphery of a typical resected proximal tibial surface, such that proper location and orientation is evident by resting the baseplate on the tibia. The baseplate periphery provides strategically positioned relief and/or clearance between the baseplate periphery and bone periphery, such as in the posterior-medial portion to prevent deep-flexion component impingement, and in the anterior-lateral portion to avoid undue interaction between the anatomic iliotibial band and prosthesis components.
Description
BACKGROUND
1. Technical Field

The present disclosure relates to orthopaedic prostheses and, specifically, to tibial components in a knee prosthesis.


2. Description of the Related Art

Orthopaedic prostheses are commonly utilized to repair and/or replace damaged bone and tissue in the human body. For example, a knee prosthesis may include a tibial baseplate that is affixed to a resected or natural proximal tibia, a femoral component attached to a resected or natural distal femur, and a tibial bearing component coupled with the tibial baseplate and disposed between the tibial baseplate and femoral component. Knee prostheses frequently seek to provide articulation similar to a natural, anatomical articulation of a knee joint, including providing a wide range of flexion.


The tibial insert component, sometimes also referred to as a tibial bearing or meniscal component, is used to provide an appropriate level of friction and contact area at the interface between the femoral component and the tibial bearing component. For a knee prosthesis to provide a sufficient range of flexion with a desirable kinematic motion profile, the tibial bearing component and tibial baseplate must be sized and oriented to interact appropriately with the femoral component of the knee prosthesis throughout the flexion range. Substantial design efforts have been focused on providing a range of prosthesis component sizes and shapes to accommodate the natural variability in bone sizes and shapes in patients with orthopaedic prostheses, while preserving flexion range and desired kinematic motion profile.


In addition to facilitating implantation and providing enhanced kinematics through manipulation of the size and/or geometry of prosthesis components, protection and/or preservation of soft tissues in the natural knee joint is also desirable.


A given prosthetic component design (i.e., a tibial baseplate, tibial bearing component, or femoral component) may be provided to a surgeon as a kit including a variety of different sizes, so that the surgeon may choose an appropriate size intraoperatively and/or on the basis of pre-surgery planning. An individual component may be selected from the kit based upon the surgeon's assessment of fit and kinematics, i.e., how closely the component matches the natural contours of a patient's bone and how smoothly the assembled knee joint prosthesis functions in conjunction with adjacent soft tissues and other anatomical structures. Soft tissue considerations include proper ligament tension and minimization of soft tissue impingement upon prosthetic surfaces, for example.


In addition to prosthetic sizing, the orientation of a prosthetic component on a resected or natural surface of a bone also impacts surgical outcomes. For example, the rotational orientation of a tibial baseplate and tibial bearing component with respect to a resected proximal tibia will affect the interaction between the corresponding femoral prosthesis and the tibial bearing component. The nature and amount of the coverage of a tibial baseplate over specific areas of the resected proximal tibia will also affect the fixation of the implant to the bone. Thus, substantial design efforts have been focused on providing prosthetic components which are appropriately sized for a variety of patient bone sizes and are adapted to be implanted in a particular, proper orientation to achieve desired prosthesis performance characteristics.


SUMMARY

The present disclosure provides an orthopaedic tibial prosthesis including a tibial baseplate with an asymmetric periphery which promotes proper positioning and orientation on a resected tibia, while also facilitating enhanced kinematics, soft-tissue interaction, and long-term fixation of the complete knee prosthesis. The asymmetric baseplate periphery is sized and shaped to substantially match portions of the periphery of a typical resected proximal tibial surface, such that proper location and orientation is evident by resting the baseplate on the tibia. The baseplate periphery provides strategically positioned relief and/or clearance between the baseplate periphery and bone periphery, such as in the posterior-medial portion to prevent deep-flexion component impingement, and in the anterior-lateral portion to avoid undue interaction between the anatomic iliotibial band and prosthesis components.


In one form thereof, the present invention provides a tibial prosthesis comprising: a distal surface; a proximal surface generally opposite the distal surface, the proximal surface having a lateral compartment and a medial compartment; and a peripheral wall extending between the distal and the proximal surface, the peripheral wall defining; an anterior edge; a lateral posterior edge generally opposite the anterior edge and forming a posterior boundary of the lateral compartment; a medial posterior edge generally opposite the anterior edge and forming a posterior boundary of the medial compartment; a lateral periphery extending from the anterior edge to the lateral posterior edge, the lateral periphery defining a plurality of adjacent lateral arcs, an adjacent pair of the plurality of adjacent lateral arcs defining a first lateral radius and a second lateral radius, respectively, the first lateral radius larger than the second lateral radius by at least 100%, whereby the lateral periphery is relatively boxy; and a medial periphery extending from the anterior edge to the medial posterior edge, the medial periphery defining a plurality of adjacent medial arcs, an adjacent pair of the plurality of adjacent medial arcs defining a first medial radius and a second medial radius, respectively, the first medial radius larger than the second medial radius by less than 75%, whereby the medial periphery is generally rounded.


In another form thereof, the present invention provides a tibial prosthesis comprising: a distal surface; a proximal surface generally opposite the distal surface; and a peripheral wall extending between the distal and the proximal surface, the peripheral wall defining: an anterior edge; a lateral periphery including: a lateral edge defining a substantially perpendicular tangent with respect to the anterior edge, an anterior-lateral corner traversing an angular sweep between the anterior edge and the lateral edge to define a boxy corner periphery having an anterior-lateral corner edge length, and a posterior-lateral corner extending away from the lateral edge and the anterior-lateral corner; and a medial periphery including: a medial edge defining a substantially perpendicular tangent with respect to the anterior edge, an anterior-medial corner traversing an angular sweep between the anterior edge and the medial edge to define a rounded corner periphery having an anterior-medial corner edge length that is longer than the anterior-lateral corner edge length, in which the angular sweep between the anterior edge and the medial edge is similar to the angular sweep between the anterior edge and the lateral edge, and a posterior-medial corner extending away from the medial edge and the anterior-medial corner.


In yet another form thereof, the present invention provides a tibial prosthesis comprising an asymmetric prosthesis periphery, the periphery comprising: an anteroposterior axis dividing the prosthesis periphery into a medial compartment and a lateral compartment; an anterior edge disposed between the medial compartment and the lateral compartment; a lateral posterior edge generally opposite the anterior edge and forming a posterior boundary of the lateral compartment; a medial posterior edge generally opposite the anterior edge and forming a posterior boundary of the medial compartment; a lateral periphery extending from the anterior edge to the lateral posterior edge, the lateral periphery defining: an anterior-lateral are having an anterior-lateral are center; and a lateral arc having a lateral arc center, the lateral arc defining a tangent parallel to the anteroposterior axis; a medial periphery extending from the anterior edge to the medial posterior edge, the medial periphery defining: an anterior-medial arc having an anterior-medial arc center; and a medial arc having a medial arc center, the medial arc defining a tangent parallel to the anteroposterior axis, a mediolateral axis defining the longest line segment within the prosthesis periphery that is also perpendicular to the anteroposterior axis, the anterior-lateral arc center disposed between the mediolateral axis and the anterior edge, the anterior-medial arc center disposed posterior of the mediolateral axis.





BRIEF DESCRIPTION OF THE DRAWINGS

The above-mentioned and other features and advantages of this invention, and the manner of attaining them, will become more apparent and the invention itself will be better understood by reference to the following description of embodiments of the invention taken in conjunction with the accompanying drawings, wherein:



FIG. 1A is an exploded, perspective view of a tibial baseplate and tibial bearing component in accordance with the present disclosure;



FIG. 1B is an assembled, perspective view of the tibial baseplate and tibial bearing component shown in FIG. 1A;



FIG. 2A is a top plan view of the peripheries of a set of nine tibial baseplates made in accordance with the present disclosure, in which the peripheries are shown to scale according to the illustrated scales in millimeters in the bottom and right-hand margins of the page;



FIG. 2B is a top plan view of the periphery of a tibial baseplate made in accordance with the present disclosure;



FIG. 2C is a graph illustrating the asymmetric growth of the posterior-medial compartment for the tibial baseplates shown in FIG. 2A;



FIG. 2D is a graph illustrating the asymmetric growth of the posterior-lateral compartment for the tibial baseplates shown in FIG. 2A;



FIG. 3A is top plan view of a periphery of a tibial baseplate made in accordance with the present disclosure, illustrating various arcs defined by the periphery;



FIG. 3B is a partial, top plan view of the periphery shown in FIG. 3A, illustrating an alternative lateral corner periphery;



FIG. 3C is a partial, top plan view of the periphery shown in FIG. 3A, illustrating an alternative medial corner periphery;



FIG. 3D is a top plan view of the periphery of a tibial baseplate made in accordance with the present disclosure, illustrating medial and lateral surface area calculations without a PCL cutout;



FIG. 4A is a top plan view of a tibial baseplate made in accordance with the present disclosure;



FIG. 4B is a side elevation view of the tibial baseplate shown in FIG. 4A;



FIG. 5 is a top plan view of a resected proximal tibial surface with a prosthetic tibial baseplate component and tibial bearing component made in accordance with the present disclosure mounted thereon;



FIG. 6 is a top plan view of a resected proximal tibial surface with a properly sized tibial trial component thereon;



FIG. 7 is a side, elevation view of the tibia and trial component shown in FIG. 6; and



FIG. 8 is a side, elevation view of the tibial components shown in FIG. 1A, in conjunction with a femoral component.





Corresponding reference characters indicate corresponding parts throughout the several views. The exemplifications set out herein illustrate exemplary embodiments of the invention, and such exemplifications are not to be construed as limiting the scope of the invention in any manner.


DETAILED DESCRIPTION

The present disclosure provides an asymmetric knee joint prosthesis which facilitates proper rotational and spatial orientation of a tibial baseplate and tibial bearing component upon a resected proximal tibia, while also offering large-area contact with the resected proximal tibia. The prosthesis permits a wide range of flexion motion, protects natural soft tissue proximate the knee joint prosthesis, and optimizes long term fixation characteristics of the prosthesis.


In order to prepare the tibia and femur for receipt of a knee joint prosthesis of the present disclosure, any suitable methods or apparatuses may be used. As used herein, “proximal” refers to a direction generally toward the torso of a patient, and “distal” refers to the opposite direction of proximal, i.e., away from the torso of the patient.


As used herein, the “periphery” of a tibial prosthesis refers to any periphery as viewed in a top plan view, e.g., in a generally transverse anatomical plane. Alternatively, the periphery of a tibial prosthesis may be any periphery as viewed in bottom plan view, e.g., in a generally transverse plane and looking at the distal surface adapted to contact a resected proximal surface of a tibial bone.


As used herein, the term “centroid” or “geometric center” refers to the intersection of all straight lines that divide a given area into two parts of equal moment about each respective line. Stated another way, a geometric center may be said to be the “average” (i.e., arithmetic mean) of all points of the given area. Stated yet another way, the geometric center is a point in a two dimensional figure from which the sum of the displacement vectors of all points on the figure equals zero.


As used herein, a “disparity” or “difference” between two numerical values (e.g., one value “larger” or “smaller” than another), typically expressed as a percentage, is the difference between the two values divided by the smaller of the two values. For example, a smaller quantity having value 75 and a larger quantity having value 150 would have a percentage disparity of (150−75)/75, or 100%.


Referring to FIG. 5, tibia T includes tibial tubercle B having mediolateral width W, with tubercle midpoint PT located on tubercle B approximately halfway across width W. While tubercle B is shown as having midpoint PT at the “peak” or point of maximum anterior eminence, it is recognized that midpoint PT of tibia T may be spaced from such a peak. Tibia T also includes attachment point CP representing the geometric center of the attachment area between the anatomic posterior cruciate ligament (PCL) and tibia T. Recognizing that the PCL typically attaches to a tibia in two ligament “bundles,” one of which is relatively anterior, lateral and proximal and the other of which relatively posterior, medial and distal, attachment point CP is contemplated as representing the anterior/lateral attachment area in an exemplary embodiment. However, it is contemplated that the posterior/medial attachment area, or the entire attachment area, could be used.


As used herein, “anterior” refers to a direction generally toward the front of a patient. “Posterior” refers to the opposite direction of anterior, i.e., toward the back of the patient.


In the context of patient anatomy, “home axis” AH refers to a generally anteroposterior axis extending from posterior point CP to an anterior point CA, in which anterior point CA is disposed on tubercle B and medially spaced from tubercle midpoint PT by an amount equal to W/6. Stated another way, anterior point CA is laterally spaced by an amount equal to W/3 from the medial end of mediolateral width W, such that point CA lies on the “medial third” of the anterior tibial tubercle.


In the context of a prosthesis, such as tibial baseplate 12 described below, “home axis” AH refers to an axis oriented with respect to baseplate 12 such that the baseplate home axis AH of baseplate 12 is aligned with home axis AH of tibia T after implantation of baseplate 12 in a proper rotational and spatial orientation (as shown in FIG. 5). In the illustrative embodiments shown in FIG. 3 and described in detail below, home axis AH bisects PCL cutout 28 at the posterior edge of periphery 200 of tibial plateau 18 (FIG. 5), and bisects anterior edge 202 at the anterior edge of periphery 200 of tibial plateau 18. It is contemplated that home axis AH may be oriented to other baseplate features, it being understood home axis AH of baseplate 12 is positioned such that that proper alignment and orientation of baseplate 12 upon tibia T positions the home axis AH of baseplate 12 coincident with home axis AH of tibia T.


Home axis AH of tibial baseplate 12 may be said to be an anteroposterior axis, as home axis AH extends generally anteriorly and posteriorly when baseplate 12 is implanted upon tibia T. Tibial baseplate also defines mediolateral axis AML, which lies along the longest line segment contained within periphery 200 that is also perpendicular to home axis AH of baseplate 12. As described below, home axis AH and mediolateral axis AML cooperate to define a coordinate system useful for quantifying certain baseplate features in accordance with the present disclosure.


The embodiments shown and described with regard to FIGS. 1A, 1B, 3A, 4A, 4B, 5 and 6 illustrate a left knee and associated features of a right-knee prosthesis, while the embodiments shown and described in FIGS. 2A, 2B and 3D illustrate the periphery of a right knee prosthesis. Right and left knee configurations are mirror images of one another about a sagittal plane. Thus, it will be appreciated that all aspects of the prosthesis described herein are equally applicable to a left- or right-knee configuration.


1. Asymmetry of the Tibial Prosthesis.


Referring now to FIGS. 1A and 1B, tibial prosthesis 10 includes tibial baseplate 12 and tibial bearing component 14. Tibial baseplate 12 may include a stem or keel 16 (FIG. 4B) extending distally from proximal tibial plateau 18, or may utilize other fixation structures for securing baseplate 12 to tibia T, such as distally extending pegs. Portions of the outer periphery defined by tibial plateau 18 closely correspond in size and shape with a resected proximal surface of tibia T, as described in detail below.


Tibial bearing component 14 and tibial baseplate 12 have a particular asymmetry, with respect to home axis AH (shown in FIG. 2A and described above), that is designed to maximize tibial coverage for a large proportion of knee-replacement candidates. This high level of coverage allows a surgeon to cover the largest possible area on the proximal resected surface of the tibia, which in turn offers maximum coverage of cortical bone. Advantageously, the maximized coverage of cortical bone facilitates superior support of tibial baseplate 12. A firm, enduring fixation of tibial baseplate 12 to tibia T is facilitated by large-area contact between the cortical and cancellous bone of tibia T and distal surface 35 of tibial plateau 18 (FIG. 4B), which may be coated with porous ingrowth material and/or bone cement.


In an analysis of a several human specimens, variations in size and geometry for a variety of anatomic tibial features were observed and characterized. Geometrical commonalties between anatomic features, or lack thereof, were noted. Mean tibial peripheral geometries were calculated based on statistical analysis and extrapolation of the collected anatomical data, in view of the observed geometrical commonalties organized around anatomic home axis AH. These calculated mean geometries were categorized by tibial size.


A comparison between the asymmetric peripheries for the present family of prostheses and the calculated mean tibial geometries was conducted. Based on the results of this comparison, it has been found that substantial tibial coverage can be achieved for a large proportion of patients using tibial components having asymmetric peripheries in accordance with the present disclosure. Moreover, this coverage can be achieved with a relatively small number of sizes, even where particular portions of the prosthesis periphery is intentionally “pulled back” from the tibial periphery in order to confer other orthopaedic benefits. Further, the particular asymmetry of tibial baseplate 12 can be expected to offer such coverage without overhanging any portion of the resected surface.


Thus, periphery 200 including the particular asymmetric profile as described below confers the benefits of maximum coverage, facilitation of proper rotation (discussed below), and long-term fixation as described herein. Such asymmetry may be demonstrated in various ways, including: by a comparison of adjacent radii in the medial and lateral compartments of the asymmetric periphery; by a comparison of the edge length in anterior-medial and anterior lateral corners of the periphery, for a comparable lateral and medial angular sweep; and by a comparison of the location of radius centers for the anterior-medial and anterior-lateral corners with respect to a mediolateral axis. Various comparisons and quantifications are presented in detail below. Specific data and other geometric details of the peripheries for the various prosthesis sizes, from which the below-identified comparisons and quantifications are derived, may be obtained from the draw-to-scale peripheries shown in FIG. 2A.


Advantageously, the asymmetry of tibial component 12 encourages proper rotational orientation of baseplate 12 upon implantation thereof onto tibia T. As described in detail below, the asymmetry of periphery 200 (FIG. 2A) of tibial plateau 18 is designed to provide a close match in selected areas of the lateral and medial compartments as compared to the anatomic bone. As such, a surgeon can select the largest possible component from among a family of different component sizes, such that the component substantially covers the resected tibia T with minimal gaps between the tibial periphery and component periphery 200, as well as little or no overhang over any portions of the tibial periphery. Because the high congruence between prosthesis periphery 200 and the tibial periphery produces only a minimal gap between the peripheries (as shown in FIG. 5), tibial baseplate 12 cannot be rotated significantly without causing tibial plateau 18 to overhang beyond the periphery of the resected tibial surface. Thus, proper rotation of baseplate 12 can be ascertained by the visual acuity between prosthesis periphery 200 and the resected tibial surface.


The following examples and data are presented with respect to tibial baseplate 12. However, as described in more detail below, tibial bearing component 14 defines perimeter wall 54 which follows peripheral wall 25 of baseplate 12 except where noted. Thus, it is appreciated that the conclusions, trends and design features gleaned from data relating to the asymmetric periphery of tibial baseplate 12 also applies to the asymmetric periphery of tibial bearing component 14, except where stated otherwise.


Lateral compartment 20 and medial compartment 22 of tibial plateau 18 are dissimilar in size and shape, giving rise to the asymmetry thereof. This asymmetry is designed so that peripheral wall 25 traces the perimeter of the resected proximal surface of tibia T, such that tibial plateau 18 covers a large proportion of the resected proximal tibial surface as shown in FIG. 5. To achieve this large tibial coverage, tibial plateau 18 closely matches the periphery of tibia T in most areas as noted above. Nevertheless, as shown in FIG. 5, for example, a small gap between periphery 200 of tibial plateau 18 and tibia T is formed to allow some freedom of positioning and rotational orientation. The gap is designed to have a substantially continuous width in most areas, including the anterior edge, anterior-medial corner, medial edge, lateral edge and lateral-posterior corner (all described in detail below).


However, certain aspects of the asymmetric shape are designed to intentionally deviate from the calculated anatomical shape to confer particular features and advantages in the context of a complete, implanted knee prosthesis. Referring to FIG. 5, for example, tibial baseplate 12 and tibial bearing component 14 have anterior-lateral “corners” (described in detail below) which are “pulled back” to create gap 56 between tibia T and prosthesis 10 in the anterior-lateral area of the resected surface of tibia T. Advantageously, gap 56 creates extra space for “soft-tissue friendly” edges of prosthesis 10, thereby minimizing impingement of the iliotibial band. In an exemplary embodiment, gap 56 may range from 0.5 mm for a small-size prosthesis (such as size 1/A described below), to 1 mm for a medium-sized prosthesis (such as size 5/E described below), to 2 mm for a large-sized prosthesis (such as size 9/J described below).


Similarly, the posterior edge of the medial compartment may be “pulled back” from the adjacent edge of tibia T to define gap 58. Gap 58 allows extra space for adjacent soft tissues, particularly in deep flexion as described below. Gap 58 also allows prosthesis 10 to be rotated about a lateral pivot by a small amount, thereby offering a surgeon the freedom to displace medial compartment 22 posteriorly as required or desired for a particular patient. In an exemplary embodiment, gap 58 is about 4 mm.


As described in detail below, the asymmetrical periphery also provides a large overall area for proximal surface 34 of baseplate 12, which creates sufficient space for large contact areas between tibial bearing component 14 and femoral component 60 (FIG. 8).


a. Medial/Lateral Peripheral Curvatures


The particular asymmetric shape of tibial plateau 18 (and of tibial bearing component 14, which defines a similar periphery as described below) gives rise to a generally “boxy” or angular periphery in lateral compartment 20, and a “rounded” or soft periphery in medial compartment 22.


Turning to FIG. 3A, the periphery 200 of tibial plateau 18 surrounds lateral compartment 20 and medial compartment 22, each of which define a plurality of lateral and medial arcs extending between anterior edge 202 and lateral and medial posterior edges 204, 206 respectively. In the illustrative embodiment of FIG. 3A, anterior edge 202, lateral posterior edge 204 and medial posterior edge 206 are substantially planar and parallel for ease of reference. However, it is contemplated that edges 202, 204, 206 may take on other shapes and configurations within the scope of the present disclosure, such as angled or arcuate.


In the exemplary embodiment of FIG. 3A, lateral compartment 20 includes five separate arcs including lateral anterior edge arc 208, anterior-lateral corner arc 210, lateral edge arc 212, posterior-lateral corner are 214, and lateral posterior edge arc 216. Each of lateral arcs 208, 210, 212, 214 and 216 defines angular sweep 1L, 2L, 3L, 4L and 5L, respectively, having radii R1L, R2L, R3L, R4L and R5L respectively. A radius of a particular angular sweep extends from the respective radius center (i.e., one of centers C1L, C2L, C3L, C4L and C5L) to periphery 200. Radii R1L, R2L. R3L, R4L and R5L each remain unchanged throughout the extent of angular sweeps 1L, 2L, 3L, 4L and 5L, respectively.


Similarly, medial compartment 22 includes three separate arcs including anterior-medial corner arc 220, medial edge arc 222 and posterior-lateral corner arc 224, defining angular sweeps 1R, 2R and 3R, respectively having radii R1R, R2R and R3R respectively.


In FIG. 2A, peripheries 200X are shown for each of nine progressively larger component sizes, with 2001 being the periphery of the smallest size (size “1” or “A”) and 2009 being the periphery of the largest size (size “9” or “J”). For purposes of the present disclosure, several quantities and features of tibial baseplate 12 may be described with the subscript “X” appearing after the reference numeral corresponding to a component size as set for in the Tables, Figures and description below. The subscript “X” indicates that the reference numeral applies to all nine differently-sized embodiments described and shown herein.


In exemplary embodiments, medial and lateral radii may be any value within the following ranges: for medial radius R1RX, between about 27 mm and about 47 mm; for medial radius R2RX, between about 21 mm and about 49 mm; for medial radius R3RX, between about 14 mm and about 31 mm; for lateral radius R1LX, between about 46 mm and about 59 mm; for lateral radius R2LX, between about 13 mm and about 27 mm; for lateral radius R3LX between about 27 mm and about 46 mm; for lateral radius R4LX between about 6 mm and about 14 mm; and for lateral radius R5LX between about 22 mm and about 35 mm.


In exemplary embodiments, medial and lateral angular extents or sweeps may be any value within the following ranges: for medial angle 1RX, between about 13 degrees and about 71 degrees; for medial angle 2RX, between about 23 degrees and about 67 degrees; for medial angle 3RX, between about 23 degrees and about 90 degrees; for lateral angle 1LX, between about 11 degrees and about 32 degrees; for lateral angle 2LX, between about 42 degrees and about 63 degrees; for lateral angle 3LX, between about 23 degrees and about 47 degrees; for lateral angle 4LX, between about 36 degrees and about 46 degrees; and for lateral angle 5LX, between about 28 degrees and about 67 degrees;


The unique asymmetry of periphery 200 defined by tibial plateau 18 can be quantified in multiple ways with respect to the curvatures of lateral and medial compartments 20 and 22 as defined by the arrangement and geometry of lateral arcs 208, 210, 212, 214, 216 and medial arcs 220, 222, 224.


One measure of the asymmetry of periphery 200 is found in a simple comparison of radii R2L and R1R, which are the anterior “corner” radii of lateral and medial compartments 20 and 22 respectively. Generally speaking, a corner of a baseplate periphery may be said to be that portion of the periphery where a transition from an anterior or posterior edge to a lateral or medial edge occurs. For example, in the illustrative embodiment of FIG. 3A, the anterior-lateral corner is principally occupied by anterior-lateral corner arc 210, which defines a substantially medial-lateral tangent at the anterior end of arc 210 and a substantially anteroposterior tangent at the lateral end of are 210. Similarly, the medial corner of periphery 200 is principally occupied by anterior-medial corner are 220, which defines a substantially medial-lateral tangent at the anterior end of arc 220 and a more anteroposterior tangent at the lateral end of arc 220. For some purposes, the anterior-medial corner of periphery 200 may be said to include a portion of medial edge arc 222, as described below.


A periphery corner may also be defined by a particular angular sweep with respect to an anteroposterior reference axis. Such reference axis may extend posteriorly from an anterior-most point of a tibial prosthesis (e.g., from the center of anterior edge 202 of periphery 200) to divide the prosthesis into medial and lateral halves. In a symmetrical prosthesis, the anteroposterior reference axis is the axis of symmetry.


In the illustrative embodiment of FIG. 3A, the anteroposterior reference axis may be home axis AH, such that the anterior-medial corner of periphery 200 occupies some or all of the 90-degree clockwise angular sweep between home axis AH (at zero degrees, i.e., the beginning of the clockwise sweep) and mediolateral axis AML (at 90 degrees, i.e., the end of the sweep). Similarly, the anterior-lateral corner of periphery 200 occupies some or all of the 90-degree counter-clockwise angular sweep between home axis AH and mediolateral axis AML.


For example, the anterior-medial and anterior-lateral corners may each occupy the central 45 degree angular sweep of their respective 90-degree angular sweeps as described above. Thus, the anterior-lateral corner of periphery 200 would begin at a position rotated 22.5 degrees counter-clockwise from home axis AH as described above, and would end at 67.5 degrees counter-clockwise from home axis AH. Similarly, the anterior-medial corner would begin at a 22.5-degree clockwise rotation and end at a 67.5 degree clockwise rotation.


It is contemplated that the anterior-lateral and anterior-medial corners may occupy any angular sweep as required or desired for a particular design. For purposes of comparison between two corners in a given prosthesis periphery, however, a comparable angular sweep for the lateral and medial sides is envisioned, i.e., the extent and location of the compared angles may be “mirror images” of one another about an anteroposterior axis. For example, in a comparison of anterior-lateral and anterior-medial radii R2L, R1R, it is contemplated that such comparison is calculated across lateral and medial angular sweeps which each begin and end at similar angular end points with respect to the chosen reference axis (e.g., home axis AH).


As best seen in FIGS. 3A and 5, one aspect of the asymmetric periphery of baseplate 12 arises from R1RX being substantially larger than R2LX. Table 1, below, also includes a comparison of radii R1RX and R2LX across nine exemplary component sizes, demonstrating that difference Δ-12L between radius R1RX and radius R2LX may be as little as 48%, 76% or 78%, and may be as much as 102%, 103% or 149%. It is contemplated that radius R1RX may be larger than radius R2LX by any percentage value within any range defined by the listed values.









TABLE 1







Comparisons of Values of Respective Medial


and Lateral Anterior Corner Radii











Δ-12RL



SIZE
R1R vs. R2L














1/A
103.0%



2/B
149.2%



3/C
82.4%



4/D
74.6%



5/E
90.9%



6/F
78.6%



7/G
102.2%



8/H
86.5%



9/J
48.1%



AVG
90.6%







All Δ values are expressed as the difference between a given pair of radii, expressed as a percentage of the smaller of the two radii






Stated another way, the smaller R2LX makes a sharper turn, thereby imparting a relatively more “boxy” appearance to the anterior corner of lateral compartment 20, while the relatively larger radius R1RX makes a more gradual turn that imparts a more “rounded” appearance to the anterior corner of medial compartment 22. In the exemplary nine sizes illustrated in FIG. 2A and shown in Table 1, an average disparity between the lateral and medial anterior corner radii R2LX and R1RX is greater than 90%. In some sizes of periphery 200X, the anterior-medial “corner” making the more gradual turn may also includes medial edge arc 222.


As described in detail below, this “rounded-medial/boxy-lateral” asymmetry of the anterior corners of tibial plateau facilitates and encourages proper rotational orientation and positioning of baseplate 12 upon tibia T upon implantation by allowing periphery 200 to closely match the periphery of a typical resected tibia T (FIG. 5), while also maximizing the surface area of proximal surface 34 of tibial plateau to allow for use of a tibial bearing component 14 with a concomitantly large proximal surface area.


As noted above, the small-radius “corner” defined by angle 2L may be considered to have a similar angular sweep as a large-radius “corner” defined by angles 1R, 2R (or a combination of portions thereof) for purposes of comparing the two radii. Given this comparable angular sweep, another measure of the asymmetry defined by the medial and lateral anterior corners is the are length of the corners. More particularly, because medial radii R1RX and R2RX are larger than lateral radius R2LX (as described above), it follows that the medial corner has a larger arc length as compared to the lateral corner are length for a given angular sweep.


Moreover, while the peripheries of lateral and medial compartments 20, 22 are shown as being generally rounded and therefore defining respective radii, it is contemplated that an asymmetric periphery in accordance with the present disclosure need not define a radius per se, but rather could include one or more straight line segments which, on the whole, define asymmetric corner edge lengths in the medial and lateral compartments. Referring to FIG. 3B, for example, it is contemplated that an alternative anterior lateral corner 210′ could be comprised of three line segments 210A, 210B, 210C which cooperate to span angular extent 2L. Similarly, an alternative anterior medial corner 220′ could be comprised of three line segments 220A, 220B, 220C which cooperate to span angular extent 1R. Any of the other arcs which define periphery 200 could be similarly configured as one or more line segments. In the variant illustrated by FIGS. 3B and 3C, the difference between corner radii would not be an appropriate measure of asymmetry because the straight line segments would not define radii. Asymmetry of the medial and lateral anterior corners would instead be quantified by comparison of the respective lengths of the medial and lateral corner edges across comparable medial and lateral angular extents.


Yet another way to quantify the asymmetry of the anterior corner arcs (i.e., anterior-lateral corner arc 210 and anterior-medial corner arc 220) is to compare the distance of the lateral and medial radius centers C2L and C1R respectively, from anterior edge 202 and/or mediolateral axis AM. (FIG. 3A). In the boxy anterior-lateral corner, center C2LX of radius R2LX is anterior of mediolateral axis AML and relatively close to anterior edge 202. For the rounded, anterior-medial corner, centers C1RX and C2RX of radii R1RX and R2RX, respectively, are posterior of mediolateral axis AMI, and relatively far from anterior edge 202.


Another metric for quantifying the “boxy vs. rounded” asymmetry of periphery 200 is a comparison between ratios of adjacent radii. In the more boxy lateral compartment 20, pairs of adjacent radii define large ratios because the large edge radii (i.e., of lateral anterior edge arc 208, lateral edge arc 212 and lateral posterior edge arc 216) are much larger than the adjacent corner radii (i.e., of anterior-lateral corner arc 210 and posterior-lateral corner arc 214). On the other hand, in the more rounded medial compartment 22, pairs of adjacent radii define small ratios (i.e., nearly 1:1) because the radii of the medial arcs (i.e., anterior-medial corner arc 220, medial edge arc 222 and posterior-medial corner arc 224) are of similar magnitude.


In the illustrated embodiment of FIG. 3A, lateral edge arc 212 is considered an “edge” because arc 212 defines tangent 212A which is substantially perpendicular to anterior edge 202. Just as a “corner” may be considered to be the portion of periphery 200 which makes a transition from anterior or posterior to medial or lateral, an edge is that portion of periphery 200 which encompasses the anterior, posterior, medial or lateral terminus of periphery 200.


Similarly, medial edge arc 222 defines tangent 222A which is also substantially perpendicular to anterior edge 202. The medial “edge” of periphery 200 may be part of the same are that extends around the anterior-medial corner and/or the anterior-lateral corner, as the medial arcs are similar. Indeed, as noted herein, medial compartment 22 may have a single arc which extends from anterior edge 202 to medial posterior edge 206.


Table 2 shows a comparison between adjacent-radii ratios for lateral and medial compartments 20 and 22. For each adjacent pair of radii, the difference between the radii magnitudes are expressed as a percentage of the smaller radius of the pair, as noted above.









TABLE 2







Comparisons of Values of Respective


Pairs of Baseplate Peripheral Radii














Δ-12R
Δ-23R
Δ-12L
Δ-23L
Δ-34L
Δ-45L



R1R vs.
R2R vs.
R1L vs.
R2L vs.
R3L vs.
R4L vs.


SIZE
R2R
R3R
R2L
R3L
R4L
R5L
















1/A
18.3%
58.6%
337.3%
141.8%
323.5%
194.1%


2/B
49.0%
62.0%
254.1%
96.7%
361.5%
315.4%


3/C
24.0%
48.8%
247.1%
58.8%
203.4%
214.6%


4/D
44.2%
34.4%
207.0%
59.2%
213.9%
244.4%


5/E
23.3%
57.9%
151.5%
80.6%
250.0%
250.0%


6/F
46.5%
37.6%
122.6%
42.9%
222.6%
260.2%


7/G
25.3%
38.9%
110.8%
64.5%
264.3%
176.2%


8/H
73.6%
21.3%
109.0%
80.9%
198.1%
142.6%


9/J
21.9%
61.2%
70.4%
68.5%
264.0%
172.0%


AVG
36.2%
46.7%
178.9%
77.1%
255.7%
218.8%





All Δ values are expressed as the difference between a given pair of radii, expressed as a percentage of the smaller of the two radii






As illustrated in Table 2, the “boxy” periphery of lateral compartment 20 gives rise to disparity values Δ-12L, Δ-23L, Δ-34L and Δ-45L that are at least 42%, 48% or 59%, and as great as 323%, 337% or 362%. It is contemplated that the disparity between a pair of adjacent radii in the boxy periphery of lateral compartment 20 may be any percentage value within any range defined by any of the listed values. It is also contemplated that the lateral disparity values may be substantially higher, as required or desired for a particular application.


Meanwhile, the “rounded” periphery of medial compartment 22 gives rise to disparity values Δ-12R and Δ-23R that are as small as 21%, 23% or 25%, and no greater than 61%, 62% or 74%. It is contemplated that the disparity between a pair of adjacent radii in the rounded periphery of medial compartment 22 may be any value within any range defined by any of the listed values. It is also contemplated that the medial disparity values may be less than 21%, and as little as zero %, as required or desired for a particular application.


Moreover, the boxy shape of lateral compartment 20 and rounded shape of medial compartment 22 is also demonstrated by the number of arcs used to define the portion of periphery 200 in lateral and medial compartments 20, 22. In lateral compartment 20, five arcs (i.e., arcs 208, 210, 212, 204, 216) are used to define the lateral periphery, which is indicative of anterior, lateral and posterior “sides” of a box joined by the relatively sharp transitions of corner arcs 210, 214. On the other hand, medial compartment 22 uses only three radii (i.e., 220, 222, 224), leaving no clear definition of any box “sides” or other transitions. Indeed, it is contemplated that medial compartment 22 could join anterior edge 202 to medial posterior edge 206 by a single radius within the scope of the present disclosure.


b. Surface Area of Medial and Lateral Baseplate Compartments


Referring still to FIG. 3A, yet another characterization of the asymmetry of periphery 200 arises from disparities in surface area for lateral and medial compartments 20, 22. For purposes of the present disclosure, surface area of lateral compartment SAL is that area contained within periphery 200, and on the lateral side of home axis AH. Similarly, the surface area of medial compartment 22 is that area contained within periphery 200, and on the medial side of home axis AH.


In an exemplary embodiment, lateral surface area SALX may be as little as 844 mm2 or may be as much as 1892 mm2, or may be any area within the range defined by the foregoing values. In an exemplary embodiment, medial surface area SAMX may be as little as 899 mm2 or may be as much as 2140 mm2, or may be any area within the range defined by the foregoing values.


Surfaces areas SAL and SAM do not include any of the area occupied by PCL cutout 28, as any such area is not within periphery 200. However, the asymmetry of surface areas SAL and SAM arises primarily from the differences in the geometry and placement of arcs 208, 210, 212, 214, 216, 220, 222, 224 rather than from any asymmetry of PCL cutout 28. In the illustrative embodiments of FIG. 2A, for example, PCL cutout 28X is symmetrical with respect to home axis AH, but extends further posteriorly in medial compartment 22.


Thus, it is contemplated that the asymmetry of surfaces areas SAL, SAM are little changed by exclusion of the PCL cutout 28 from the area calculation. As illustrated in FIG. 3D, PCL cutout 28 is effectively excluded from calculation by extrapolating the line formed by lateral posterior edge 204 and medial posterior edge 206 inwardly to intersect with home axis AH. In lateral compartment 20, such extrapolation cooperates with the lateral side of PCL cutout 28 to define lateral fill area 80. In medial compartment 22, such extrapolation cooperates with the medial side of PCL cutout 28 to define medial fill area 82.


In the illustrative embodiment of FIG. 3D, lateral surface area SALX′ may be as little as 892 mm2 or may be as much as 2066 mm2, or may be any area within the range defined by the foregoing values. In an exemplary embodiment, medial surface area SAMX′ may be as little as 986 mm2 or may be as much as 2404 mm2, or may be any area within the range defined by the foregoing values.


Tables 3 and 4 below illustrate that medial surface area SAMX occupies a greater percentage of the total surface area contained within periphery 200X, regardless of whether PCL cutout 28 is included in the calculation. That is to say, medial fill area 82 is larger than lateral fill area 80 by approximately the same proportion as medial and lateral surfaces areas SAMX, SALX. In the exemplary embodiments of FIG. 3A, medial surface area SAMX occupies between 52% and 53% of the total surface area regardless, while lateral surface area SAMX occupies the remainder. If the PCL cutout is excluded from the calculation as shown in FIG. 3D, medial surface area SAMX′ occupies between 52% and 54% of the total surface area, while lateral surface area SAMX′ occupies the remainder. With or without the PCL cutout included in the calculation, it is contemplated that medial surface areas SAMX, SAMX′ may occupy as little as 51% of the total surface area, and as much as 60% of the total surface area.









TABLE 3







Medial vs. Lateral Tibial Baseplate Surface Areas for


Baseplates with a PCL Cutout (FIGS. 2A and 3A)


With PCL Notch











Medial Surface Area SAMX



Size
as % of Total Surface Area







1/A
52%



2/B
52%



3/C
52%



4/D
52%



5/E
52%



6/F
52%



7/G
53%



8/H
53%



9/J
53%

















TABLE 4







Medial vs. Lateral Tibial Baseplate Surface Areas for


Baseplates without a PCL Cutout (FIG. 3D)


Without PCL Notch











Medial Surface Area SAMX



Size
as % of Total Surface Area







1/A
53%



2/B
52%



3/C
53%



4/D
53%



5/E
53%



6/F
53%



7/G
53%



8/H
54%



9/J
54%










c. Anteroposterior Extent of Medial and Lateral Compartments


Still another way to characterize and quantify the asymmetry of tibial periphery 200 is to compare the overall anteroposterior extent of lateral and medial compartments 20, 22.


Turning to FIG. 2A (which is drawn to scale, according to scales 230 and 232) and FIG. 2B, lateral compartment 20 of tibial plateau 18 defines overall lateral anteroposterior extent DAPLX, while medial compartment 22 of tibial plateau 18 defines overall medial anteroposterior extent DAPMX, where X is an integer between 1 and 9 corresponding to a particular component size as shown in FIG. 2A, as noted above. As illustrated in Table 5 below, lateral anteroposterior extent DAPLX is less than medial anteroposterior extent DAPMX, for all component sizes.


This disparity in anteroposterior extent can be said to result from medial compartment 22 extending posteriorly further than lateral compartment 20. In the illustrative embodiment of FIG. 2B, lateral anteroposterior extent DAPLX extends from anterior edge 202 to lateral posterior edge 204, while medial anteroposterior extent DAPMX extends from anterior edge 202 to medial posterior edge 206. Thus, if one takes anterior edge 202 to be the anteroposterior “zero point,” the additional anteroposterior extent defined by medial compartment 22 is due entirely to the further posterior position of medial posterior edge 206.


As set forth in the right-hand column of Table 5, exemplary embodiments of tibial baseplate 12 may define medial anteroposterior extent DAPMX that is larger than lateral anteroposterior extent DAPLX by as little as 12.1%, 12.2% or 12.4%, and as much as 13.7%, 14.2% or 14.5%. It is contemplated that such disparity between medial and lateral anteroposterior extents DAPMX, DAPLX may be any percentage within any range defined by the listed values of Table 5. Advantageously, the particular asymmetric arrangement of tibial baseplate 12 with respect to anteroposterior extent of lateral and medial compartments 20, 22 facilitates substantially complete coverage of tibia T, without overhanging the edge of tibia T, in a wide variety of patients.









TABLE 5







Overall A/P and M/L Dimensions for


Tibial Baseplates (FIGS. 2A and 2B)











Growth in A/P
Growth in A/P
Additional



Medial Dimension
Lateral Dimension
A/P Extent of


Size
(DAPM), from next-
(DAPL), from next-
DAPM vs. DAPL,


(X)
smaller size, mm
smaller size, mm
% of DAPL





1/A


14.5%


2/B
2.3
2.13
14.2%


3/C
2.4
2.25
13.7%


4/D
2.3
2.27
13.1%


5/E
3
2.8
12.7%


6/F
3.1
2.85
12.4%


7/G
3.2
2.81
12.5%


8/H
3.3
3.11
12.2%


9/J
3.73
3.34
12.1%









For example, in an exemplary family of prosthesis sizes, at least 60% and as much as 90% coverage of the resected proximal surface is provided by tibial plateau 18 of tibial baseplate 12 when rotation is limited to +/−5 degrees from home axis AH. In a majority of all patients, such coverage is between 75-85%. Coverage of up to 100% may be achieved within the scope of the present disclosure, such as by fully extending the posterior-medial and anterior-lateral coverage of tibial plateau (which intentionally leave gaps between tibial plateau 18 and the periphery of tibia T as noted herein).


The additional posteromedial material of tibial plateau 18 includes chamfer 32, described in detail below with respect to the assembly of tibial baseplate 12 to tibial bearing component 14. Chamfer 32 is formed in peripheral wall 25, such that chamfer 32 forms angle α (FIG. 8) with the distal or bone-contacting surface 35 of tibial plateau 18. In the illustrated embodiment, chamfer 32 defines a substantially linear sagittal cross-sectional profile, with angle α between about 35 degrees and about 55 degrees. In addition, it is contemplated that chamfer 32 may have an arcuate profile in a sagittal, coronal and/or transverse plane, and may include convex or concave curvature as required or desired for a particular application.


2. Progressive Peripheral Growth Between Implant Sizes


In addition to the asymmetry of each individual size/embodiment of tibial baseplate 12, described in detail above, the present disclosure also provides asymmetry in the way periphery 200 grows from one size to the next. Advantageously, this asymmetric peripheral growth accommodates observed growth trends in tibias T of differently-sized patients, while also preserving the optimal fit and coverage provided by baseplate 12, and offering the other advantages of designs in accordance with the present disclosure as described herein.


In symmetrical peripheral growth, a larger size of baseplate is a scaled-up version of a smaller size and vice-versa. In the present asymmetrical peripheral growth, by contrast, certain parameters of tibial baseplate 12 grow faster than others as the overall size of the baseplate gets larger (i.e., from smallest size 1/A through largest size 9/J). Thus, differently-sized components made in accordance with the present disclosure are not proportional to one another in all respects, in that a larger tibial prosthesis is not proportionally larger than a smaller tibial prosthesis in all aspects.


Referring now to FIG. 2B, periphery 200X defines centroid CX, which is medially biased with respect to home axis AH owing to medial surface area SAM being larger than lateral surface area SAL (as described in detail above). Posterior-medial distance DMPX extends from centroid CX toward the posterior-medial “corner” of periphery 200X (i.e., toward posterior-medial corner arc 224, shown in FIG. 3A and described above) at an angle of 130 counter-clockwise degrees from home axis AH. Similarly, posterior-lateral distance DLPX extends from centroid CX toward the posterior-lateral “corner” of periphery 200X (i.e., toward posterior-lateral corner arc 214, shown in FIG. 3A and described above) at an angle of 120 clockwise degrees from home axis AH. The posterior-lateral and posterior-medial corners are defined in a similar fashion as the anterior-lateral and anterior-medial corners, described in detail above. Moreover, while the asymmetric posterior-medial and posterior lateral growth among consecutive sizes is described below with respect to distances DLPX, DMPX, such growth occurs in the entire area occupied by the posterior-medial and posterior-lateral corners.


As illustrated in FIG. 2A and shown in Table 6 below, lateral- and medial-posterior distances DLPX, DMPX do not grow linearly as smallest size 1/A progresses among consecutive sizes to eventually reach largest size 9/J. Rather, lateral- and medial-posterior distances DLPX, DMPX exhibit an increase in the magnitude of growth as the sizes progress consecutively from size 1/A to size 9/J. This non-linear, asymmetric growth is illustrated in the graphs of FIGS. 2C and 2D and in Table 6 below.









TABLE 6







Growth of the Posterior-Medial and Posterior-Lateral


Corners of Baseplate Periphery (FIGS. 2A and 2B)










Growth in medial-posterior
Growth in lateral-posterior



distance DMPx from
distance (DLPx) from


Size
centroid (Cx), compared
centroid (Cx), compared


(X)
to next-smaller size, mm
to next-smaller size, mm





1




2
2.42
2.48


3
2.56
2.8


4
2.76
2.55


5
2.86
3.26


6
3.71
2.64


7
3.28
2.83


8
3.52
2.28


9
3.76
3.29









In FIG. 2C, the amount of growth in DMPX is plotted against size no. X. As illustrated, the family of tibial baseplates 12 illustrated in FIG. 2A exhibit a steadily increasing growth in DMPX, with nearly 20% average increase in growth from one size to the next consecutive size (as represented by the slope of the linear trend line having equation y=0.1975x+2.0225).


In FIG. 2D, the amount of growth in DLPX is plotted against size no. X, and illustrates a smaller, but still positive growth increase across baseplate sizes. More specifically, the family of tibial baseplates 12 illustrated in FIG. 2A exhibit a nearly 4% average increase in growth from one size to the next consecutive size (as represented by the slope of the linear trend line having equation y=0.0392x+2.5508).


As used herein, a “family” of prostheses refers to a set or kit of prostheses sharing common geometrical and/or performance characteristics. For example, the family of nine tibial baseplates whose peripheries 200X are shown in FIG. 2A share a common asymmetry as described herein, such that each tibial baseplate is adapted to provide substantial tibial coverage, facilitate proper implant rotation and avoid impingement with various soft tissues of the knee. Typically, a family of prostheses includes a plurality of differently-sized components, with consecutively larger/smaller components sized to accommodate a variety of differently-sized bones. In the exemplary embodiments of the present disclosure, a size “1” or “A” prosthesis is the smallest prosthesis of the family, a size “9” or “J” prosthesis is the largest prosthesis of the family, and each of the intermediate sizes “2” or “B” through “8” or “H” are consecutively larger sizes.


Advantageously, in the family or kit of prosthesis peripheries shown in FIG. 2A, each tibial baseplate 12 (FIG. 1A) having periphery 200X provides a close match to a particular subset of patient tibias T having a unique size and shape. Particular features of periphery 200X have been designed with non-linear growth which is calculated to provide the closest possible fit for the largest number of particular natural geometries found in anatomic tibias T, as described in detail herein. This close fit allows for maximum coverage of the resected proximal tibial periphery 200X, by accommodating the non-linear changes which may occur across anatomic tibial periphery sizes. Lateral- and medial-posterior distances DLPX, DMPX are exemplary non-linear growth parameters found in a family of tibial baseplates 12, and are reflective of non-linear growth in mediolateral extent DMLX and anteroposterior extents DAPMX and DAPLX across the various sizes.


3. PCL Cutout Aligned with Home Axis and Associated Technique


In the illustrated embodiment, tibial plateau 18 includes PCL cutout 28 disposed between compartments 20, 22, as described above. PCL cutout leaves PCL attachment point CP accessible, thereby allowing the PCL to pass therethrough during and after implantation of tibial baseplate 12. Tibial bearing component 14 (FIG. 5) may similarly include cutout 30.


Thus, the illustrated embodiment of tibial prosthesis 10 is adapted for a cruciate retaining (CR) surgical procedure, in which the posterior cruciate ligament is not resected during implantation of tibial prosthesis 10. Further, as noted above, home axis AH includes reference to PCL attachment point CP when tibial baseplate 12 is mounted upon tibia T. In order to facilitate alignment of home axis AH with respect to tibial baseplate 12 and tibia T, alignment indicia 70A, 70P (FIGS. 4A and 4B) may be marked on proximal surface 34 and/or peripheral wall 25. When tibial baseplate 12 is implanted (as described below), anterior alignment indicia 70A (FIGS. 4A and 4B) is aligned with anterior point CA at the “medial third” of the anterior tibial tubercle T, and posterior alignment indicia 70P is aligned with the natural PCL attachment point CP of tibia T.


However, it is contemplated that a prosthesis in accordance with the present disclosure may be made for a design in which the posterior cruciate ligament is resected during surgery, such as “posterior stabilized” (PS) or “ultra congruent” (UC) designs. The PS and UC designs may exclude PCL cutout 30 in bearing component 14, thereby obviating the need for PCL cutout 28 in tibial baseplate 12. Continuous material may instead occupy cutout 28 (as schematically shown in FIG. 3D). Moreover, it is contemplated that PCL cutouts 28, 30 may have any shape and/or size within the scope of the present disclosure. For example, PCL cutouts 28, 30 may be asymmetrical with respect to an anteroposterior axis. For purposes of the present disclosure “bisecting” an asymmetric PCL cutout with an anteroposterior axis refers to dividing such cutout into two equal areas for a given anteroposterior section of the anteroposterior axis


4. Tibial Bearing Component and Deep Flexion Enablement


Turning again to FIG. 1A, tibial bearing component 14 includes lateral portion 39, medial portion 41, inferior surface 36 adapted to couple to tibial baseplate 12, and superior surface 38 adapted to articulate with condyles of a femoral component (such as femoral component 60 shown in FIG. 8 and described in detail below). Superior surface 38 includes lateral articular surface 40 in lateral portion 39 and medial articular surface 42 in medial portion 41, with eminence 44 (FIG. 5) disposed between articular surfaces 40, 42. Referring to FIG. 5, eminence 44 generally corresponds in shape and size with a natural tibial eminence of tibia T prior to resection.


Referring now to FIG. 1A, tibial plateau 18 of tibial baseplate 12 further includes a distal or bone contacting surface 35 and an opposing proximal or superior surface 34, with superior surface 34 having raised perimeter 24 and locking mechanism 26 formed between lateral and medial compartments 20, 22. Raised perimeter 24 and locking mechanism 26 cooperate to retain tibial bearing component 14 upon tibial baseplate 12, as described in detail below. Exemplary baseplate locking mechanisms are described in U.S. provisional patent application Ser. Nos. 61/367,374 and 61/367,375, both entitled TIBIAL PROSTHESIS and both incorporated by reference as stated above.


Inferior surface 36 of tibial bearing component 14 includes recess 46 at the periphery thereof and a tibial bearing locking mechanism (not shown) disposed between lateral and medial articular surfaces 40, 42. Exemplary bearing component locking mechanisms are disclosed in U.S. provisional patent application Ser. Nos. 61/367,374 and 61/367,375, both entitled TIBIAL PROSTHESIS. Recess 46 is sized and positioned to correspond with raised perimeter 24 of tibial plateau 18, and the tibial bearing locking mechanism cooperates with locking mechanism 26 of tibial plateau 18 to fix tibial bearing component 14 to tibial baseplate 12 in a desired position and orientation as described in detail below. However, it is contemplated that tibial bearing component 14 may be affixed to baseplate 12 by any suitable mechanism or method within the scope of the present disclosure, such as by adhesive, dovetail tongue/groove arrangements, snap-action mechanisms, and the like.


As best seen in FIGS. 1B, 5 and 8, the outer periphery of tibial bearing component 14 generally corresponds with the outer periphery of tibial plateau 18, except for the posteromedial extent of plateau 18 as compared with tibial bearing component 14. The anterolateral “corner” of tibial bearing component 14 defines radius R3 (FIG. 5) having a generally common center with radius R2L of baseplate 12 in a transverse plane, i.e., radii R2L and R3 are substantially coincident in a plan view. Similarly, the anteromedial “corner” of tibial bearing component 14 defines radius R4 having a generally common center with radius R1R of baseplate 12 in a transverse plane, i.e., radii R1R and R4 are substantially coincident in a plan view.


R3 defines a slightly smaller radial length as compared to R2L, and R4 defines a slightly smaller radial length as compared to R1R, such that the anterior portion of perimeter wall 54 of tibial bearing component 14 is set back from the anterior portion of peripheral wall 25 (i.e., from anterior edge 202 and adjacent arcs, as described above) of tibial baseplate 12. As with the above-described comparison between radii R2L and R1R, anteromedial radius R4 is substantially larger than anterolateral radius R3.


Given that medial portion 41 of tibial bearing component 14 has a lesser anteroposterior extent compared to medial compartment 22 of tibial plateau 18, medial portion 41 must be biased anteriorly in order for the anterior-medial “corners” of tibial bearing component 14 and tibial plateau 18 to coincide as shown in FIG. 5. In view of this anterior bias, it may be said that tibial bearing component 14 is asymmetrically oriented upon tibial plateau 18. More particularly, although lateral articular surface 40 is generally centered with respect to lateral compartment 20 of tibial plateau 18, medial articular surface 42 is anteriorly biased with respect to medial compartment 22 of tibial plateau 18 in order to leave chamfer 32 exposed at the posterior-lateral corner. This asymmetric mounting of tibial bearing component 14 upon tibial plateau 18 ensures a desired articular interaction between tibial prosthesis 10 and femoral component 60, as described in detail below.


Tibial plateau 18 of tibial baseplate 12 deviates from the periphery of tibial bearing component 14 in the posteromedial portion of each component, leaving medial portion 41 incongruent with medial compartment 22 of tibial baseplate 12. More particularly, tibial plateau 18 extends posteromedially to substantially cover the proximal resected surface of tibia T, as shown in FIG. 5 and described in above, while tibial bearing component 14 does not extend posteromedially beyond the superior terminus of chamfer 32 (i.e., tibial bearing component 14 does not “overhang” chamfer 32). In addition, tibial bearing component 14 includes chamfer 50 formed in peripheral wall 54, with chamfer 50 having a profile and geometrical arrangement corresponding with chamfer 32 of tibial plateau 18. More particularly, when tibial bearing component 14 is assembled to tibial baseplate 12 as shown in FIGS. 1B and 8, the anterior orientation or “bias” of the medial portion of tibial bearing component 14 (as described above) aligns chamfers 32, 50, which in turn cooperate to create a substantially continuous chamfer extending from tibia T to medial articular surface 42. Referring to FIG. 8, chamfers 32, 50 further cooperate to define void 52 formed between femur F and tibial plateau 18 when tibial prosthesis 10 is in a deep flexion orientation. In the illustrated embodiment of FIG. 8, the deep flexion orientation is defined by angle β between anatomic tibia axis AT and anatomic femoral axis AF of up to about 25 degrees to about 40 degrees, for example (i.e., about 140 degrees to 155 degrees of flexion or more).


Advantageously, void 52 cooperates with the “pulled back” or incongruent posterior medial edge 206 and posterior medial corner 224, as compared to a typical tibial periphery (described above), to allow the deep flexion orientation to be achieved without impingement of femoral component 60 and/or femur F upon tibial plateau 18 and/or tibial bearing component 14. Soft tissues in the region of void 52 are therefore also accommodated with little or no impingement on the surrounding components.


In addition, the relatively large size of tibial plateau 18 (covering a large proportion of the resected proximal surface of tibia T) also allows tibial bearing component 14 to be relatively large, so that tibial bearing component 14 provides sufficient non-articular surface area at chamfers 32, 50 and around the periphery of lateral and medial articular surfaces 40, 42 to allow relatively large-radius, rounded transitions between articular surfaces 40, 42 and peripheral wall 54 of tibial bearing component 14. These gradual, large-radius transitions prevent undue friction between tibial prosthesis 10 and any surrounding soft tissues which may remain in place after implantation of the prosthesis, such as the iliotibial (IT) band.


In certain ranges of prosthesis articulation, for example, the human iliotibial (IT) band may touch the anterolateral “corner”, i.e., the portion of tibial bearing component 14 having radius R3. Because the anterolateral extent of tibial bearing component 14 follows the anterolateral extent of tibial plateau 18 (as described above), the transition between lateral articular surface 40 and peripheral wall 54 at the point of contact between an IT band and tibial bearing component 14 can have a relatively large convex portion while still leaving sufficient concave space for articular surface 40. This large convex portion results in a large contact area if the IT band does contact tibial bearing component 14, which in turn results in relatively low pressures on the IT band. Further, the anterolateral “pull back” or incongruence between the anterior-lateral corner are 210 of periphery 200 and a typical tibial periphery, described in detail above, allows the corresponding anterior-lateral corner of bearing component 14 to maintain separation from the IT band through a wide range of flexion, and low contact pressures where contact does occur.


However, to any such contact between the IT band and tibial bearing component 14 may be avoided or minimized by designing periphery 200 such that anterior-lateral corner arc 210 and/or lateral edge arc 212 is brought away from the expected periphery of a typical tibia T (as calculated from anatomical data, described above). This extra spacing designed into periphery 200 provides extra clearance for the iliotibial band. In addition, this extra clearance assures that the substantial proportion of prospective patients lacking Gerdy's tubercle, which is an eminence located at the anterior-lateral portion of tibia T, will not experience any “overhang” of tibial plateau 18 beyond the anatomic periphery of resected tibia T.


Thus, generally speaking, tibial prosthesis 10 can be considered “soft tissue friendly” because the edges of tibial bearing component 14 and tibial plateau 18, including chamfers 32, 50, are smooth and rounded, so that any soft tissue coming into contact with these edges will be less likely to chafe or abrade.


Advantageously, the relatively large inferior/distal surface area of tibial plateau 18 facilitates a large amount of bone ingrowth where bone ingrowth material is provided in tibial baseplate 12. For example, baseplate 12 may also be constructed of, or may be coated with, a highly porous biomaterial. A highly porous biomaterial is useful as a bone substitute and as cell and tissue receptive material. A highly porous biomaterial may have a porosity as low as 55%, 65%, or 75% or as high as 80%, 85%, or 90%. An example of such a material is produced using Trabecular Metal™ Technology generally available from Zimmer, Inc., of Warsaw, Ind. Trabecular Metal™ is a trademark of Zimmer, Inc. Such a material may be formed from a reticulated vitreous carbon foam substrate which is infiltrated and coated with a biocompatible metal, such as tantalum, by a chemical vapor deposition (“CVD”) process in the manner disclosed in detail in U.S. Pat. No. 5,282,861 to Kaplan, the entire disclosure of which is expressly incorporated herein by reference. In addition to tantalum, other metals such as niobium, or alloys of tantalum and niobium with one another or with other metals may also be used.


Generally, the porous tantalum structure includes a large plurality of ligaments defining open spaces therebetween, with each ligament generally including a carbon core covered by a thin film of metal such as tantalum, for example. The open spaces between the ligaments form a matrix of continuous channels having no dead ends, such that growth of cancellous bone through the porous tantalum structure is uninhibited. The porous tantalum may include up to 75%, 85%, or more void space therein. Thus, porous tantalum is a lightweight, strong porous structure which is substantially uniform and consistent in composition, and closely resembles the structure of natural cancellous bone, thereby providing a matrix into which cancellous bone may grow to provide fixation of implant [#] to the patient's bone.


The porous tantalum structure may be made in a variety of densities in order to selectively tailor the structure for particular applications. In particular, as discussed in the above-incorporated U.S. Pat. No. 5,282,861, the porous tantalum may be fabricated to virtually any desired porosity and pore size, and can thus be matched with the surrounding natural bone in order to provide an improved matrix for bone ingrowth and mineralization.


5. Trial Tibial Components


Tibial prosthesis 10 may be provided in a variety of sizes and configurations to accommodate different bone sizes and geometries. The choice of one particular size may be planned preoperatively such as through preoperative imaging and other planning procedures. Alternatively, an implant size may be chosen, or a previous size choice modified, intraoperatively. To facilitate proper intraoperative selection of a particular size for tibial prosthesis 10 from among the family of sizes shown in FIG. 2A, and to promote proper orientation of the chosen prosthesis 10, tibial prosthesis 10 may be part of a kit including one or more template or “sizing” components.


Referring now to FIGS. 6 and 7, trial prosthesis 100 may be temporarily coupled to tibia T for intraoperative sizing evaluation of tibial prosthesis 10 and initial steps in the implantation of tibial prosthesis 10. Trial prosthesis 100 is one of a set of trial prostheses provided as a kit, with each trial prosthesis having a different size and geometrical configuration. Each trial prosthesis in the set of trial prostheses corresponds to a permanent prosthesis 10, such as sizes 1/A-9/J of tibial baseplate 12 as described above.


For example, as shown in FIG. 6, trial prosthesis 100 defines superior surface 112 generally corresponding in size and shape to proximal surface 34 of tibial plateau 18, and including lateral portion 102 and medial portion 104. Superior surface 112 is asymmetrical about home axis AH, with lateral portion 102 having a generally shorter overall anteroposterior extent as compared to medial portion 104 (which includes void indicator 106, discussed below). In addition, the anterolateral “corner” of lateral portion 102 defines radius R2L, which is identical to radius R2L of tibial plateau 18, while the anteromedial “corner” of medial portion 104 defines radius R1R, which is identical to radius R1R of tibial plateau 18 and greater than radius R2L.


Moreover, perimeter wall 114 of trial prosthesis 100 is substantially identical to peripheral wall 25 of tibial plateau 18, and therefore defines periphery 200 with the same features and shapes of perimeter 200 described above with respect to tibial plateau 18. Thus, trial prosthesis 100 is asymmetrical about home axis AH in a similar manner to tibial plateau 18 of tibial baseplate 12, with the nature of this asymmetry changing across the various other sizes of tibial prosthesis provided in the kit including trial prosthesis 100.


In an alternative embodiment, a trial prosthesis may be provided which extends completely to the posterior-medial edge of the natural tibial resection periphery. Thus, such a trial would substantially completely cover the resected tibial surface, thereby aiding in determination of a proper rotational orientation of the trial (and, therefore, of the final tibial baseplate 12). In this alternative embodiment, the trial prosthesis lacks the posterior-medial “pull back” of tibial plateau 18, described above.


Trial prosthesis 100 includes void indicator 106 disposed at the posterior portion of medial portion 104, consuming a given posteromedial area of superior surface 34 and peripheral wall 25. Void indicator 106 indicates where void 52 (discussed above) will be located with respect to tibia T after implantation of tibial prosthesis 10. Void indicator 106 facilitates proper rotational and spatial orientation of trial prosthesis 100 on the resected proximal surface of tibia T by allowing a surgeon to visually match tibial bearing component 14 with trial prosthesis 100, as described in detail below. In the illustrated embodiment, void indicator 106 is an area of visual and/or tactile contrast with the remainder of tibial plateau 18. This contrast may include, for example, a contrasting color, texture, surface finish, or the like, or may be formed by a geometric discrepancy such as a step or lip, for example.


Referring specifically to FIG. 6, trial prosthesis 100 further includes a plurality of peg hole locators 108 corresponding to the proper location for peg holes in tibia T to receive pegs (not shown) extending inferiorly from tibial plateau 18 of tibial baseplate 12. Advantageously, peg hole locators 108 allow a surgeon to demarcate the proper center for peg holes in tibia T once the proper size and orientation for trial prosthesis 100 has been found, as discussed in detail below. Alternatively, peg hole locators 108 may be used as drill guides to drill appropriately positioned peg holes while trial prosthesis is still positioned on tibia T.


6. Tibial Prosthesis Implantation


In use, a surgeon first performs a resection of tibia T using conventional procedures and tools, as are well-known in the art. In an exemplary embodiment, a surgeon will resect the proximal tibia to leave a planar surface prepared for receipt of a tibial baseplate. This planar surface may define a tibial slope, which is chosen by the surgeon. For example, the surgeon may wish to perform a resection resulting in positive tibial slope in which the resected tibial surface slopes proximally from posterior to anterior (i.e., the resected surface runs “uphill” from posterior to anterior). Alternatively, the surgeon may instead opt for negative tibial slope in which the resected tibial surface slopes distally from posterior to anterior (i.e., the resected surface runs “downhill” from posterior to anterior). Varus or valgus slopes may also be employed, in which the resected surface slopes proximally or distally from medial to lateral. The choice of a tibial and/or varus/valgus slope, and the amount or angle of such slopes, may depend upon a variety of factors including correction of deformities, mimicry of the native/preoperative tibial slope, and the like.


In an exemplary embodiment, keel 16 (FIG. 4B) defines a 5-degree, anteriorly-extending angle with respect to bone-contacting surface 35 of tibial plateau 18. Tibial baseplate 12 is appropriate for use with a positive tibial slope of as little as zero degrees and as much as 9 degrees, and with a varus or valgus slope of up to 3 degrees. However, it is contemplated that a tibial baseplate made in accordance with the present disclosure may be used with any combination of tibial and/or varus/valgus slopes, such as by changing the angular configuration of the keel with respect to the bone-contacting surface.


With a properly resected proximal tibial surface, the surgeon selects trial prosthesis 100 from a kit of trial prostheses, with each prosthesis in the kit having a different size and geometrical configuration (as discussed above). Trial prosthesis 100 is overlaid on the resected surface of tibia T. If trial prosthesis 100 is appropriately sized, a small buffer zone 110 of exposed bone of resected tibia T will be visible around the periphery of trial prosthesis 100. Buffer 110 is large enough to allow a surgeon to rotate and/or reposition trial prosthesis 100 within a small range, thereby offering the surgeon some flexibility in the final positioning and kinematic profile of tibial prosthesis 10. However, buffer 110 is small enough to prevent trial prosthesis 100 from being rotated or moved to an improper location or orientation, or from being implanted in such as way as to produce excessive overhang of the edge of trial prosthesis 100 past the periphery of the resected tibial surface. In one exemplary embodiment, for example, trial prosthesis may be rotated from a centered orientation by up to +/−5 degrees (i.e., in either direction), though it is contemplated that such rotation may be as much as +/−10 degrees or +/−15 degrees.


To aid in rotational orientation, trial prosthesis may include anterior and posterior alignment indicia 70A, 70P, which are the same marks in the same location as indicia 70A, 70P provided on tibial plateau 18 as described above. The surgeon can align indicia 70A with anterior point CA and indicia 70P with PCL attachment point CP, in similar fashion as described above, to ensure the anatomical and component home axes AH are properly aligned. Alternatively, a surgeon may use indicia 70A, 70P to indicate a desired deviance from alignment with home axis AH. As noted above, deviation of up to 5 degrees is envisioned with the exemplary embodiments described herein. A surgeon may choose to orient indicia 70A, 70P to another tibial landmark, such as the middle of the patella or the medial end of tibial tubercle B.


Thus, the large coverage of trial prosthesis 100 (and, concomitantly, of tibial plateau 18) ensures that tibial baseplate 12 will be properly positioned and oriented on tibia T upon implantation, thereby ensuring proper kinematic interaction between tibial prosthesis 10 and femoral component 60. If buffer zone 110 is either nonexistent or too large, another trial prosthesis 100 is selected from the kit and compared in a similar fashion. This process is repeated iteratively until the surgeon has a proper fit, such as the fit illustrated in FIGS. 6 and 7 between trial prosthesis 100 and tibia T.


With the proper size for trial prosthesis 100 selected and its orientation on tibia T settled, trial prosthesis 100 is secured to tibia T, such as by pins, screws, temporary adhesive, or any other conventional attachment methods. Once trial prosthesis is so secured, other trial components, such as trial femoral components and trial tibial bearing components (not shown) may be positioned and used to articulate the leg through a range of motion to ensure a desired kinematic profile. During such articulation, void indicator 106 indicates to the surgeon that any impingement of femoral component 60 and/or femur F upon trial prosthesis 100 at void indicator 106 will not occur when tibial prosthesis 10 is implanted. Once the surgeon is satisfied with the location, orientation and kinematic profile of trial prosthesis 100, peg hole locators 108 may be used to demarcate the appropriate location of peg holes in tibia T for tibial baseplate 12. Such peg holes may be drilled in tibia T with trial prosthesis 100 attached, or trial prosthesis 100 may be removed prior to drilling the holes.


With tibia T prepared for receipt of tibial prosthesis 10, tibial baseplate 12 may be provided by the surgeon (such as from a kit or surgical inventory), and is implanted on tibia T, with pegs fitting into holes previously identified and demarcated using peg hole locators 108 of trial prosthesis 100. Tibial baseplate 12 is selected from the family of tibial baseplates illustrated in FIG. 2A to correspond with the trial component 100 chosen, which ensures that tibial plateau 18 will cover a large proportion of the resected proximal surface of tibia T, as trial prosthesis 100 did prior to removal. Tibial baseplate is affixed to tibia T by any suitable method, such as by keel 16 (FIG. 4B), adhesive, bone-ingrowth material, and the like.


With tibial baseplate 12 installed, tibial bearing component 14 may be coupled with tibial baseplate 12 to complete tibial prosthesis 10. However, once attached, tibial bearing component 14 does not fully cover tibial plateau 18 of tibial baseplate 12. Rather, tibial bearing component 14 leaves a posteromedial portion of tibial baseplate 12 uncovered to create void 52 (as shown in FIG. 8 and discussed above). Thus, a surgeon may wish to verify that this anterior-biased, “asymmetrical” orientation of medial articular surface 42 is proper prior to permanent affixation of tibial bearing component 14 to tibial baseplate 12.


To accomplish such verification, tibial bearing component 14 is placed side-by-side with trial prosthesis 100, with inferior surface 36 of tibial bearing component 14 in contact with superior surface 112 of trial prosthesis 100. Tibial bearing component 14 will substantially cover superior surface 112, but will not cover void indicator 106. Put another way, peripheral wall 54 of tibial bearing component 14 will trace perimeter wall 114 of tibial trial prosthesis 100, excluding the posteromedial area defined by void indicator 106. If inferior surface 36 of tibial bearing component 14 is a match with superior surface 112 of trial prosthesis 100 except for void indicator 106 (which is left uncovered by tibial bearing component 14), then tibial bearing component 14 is the proper size component and may be confidently installed upon tibial plateau 18 of tibial baseplate 12.


Tibial baseplate 12 may then be implanted upon the proximal surface of tibia T in accordance with accepted surgical procedures. Exemplary surgical procedures and associated surgical instruments are disclosed in “Zimmer LPS-Flex Fixed Bearing Knee, Surgical Technique,” “NEXGEN COMPLETE KNEE SOLUTION, Surgical Technique for the CR-Flex Fixed Bearing Knee” and “Zimmer NexGen Complete Knee Solution Extramedullary/Intramedullary Tibial Resector, Surgical Technique” (collectively, the “Zimmer Surgical Techniques”), copies of which are submitted on even date herewith, the entire disclosures of which are hereby expressly incorporated by reference herein.


When the surgeon is satisfied that tibial bearing component 14 is properly matched and fitted to the installed tibial baseplate 12, bearing component 14 is secured using locking mechanism 26 and the corresponding tibial bearing locking mechanism an appropriate instrumentation (not shown). Proper location and rotational orientation of tibial bearing component 14 upon tibial plateau 18 is ensured by raised perimeter 24 cooperating with recess 46, and locking mechanism 26 cooperating with the corresponding tibial bearing locking mechanism (not shown). Such proper orientation results in medial articular surface 42 being generally anteriorly disposed with respect to medial compartment 22 of tibial plateau 18.


Femoral component 60 may be affixed to a distal end of femur F, if appropriate, using any conventional methods and/or components. Exemplary surgical procedures and instruments for such affixation are disclosed in the Zimmer Surgical Techniques, incorporated by reference above. Femur F and tibia T may then be articulated with respect to one another to ensure that neither femur F nor femoral component 60 impinges upon tibial baseplate 12 and/or tibial bearing component 14 in deep flexion, such as at a flexion angle β of 155° as shown in FIG. 8. When the surgeon is satisfied with the location, orientation and kinematic profile of tibial prosthesis 10, the knee replacement surgery is completed in accordance with conventional procedures.


While this invention has been described as having an exemplary design, the present invention can be further modified within the spirit and scope of this disclosure. This application is therefore intended to cover any variations, uses, or adaptations of the invention using its general principles. Further, this application is intended to cover such departures from the present disclosure as come within known or customary practice in the art to which this invention pertains and which fall within the limits of the appended claims.

Claims
  • 1. A tibial baseplate comprising: a distal surface comprising a bone contacting surface;a proximal surface comprising a tibial bearing engagement surface generally opposite the distal surface; anda peripheral wall extending between the distal and the proximal surface, the peripheral wall defining:an anterior edge;a lateral periphery including: a lateral edge defining a substantially perpendicular tangent with respect to the anterior edge,an anterior-lateral corner traversing an angular sweep between the anterior edge and the lateral edge to define an anterior-lateral corner edge length, anda posterior-lateral corner extending away from the lateral edge and the anterior-lateral corner; anda medial periphery, wherein the medial periphery is asymmetric with respect to the lateral periphery about an anteroposterior axis, the medial periphery including: a medial edge defining a substantially perpendicular tangent with respect to the anterior edge,an anterior-medial corner traversing an angular sweep between the anterior edge and the medial edge to define an anterior-medial corner edge length that is longer than the anterior-lateral corner edge length, in which the angular sweep between the anterior edge and the medial edge is similar to the angular sweep between the anterior edge and the lateral edge, anda posterior-medial corner extending away from the medial edge and the anterior-medial corner.
  • 2. The tibial baseplate of claim 1, wherein: the lateral edge comprises a lateral edge arc defining a lateral edge radius, the anterior-lateral corner comprises an anterior-lateral corner arc defining an anterior-lateral corner radius, andthe lateral edge radius is larger than the anterior-lateral corner radius by at least 42%.
  • 3. The tibial baseplate of claim 2, wherein the lateral edge radius is larger than the anterior-lateral corner radius by up to 142%.
  • 4. The tibial baseplate of claim 1, wherein: the lateral edge comprises a lateral edge arc defining a lateral edge radius, the posterior-lateral corner comprises a posterior-lateral corner arc defining a posterior-lateral corner radius, andthe lateral edge radius is larger than the posterior-lateral corner radius by at least 198%.
  • 5. The tibial baseplate of claim 4, wherein the lateral edge radius is larger than the posterior-lateral corner radius by up to 324%.
  • 6. The tibial baseplate of claim 1, wherein: the medial edge comprises a medial edge arc defining a medial edge radius,the anterior-medial corner comprises an anterior-medial corner arc defining an anterior-medial corner radius, andthe medial edge radius is larger than the anterior-medial corner radius by up to 74%.
  • 7. The tibial baseplate of claim 1, wherein: the medial edge comprises a medial edge arc defining a medial edge radius,the posterior-medial corner comprises a posterior-medial corner arc defining a posterior-medial corner radius, andthe medial edge radius is larger than the posterior-medial corner radius by up to 61%.
  • 8. The tibial baseplate of claim 1, wherein: the anterior-medial corner defines an anterior-medial corner arc defining an anterior-medial corner radius, the anterior-lateral corner defines an anterior-lateral corner arc defining an anterior-lateral corner radius,the anterior-medial corner radius is different from the anterior-lateral corner radius.
  • 9. The tibial baseplate of claim 1, wherein the lateral periphery defines an arcuate anterior section between the anterior edge and the anterior-lateral corner.
  • 10. The tibial baseplate of claim 1, wherein: the lateral periphery defines a plurality of adjacent lateral arcs,the medial periphery defines a plurality of adjacent medial arcs, the plurality of adjacent lateral arcs are greater in number as compared to the plurality of adjacent medial arcs.
  • 11. The tibial baseplate of claim 10, wherein the plurality of adjacent lateral arcs comprises at least five adjacent lateral arcs.
  • 12. The tibial baseplate of claim 10, wherein the plurality of adjacent medial arcs comprises up to three adjacent lateral arcs.
  • 13. The tibial baseplate of claim 1, wherein: the anterior-lateral corner comprises an anterior-lateral corner arc defining an anterior-lateral corner radius, andthe anterior-medial corner comprises an anterior-medial corner arc defining an anterior-medial corner radius,the anterior-medial corner radius is larger than the anterior-lateral corner radius.
  • 14. The tibial baseplate of claim 1, wherein the tibial baseplate is sized and shaped to cover between about 60% and about 90% of a resected proximal surface of a tibia to create a buffer zone on all sides between a perimeter of a surface of the tibia and the peripheral wall.
  • 15. The tibial baseplate of claim 1, wherein: the anterior-lateral corner comprises an anterior-lateral corner arc defining an anterior-lateral corner radius having a first radius center, andthe anterior-medial corner comprises an anterior-medial corner arc defining an anterior-medial corner radius having a second radius center,the tibial baseplate in combination with a tibial bearing component is mountable to the tibial baseplate, the tibial bearing component comprising:a lateral portion defining an anterior-lateral bearing corner defining a third radius having a third radius center, the third radius center is substantially coincident with the first radius center in a transverse plane when the tibial bearing component is mounted to the tibial baseplate, the third radius is smaller than the anterior-lateral corner radius; and a medial portion defining an anterior-medial bearing corner defining a fourth radius having a fourth radius center, the fourth radius center is substantially coincident with the second radius center in the transverse plane when the tibial bearing component is mounted to the tibial baseplate, the fourth radius is smaller than the anterior-medial corner radius, the fourth radius substantially larger than the third radius.
  • 16. The tibial baseplate of claim 1, wherein the anteroposterior axis is aligned with a home axis when the tibial baseplate is mounted to a tibia, the home axis defined as a line extending from a posterior point at a geometric center of an attachment area between a posterior cruciate ligament and the tibia, to an anterior point disposed on an anterior tubercle of the tibia, the tubercle having a tubercle width, the anterior point disposed on the tubercle at a location medially spaced from a midpoint of the tubercle by an amount equal to W/6.
  • 17. The tibial baseplate of claim 1, wherein: the tibial baseplate includes a PCL cutout area generally opposite the anterior edge and between the lateral periphery and the medial periphery, andthe anteroposterior axis bisects the anterior edge and bisects the PCL cutout area.
  • 18. The tibial baseplate of claim 1, wherein: the medial periphery cooperates with the anteroposterior axis to bound a medial surface area,the lateral periphery cooperates with the anteroposterior axis to bound a lateral surface area, andthe medial surface area is larger than the lateral surface area.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/827,654, filed on Nov. 30, 2017 and entitled ASYMMETRIC TIBIAL COMPONENTS FOR A KNEE PROSTHESIS, now issued as U.S. Pat. No. 10,470,889, which is a continuation of U.S. patent application Ser. No. 14/034,937, filed on Sep. 24, 2013 and entitled ASYMMETRIC TIBIAL COMPONENTS FOR A KNEE PROSTHESIS, now issued as U.S. Pat. No. 9,861,490, which is a continuation of U.S. patent application Ser. No. 13/189,336, filed on Jul. 22, 2011 and entitled ASYMMETRIC TIBIAL COMPONENTS FOR A KNEE PROSTHESIS, now issued as U.S. Pat. No. 8,613,775, which claims the benefit under Title 35, U.S.C. § 119(e) of U.S. Provisional Patent Application Ser. No. 61/381,800, filed on Sep. 10, 2010 and entitled TIBIAL PROSTHESIS FACILITATING ROTATIONAL ALIGNMENT, and U.S. Provisional Patent Application Ser. No. 61/367,375, filed on Jul. 24, 2010 and entitled TIBIAL PROSTHESIS, the entire disclosures of which are hereby expressly incorporated by reference herein.

US Referenced Citations (498)
Number Name Date Kind
3774244 Walker Nov 1973 A
4016606 Murray et al. Apr 1977 A
4257129 Volz Mar 1981 A
4340978 Buechel et al. Jul 1982 A
4501266 McDaniel Feb 1985 A
4568348 Johnson et al. Feb 1986 A
4711639 Grundei Dec 1987 A
4714474 Brooks, Jr. et al. Dec 1987 A
4759767 Lacey Jul 1988 A
4769040 Wevers Sep 1988 A
4770661 Oh Sep 1988 A
4795468 Hodorek et al. Jan 1989 A
4822365 Walker et al. Apr 1989 A
4936853 Fabian et al. Jun 1990 A
4944756 Kenna Jul 1990 A
4944757 Martinez et al. Jul 1990 A
4950298 Gustilo et al. Aug 1990 A
4959071 Brown et al. Sep 1990 A
4963152 Hofmann et al. Oct 1990 A
5007933 Sidebotham et al. Apr 1991 A
5047057 Lawes Sep 1991 A
5047058 Roberts et al. Sep 1991 A
5059216 Winters Oct 1991 A
5061271 Van Zile Oct 1991 A
5071438 Jones et al. Dec 1991 A
5108442 Smith Apr 1992 A
5116375 Hofmann May 1992 A
5133758 Hollister Jul 1992 A
5137536 Koshino Aug 1992 A
5147405 Van Zile Sep 1992 A
5171283 Pappas et al. Dec 1992 A
5192328 Winters Mar 1993 A
5194066 Van Zile Mar 1993 A
5197488 Kovacevic Mar 1993 A
5219362 Tuke et al. Jun 1993 A
5226915 Bertin Jul 1993 A
5236461 Forte Aug 1993 A
5246459 Elias Sep 1993 A
5271737 Baldwin et al. Dec 1993 A
5275603 Ferrante et al. Jan 1994 A
5282861 Kaplan Feb 1994 A
5282868 Bahler Feb 1994 A
5282870 Moser et al. Feb 1994 A
5290313 Heldreth Mar 1994 A
5310480 Vidueira May 1994 A
5326361 Hollister Jul 1994 A
5344460 Turanyi et al. Sep 1994 A
5344461 Phlipot Sep 1994 A
5360016 Kovacevic Nov 1994 A
5364402 Mumme et al. Nov 1994 A
5370699 Hood et al. Dec 1994 A
5387239 Bianco et al. Feb 1995 A
5387240 Pottenger et al. Feb 1995 A
5395401 Bahler Mar 1995 A
5405396 Heldreth et al. Apr 1995 A
5413604 Hodge May 1995 A
5413605 Ashby et al. May 1995 A
5425775 Kovacevic et al. Jun 1995 A
5445642 McNulty et al. Aug 1995 A
5458637 Hayes Oct 1995 A
5470354 Hershberger et al. Nov 1995 A
5489311 Cipolletti Feb 1996 A
5507820 Pappas Apr 1996 A
5549688 Ries et al. Aug 1996 A
5556433 Gabriel et al. Sep 1996 A
5571194 Gabriel Nov 1996 A
5609639 Walker Mar 1997 A
5609641 Johnson et al. Mar 1997 A
5609643 Colleran et al. Mar 1997 A
5609645 Vinciuerra Mar 1997 A
5613970 Houston et al. Mar 1997 A
5656785 Trainor et al. Aug 1997 A
5658341 Delfosse Aug 1997 A
5658342 Draganich et al. Aug 1997 A
5658344 Hurlburt Aug 1997 A
5683470 Johnson et al. Nov 1997 A
5702463 Pothier et al. Dec 1997 A
5702464 Lackey et al. Dec 1997 A
5733292 Gustilo et al. Mar 1998 A
5755801 Walker et al. May 1998 A
5755802 Gerber May 1998 A
5776200 Johnson et al. Jul 1998 A
5782925 Collazo et al. Jul 1998 A
5824100 Kester et al. Oct 1998 A
5824102 Buscayret Oct 1998 A
5824103 Williams et al. Oct 1998 A
5871539 Pappas Feb 1999 A
5871541 Gerber Feb 1999 A
5871543 Hofmann Feb 1999 A
5871545 Goodfellow et al. Feb 1999 A
5879394 Ashby et al. Mar 1999 A
5906643 Walker May 1999 A
5911723 Ashby et al. Jun 1999 A
5928286 Ashby et al. Jul 1999 A
5964808 Blaha et al. Oct 1999 A
5968099 Badorf et al. Oct 1999 A
5976147 LaSalle et al. Nov 1999 A
6004351 Tomita et al. Dec 1999 A
6004352 Buni Dec 1999 A
6010534 O'neil et al. Jan 2000 A
6013103 Kaufman et al. Jan 2000 A
6039764 Pottenger et al. Mar 2000 A
6068658 Insall et al. May 2000 A
6074425 Pappas Jun 2000 A
6080195 Colleran et al. Jun 2000 A
6090144 Letot et al. Jul 2000 A
6102954 Albrektsson et al. Aug 2000 A
6102955 Mendes et al. Aug 2000 A
6123729 Insall et al. Sep 2000 A
6126692 Robie et al. Oct 2000 A
6143034 Burrows Nov 2000 A
6197064 Haines et al. Mar 2001 B1
6203576 Afriat et al. Mar 2001 B1
6206927 Fell et al. Mar 2001 B1
6210443 Marceaux et al. Apr 2001 B1
6217618 Hileman Apr 2001 B1
RE37277 Baldwin et al. Jul 2001 E
6258127 Schmotzer Jul 2001 B1
6306172 O'Neil et al. Oct 2001 B1
6325828 Dennis et al. Dec 2001 B1
6379388 Ensign et al. Apr 2002 B1
6406497 Takei et al. Jun 2002 B2
6413279 Metzger et al. Jul 2002 B1
6428577 Evans Aug 2002 B1
6436145 Miller Aug 2002 B1
6491726 Pappas Dec 2002 B2
6506215 Letot et al. Jan 2003 B1
6506216 McCue et al. Jan 2003 B1
6558426 Masini May 2003 B1
6607559 Ralph et al. Aug 2003 B2
6623526 Lloyd Sep 2003 B1
6632225 Sanford et al. Oct 2003 B2
6660039 Evans et al. Dec 2003 B1
6702821 Bonutti Mar 2004 B2
6709461 O'neil et al. Mar 2004 B2
6743258 Keller Jun 2004 B1
6755864 Brack et al. Jun 2004 B1
6770078 Bonutti Aug 2004 B2
6869448 Tuke Mar 2005 B2
6923832 Sharkey et al. Aug 2005 B1
6942670 Heldreth et al. Sep 2005 B2
6953479 Carson et al. Oct 2005 B2
6974481 Carson Dec 2005 B1
6986791 Metzger Jan 2006 B1
7025788 Metzger et al. Apr 2006 B2
7060074 Rosa et al. Jun 2006 B2
7081137 Servidio Jul 2006 B1
7083652 McCUe et al. Aug 2006 B2
7153326 Metzger Dec 2006 B1
7160330 Axelson, Jr. et al. Jan 2007 B2
7189262 Hayes, Jr. et al. Mar 2007 B2
7261740 Tuttle Aug 2007 B2
7264635 Suguro Sep 2007 B2
7294149 Hozack et al. Nov 2007 B2
7309362 Yasuda et al. Dec 2007 B2
7309363 Dietz Dec 2007 B2
7326252 Otto et al. Feb 2008 B2
7351263 Afriat Apr 2008 B2
7364581 Michalowicz Apr 2008 B2
7412897 Crottet et al. Aug 2008 B2
7413577 Servidio Aug 2008 B1
7442196 Fisher et al. Oct 2008 B2
7445639 Metzger et al. Nov 2008 B2
7488330 Stad Feb 2009 B2
7497874 Metzger et al. Mar 2009 B1
7513912 Hayes, Jr. et al. Apr 2009 B2
7544211 Rochetin Jun 2009 B2
7547327 Collazo Jun 2009 B2
7575602 Amirouche et al. Aug 2009 B2
7578821 Fisher et al. Aug 2009 B2
7585328 Haas Sep 2009 B2
7587945 Crottet et al. Sep 2009 B2
7591854 Wasielewski Sep 2009 B2
7625407 Akizuki Dec 2009 B2
7628818 Hazebrouck et al. Dec 2009 B2
7632283 Heldreth Dec 2009 B2
7632314 Dietz Dec 2009 B2
7635390 Bonutti Dec 2009 B1
7678152 Suguro et al. Mar 2010 B2
7695519 Collazo Apr 2010 B2
7695520 Metzger et al. Apr 2010 B2
7776085 Bernero et al. Aug 2010 B2
7837691 Cordes et al. Nov 2010 B2
7850698 Straszheim-Morley et al. Dec 2010 B2
8012216 Metzger Sep 2011 B2
8065927 Crottet et al. Nov 2011 B2
8141437 Amirouche et al. Mar 2012 B2
8163028 Metzger et al. Apr 2012 B2
8187280 May et al. May 2012 B2
8197549 Amirouche et al. Jun 2012 B2
8211041 Fisher et al. Jul 2012 B2
8245583 Stein Aug 2012 B2
8268006 Meyers et al. Sep 2012 B2
8317870 Wagner et al. Nov 2012 B2
8328873 Metzger et al. Dec 2012 B2
8366782 Wright Feb 2013 B2
8491589 Fisher et al. Jul 2013 B2
8506571 Chana et al. Aug 2013 B2
RE44476 Meyers et al. Sep 2013 E
8568486 Wentorf et al. Oct 2013 B2
8574304 Wentorf et al. Nov 2013 B2
8591594 Parisi et al. Nov 2013 B2
8603101 Claypool et al. Dec 2013 B2
8613775 Wentorf et al. Dec 2013 B2
8617250 Metzger Dec 2013 B2
8628580 Sanford et al. Jan 2014 B2
8690954 Parisi et al. Apr 2014 B2
8740984 Hartdegen et al. Jun 2014 B2
8758444 Wentorf et al. Jun 2014 B2
8764838 Parisi et al. Jul 2014 B2
8764840 Sanford et al. Jul 2014 B2
8795282 Earl et al. Aug 2014 B2
8808387 Hawkins et al. Aug 2014 B2
8858643 Parisi Oct 2014 B2
8932298 Colquhoun et al. Jan 2015 B2
8932365 Parisi et al. Jan 2015 B2
8979847 Belcher et al. Mar 2015 B2
8979936 White et al. Mar 2015 B2
8998997 Ries et al. Apr 2015 B2
9011459 Claypool et al. Apr 2015 B2
9072607 Parisi et al. Jul 2015 B2
9131945 Aram et al. Sep 2015 B2
9149206 Claypool et al. Oct 2015 B2
9173744 Donno et al. Nov 2015 B2
9186255 Parisi Nov 2015 B2
9192480 Wentorf et al. Nov 2015 B2
9204970 Parisi et al. Dec 2015 B2
9283082 Sanford et al. Mar 2016 B2
9295557 Wentorf et al. Mar 2016 B2
9295558 Parisi et al. Mar 2016 B2
9308095 Parisi et al. Apr 2016 B2
9308096 Wentorf et al. Apr 2016 B2
9314343 Parisi et al. Apr 2016 B2
9381090 Wentorf et al. Jul 2016 B2
9427337 Claypool et al. Aug 2016 B2
9492290 Claypool et al. Nov 2016 B2
9539116 Claypool Jan 2017 B2
9592133 Toler et al. Mar 2017 B2
9597090 Claypool et al. Mar 2017 B2
9655728 Parisi et al. May 2017 B2
9655729 Parisi et al. May 2017 B2
9707089 Grey et al. Jul 2017 B2
9763794 Sanford et al. Sep 2017 B2
9763795 Parisi et al. Sep 2017 B2
9763796 Wentorf et al. Sep 2017 B2
9763807 Claypool et al. Sep 2017 B2
9788954 Parisi et al. Oct 2017 B2
9861490 Wentorf et al. Jan 2018 B2
9901331 Toler et al. Feb 2018 B2
9918844 Sanford et al. Mar 2018 B2
9925050 Parisi et al. Mar 2018 B2
9925052 Dai et al. Mar 2018 B2
10010330 Claypool et al. Jul 2018 B2
10092407 Faccioli et al. Oct 2018 B2
10188530 Claypool et al. Jan 2019 B2
10195041 Wentorf et al. Feb 2019 B2
10265181 Wentorf et al. Apr 2019 B2
10278827 Drury May 2019 B2
10413415 Parisi et al. Sep 2019 B2
10470889 Wentorf et al. Nov 2019 B2
10500054 Croll Dec 2019 B2
10543099 Sanford et al. Jan 2020 B2
10575956 Dai et al. Mar 2020 B2
10675153 Byrd et al. Jun 2020 B2
10835380 Drury et al. Nov 2020 B2
20010047210 Wolf Nov 2001 A1
20020058997 O'connor et al. May 2002 A1
20020072802 O'Neil et al. Jun 2002 A1
20020120340 Metzger et al. Aug 2002 A1
20020161448 Hayes, Jr. et al. Oct 2002 A1
20030055509 Mccue et al. Mar 2003 A1
20040019382 Amirouche et al. Jan 2004 A1
20040019383 Beguec Jan 2004 A1
20040034432 Hughes et al. Feb 2004 A1
20040059340 Serra et al. Mar 2004 A1
20040064191 Wasielewski Apr 2004 A1
20040122441 Muratsu Jun 2004 A1
20040153066 Coon et al. Aug 2004 A1
20040162620 Wyss Aug 2004 A1
20040167537 Errico et al. Aug 2004 A1
20040186582 Yasuda et al. Sep 2004 A1
20040204765 Fenning et al. Oct 2004 A1
20040225368 Plumet et al. Nov 2004 A1
20040236429 Ensign et al. Nov 2004 A1
20040243244 Otto et al. Dec 2004 A1
20040267371 Hayes, Jr. et al. Dec 2004 A1
20050055102 Tornier et al. Mar 2005 A1
20050096747 Tuttle et al. May 2005 A1
20050143831 Justin et al. Jun 2005 A1
20050143832 Carson Jun 2005 A1
20050177170 Fisher et al. Aug 2005 A1
20050019771 Naegerl Sep 2005 A1
20050209701 Suguro et al. Sep 2005 A1
20050209702 Todd et al. Sep 2005 A1
20050246030 Yao Nov 2005 A1
20050267485 Cordes et al. Dec 2005 A1
20050267584 Burdulis, Jr. et al. Dec 2005 A1
20050278035 Wyss et al. Dec 2005 A1
20060004460 Engh et al. Jan 2006 A1
20060020343 Ek Jan 2006 A1
20060030945 Wright Feb 2006 A1
20060052782 Morgan et al. Mar 2006 A1
20060069436 Sutton et al. Mar 2006 A1
20060089653 Auger et al. Apr 2006 A1
20060142869 Gross Jun 2006 A1
20060161259 Cheng et al. Jul 2006 A1
20060184176 Straszheim-Morley et al. Aug 2006 A1
20060189864 Paradis et al. Aug 2006 A1
20060190087 O'Connor Aug 2006 A1
20060195195 Burstein et al. Aug 2006 A1
20060111726 Felt et al. Oct 2006 A1
20060224244 Thomas et al. Oct 2006 A1
20060265080 Mcminn Nov 2006 A1
20070010890 Collazo Jan 2007 A1
20070123992 Sanford May 2007 A1
20070129808 Justin et al. Jun 2007 A1
20070135924 Verhoogen Jun 2007 A1
20070135926 Walker Jun 2007 A1
20070185581 Akizuki et al. Aug 2007 A1
20070198022 Lang et al. Aug 2007 A1
20070233269 Steines et al. Oct 2007 A1
20070234819 Amirouche et al. Oct 2007 A1
20070239165 Amirouche Oct 2007 A1
20080021566 Peters et al. Jan 2008 A1
20080051908 Angibaud et al. Feb 2008 A1
20080058947 Earl et al. Mar 2008 A1
20080091271 Bonitati et al. Apr 2008 A1
20080091272 Aram et al. Apr 2008 A1
20080091273 Hazebrouck Apr 2008 A1
20080103603 Hlntermann May 2008 A1
20080114462 Guidera et al. May 2008 A1
20080119938 Oh May 2008 A1
20080119940 Otto et al. May 2008 A1
20080140212 Metzger et al. Jun 2008 A1
20080161918 Fankhauser et al. Jul 2008 A1
20080167722 Metzger et al. Jul 2008 A1
20080215156 Duggal et al. Sep 2008 A1
20080243258 Sancheti Oct 2008 A1
20080262624 White et al. Oct 2008 A1
20080281426 Fitz et al. Nov 2008 A1
20080288080 Sancheti Nov 2008 A1
20080300689 Mc Kinnon et al. Dec 2008 A1
20080300690 Burstein et al. Dec 2008 A1
20090005708 Johanson et al. Jan 2009 A1
20090036992 Tsakonas Feb 2009 A1
20090043395 Hotokebuchi et al. Feb 2009 A1
20090062806 Scott et al. Mar 2009 A1
20090082873 Hazebrouck et al. Mar 2009 A1
20090088862 Thomas et al. Apr 2009 A1
20090125114 May et al. May 2009 A1
20090149963 Sekel Jun 2009 A1
20090149964 May et al. Jun 2009 A1
20090204221 Walker Aug 2009 A1
20090204222 Burstein et al. Aug 2009 A1
20090210066 Jasty Aug 2009 A1
20090222103 Fitz et al. Sep 2009 A1
20090259314 Linder-ganz et al. Oct 2009 A1
20090264894 Wasielewski Oct 2009 A1
20090265011 Mandell Oct 2009 A1
20090265013 Mandell Oct 2009 A1
20090028731 Fisher et al. Nov 2009 A1
20090306786 Samuelson Dec 2009 A1
20090306787 Crabtree et al. Dec 2009 A1
20090319047 Walker Dec 2009 A1
20090319048 Shah et al. Dec 2009 A1
20090319049 Shah et al. Dec 2009 A1
20090326663 Dun Dec 2009 A1
20090326665 Wyss et al. Dec 2009 A1
20090326666 Wyss et al. Dec 2009 A1
20090326668 Dun Dec 2009 A1
20100010494 Quirno Jan 2010 A1
20100016976 Siebel Jan 2010 A1
20100016977 Masini Jan 2010 A1
20100016978 Williams et al. Jan 2010 A1
20100016979 Wyss et al. Jan 2010 A1
20100036499 Pinskerova Feb 2010 A1
20100036500 Heldreth et al. Feb 2010 A1
20100063594 Hazebrouck et al. Mar 2010 A1
20100063595 Dietz Mar 2010 A1
20100076563 Otto et al. Mar 2010 A1
20100082111 Thomas Apr 2010 A1
20100100011 Roche Apr 2010 A1
20100100189 Metzger Apr 2010 A1
20100100191 May et al. Apr 2010 A1
20100125339 Earl et al. May 2010 A1
20100152858 Lu et al. Jun 2010 A1
20100191298 Earl et al. Jul 2010 A1
20100191341 Byrd Jul 2010 A1
20100198275 Chana et al. Aug 2010 A1
20100222890 Barnett et al. Sep 2010 A1
20100249660 Sherman et al. Sep 2010 A1
20100249789 Rock et al. Sep 2010 A1
20100262253 Cipolletti et al. Oct 2010 A1
20100286788 Komistek Nov 2010 A1
20100292804 Samuelson Nov 2010 A1
20100305708 Lang Dec 2010 A1
20100329530 Lang et al. Dec 2010 A1
20110022179 Andriacchi et al. Jan 2011 A1
20110029091 Bojarski et al. Feb 2011 A1
20110040387 Ries et al. Feb 2011 A1
20110082558 Kim et al. Apr 2011 A1
20110082559 Hartdegen et al. Apr 2011 A1
20110087332 Bojarski et al. Apr 2011 A1
20110098824 Jukes et al. Apr 2011 A1
20110100011 Staffend May 2011 A1
20110125278 Bercovy et al. May 2011 A1
20110144760 Wong et al. Jun 2011 A1
20110153026 Heggendorn et al. Jun 2011 A1
20110190898 Lenz et al. Aug 2011 A1
20110202139 Metzger et al. Aug 2011 A1
20110251695 Lenz et al. Oct 2011 A1
20120022658 Wentorf Jan 2012 A1
20120022659 Wentorf Jan 2012 A1
20120022660 Wentorf Jan 2012 A1
20120035735 Sanford et al. Feb 2012 A1
20120035737 Sanford Feb 2012 A1
20120095563 Sanford et al. Apr 2012 A1
20120101585 Parisi et al. Apr 2012 A1
20120158152 Claypool et al. Jun 2012 A1
20120179069 Amirouche Jul 2012 A1
20120185054 Maloney et al. Jul 2012 A1
20120185055 Maloney et al. Jul 2012 A1
20120232429 Fischer et al. Sep 2012 A1
20120290088 Amirouche et al. Nov 2012 A1
20120296437 Wyss et al. Nov 2012 A1
20120310246 Belcher et al. Dec 2012 A1
20120310361 Zubok et al. Dec 2012 A1
20120323335 Parisi et al. Dec 2012 A1
20120323336 Parisi et al. Dec 2012 A1
20130013076 Fisher et al. Jan 2013 A1
20130024001 Wentorf et al. Jan 2013 A1
20130079671 Stein et al. Mar 2013 A1
20130096567 Fisher et al. Apr 2013 A1
20130102929 Haight et al. Apr 2013 A1
20130103038 Fischer et al. Apr 2013 A1
20130131816 Parisi et al. May 2013 A1
20130131817 Parisi et al. May 2013 A1
20130131818 Parisi et al. May 2013 A1
20130131819 Parisi May 2013 A1
20130131820 Wentorf et al. May 2013 A1
20130017301 Irwin Jul 2013 A1
20130226305 Donno et al. Aug 2013 A1
20130253378 Claypool et al. Sep 2013 A1
20130261504 Claypool et al. Oct 2013 A1
20130261757 Claypool et al. Oct 2013 A1
20130261758 Claypool et al. Oct 2013 A1
20130345820 Maloney et al. Dec 2013 A1
20140025175 Wentorf et al. Jan 2014 A1
20140025176 Wentorf Jan 2014 A1
20140025177 Wentorf et al. Jan 2014 A1
20140052268 Sanford et al. Feb 2014 A1
20140052269 Claypool et al. Feb 2014 A1
20140156015 Parisi et al. Jun 2014 A1
20140163687 Parisi et al. Jun 2014 A1
20140249641 Wentorf et al. Sep 2014 A1
20140257505 Parisi et al. Sep 2014 A1
20140257506 Sanford et al. Sep 2014 A1
20140296859 Claypool et al. Oct 2014 A1
20150005890 Parisi et al. Jan 2015 A1
20150025644 Heggendorn et al. Jan 2015 A1
20150066150 Dai et al. Mar 2015 A1
20150088140 Toler et al. Mar 2015 A1
20150190243 Claypool et al. Jul 2015 A1
20150282936 Parisi et al. Oct 2015 A1
20150320564 Parisi et al. Nov 2015 A1
20150359642 Claypool et al. Dec 2015 A1
20160030053 Yager et al. Feb 2016 A1
20160038294 Parisi et al. Feb 2016 A1
20160045322 Parisi et al. Feb 2016 A1
20160135959 Sanford et al. May 2016 A1
20160158019 Grey et al. Jun 2016 A1
20160184107 Parisi et al. Jun 2016 A1
20160287397 Wentorf Oct 2016 A1
20160324647 Claypool et al. Nov 2016 A1
20170079801 Drury et al. Mar 2017 A1
20170143324 Toler et al. May 2017 A1
20170156736 Claypool et al. Jun 2017 A1
20170231773 Lu Aug 2017 A1
20170266011 Wentorf et al. Sep 2017 A1
20170281354 Soffiatti et al. Oct 2017 A1
20180000601 Sanford et al. Jan 2018 A1
20180000602 Wentorf et al. Jan 2018 A1
20180000612 Claypool et al. Jan 2018 A1
20180021143 Parisi et al. Jan 2018 A1
20180021144 Parisi et al. Jan 2018 A1
20180085225 Wentorf et al. Mar 2018 A1
20180161166 Dai et al. Jun 2018 A1
20180256346 Byrd et al. Sep 2018 A1
20180325684 Croll Nov 2018 A1
20190142594 Yager May 2019 A1
20190209333 Drury et al. Jul 2019 A1
20190328535 Drury et al. Oct 2019 A1
20190350718 Parisi et al. Nov 2019 A1
20200069433 Croll Mar 2020 A1
20200113702 Sanford et al. Apr 2020 A1
20200146830 Dai et al. May 2020 A1
20200237518 Byrd et al. Jul 2020 A1
20210022875 Drury et al. Jan 2021 A1
Foreign Referenced Citations (227)
Number Date Country
2011343440 Apr 2014 AU
2011286306 Oct 2014 AU
2190029 Nov 1995 CA
2856070 Jul 2016 CA
687584 Jan 1997 CH
1087506 Jun 1994 CN
1174498 Feb 1998 CN
1179709 Apr 1998 CN
1440262 Sep 2003 CN
1549695 Nov 2004 CN
2768715 Apr 2006 CN
1780594 May 2006 CN
1874738 Dec 2006 CN
101214175 Jul 2008 CN
101222886 Jul 2008 CN
101288597 Oct 2008 CN
101347359 Jan 2009 CN
201175391 Jan 2009 CN
101361684 Feb 2009 CN
101401750 Apr 2009 CN
101426453 May 2009 CN
101522136 Sep 2009 CN
101646392 Feb 2010 CN
101658446 Mar 2010 CN
101683289 Mar 2010 CN
101711701 May 2010 CN
101795643 Aug 2010 CN
101835441 Sep 2010 CN
102018584 Apr 2011 CN
102048594 May 2011 CN
102058446 May 2011 CN
102058448 May 2011 CN
102917670 Feb 2013 CN
103118634 May 2013 CN
103118635 May 2013 CN
103118636 May 2013 CN
103370025 Oct 2013 CN
103379880 Oct 2013 CN
103732186 Apr 2014 CN
104039273 Sep 2014 CN
104066402 Sep 2014 CN
104093380 Oct 2014 CN
104135969 Nov 2014 CN
104203160 Dec 2014 CN
104321263 Jan 2015 CN
104379094 Feb 2015 CN
104736105 Jun 2015 CN
105055052 Nov 2015 CN
105167889 Dec 2015 CN
103118634 Aug 2016 CN
103118636 Aug 2016 CN
104093380 Aug 2016 CN
103370025 Nov 2016 CN
106073949 Nov 2016 CN
106214292 Dec 2016 CN
108135701 Jun 2018 CN
106073949 Dec 2018 CN
109310504 Feb 2019 CN
110022798 Jul 2019 CN
110402123 Nov 2019 CN
110636818 Dec 2019 CN
0021421 Jan 1981 EP
0327495 Aug 1989 EP
340919 Nov 1989 EP
0340919 Nov 1989 EP
0372811 Jun 1990 EP
0306744 Apr 1992 EP
0495340 Jul 1992 EP
0636353 Feb 1995 EP
0672397 Sep 1995 EP
0552950 Sep 1996 EP
0536457 Jan 1997 EP
0642328 Dec 1998 EP
0592750 Jan 1999 EP
0903125 Mar 1999 EP
0956836 Nov 1999 EP
0956836 Nov 1999 EP
1025818 Aug 2000 EP
1097679 May 2001 EP
0709074 Dec 2002 EP
1327424 Jul 2003 EP
1378216 Jan 2004 EP
1477143 Nov 2004 EP
1568336 Aug 2005 EP
1719478 Nov 2006 EP
1722721 Nov 2006 EP
1354571 Jun 2007 EP
1396240 Apr 2008 EP
1604623 Jun 2008 EP
1996122 Dec 2008 EP
0927009 Jan 2009 EP
2011455 Jan 2009 EP
1696835 Feb 2009 EP
1132063 Sep 2009 EP
1591082 Sep 2009 EP
2140838 Jan 2010 EP
2140839 Jan 2010 EP
2143403 Jan 2010 EP
2237177 Oct 2010 EP
1555962 Feb 2011 EP
2319460 May 2011 EP
2324799 May 2011 EP
2335654 Jun 2011 EP
2347733 Jul 2011 EP
0689808 Sep 2012 EP
2595573 May 2013 EP
2782525 Oct 2014 EP
2830543 Feb 2015 EP
2830544 Feb 2015 EP
2830544 Sep 2016 EP
2918235 Jan 2017 EP
3143964 Mar 2017 EP
2595574 May 2017 EP
3111894 Dec 2018 EP
2728782 Jul 1996 FR
2736819 Jan 1997 FR
2747914 Oct 1997 FR
2778332 Nov 1999 FR
2788964 Aug 2000 FR
2824260 Nov 2002 FR
2852819 Oct 2004 FR
2926719 Jul 2009 FR
225347 Dec 1924 GB
2253147 Sep 1992 GB
2345446 Jul 2000 GB
7145DELNP2014 Apr 2015 IN
61247449 Nov 1986 JP
62270153 Nov 1987 JP
06203576 Jul 1994 JP
09289998 Nov 1997 JP
09511668 Nov 1997 JP
2000000255 Jan 2000 JP
2000245758 Sep 2000 JP
2003516183 May 2003 JP
2004166802 Jun 2004 JP
2004254811 Sep 2004 JP
3734270 Jan 2006 JP
2007054488 Mar 2007 JP
2007509709 Apr 2007 JP
2007222616 Sep 2007 JP
2009082713 Apr 2009 JP
2009245619 Oct 2009 JP
2010022827 Feb 2010 JP
2010188051 Sep 2010 JP
2010240406 Oct 2010 JP
2010259808 Nov 2010 JP
2011092738 May 2011 JP
2012500667 Jan 2012 JP
2012531265 Dec 2012 JP
2015512307 Apr 2013 JP
2013535276 Sep 2013 JP
2013536005 Sep 2013 JP
2013536006 Sep 2013 JP
2013536007 Sep 2013 JP
2014505517 Mar 2014 JP
2014508554 Apr 2014 JP
2014522292 Sep 2014 JP
2014239900 Dec 2014 JP
2015502203 Jan 2015 JP
2015504333 Feb 2015 JP
2015504759 Feb 2015 JP
2015513966 May 2015 JP
2015231566 Dec 2015 JP
2016028729 Mar 2016 JP
5980341 Aug 2016 JP
2016195841 Nov 2016 JP
2017221732 Dec 2017 JP
WO-9305729 Apr 1993 WO
WO-9409725 May 1994 WO
WO-9514444 Jun 1995 WO
WO-9514446 Jun 1995 WO
WO-9530389 Nov 1995 WO
WO-9535074 Dec 1995 WO
WO-9934755 Jul 1999 WO
WO-0141680 Jun 2001 WO
WO-200141680 Jun 2001 WO
WO-03099106 Dec 2003 WO
WO-2004058108 Jul 2004 WO
WO-2005037147 Apr 2005 WO
WO-2005051240 Jun 2005 WO
WO-2005122967 Dec 2005 WO
WO-2006058057 Jun 2006 WO
WO-2006092167 Sep 2006 WO
WO-2007108804 Sep 2007 WO
WO-2007109641 Sep 2007 WO
WO-2007119173 Oct 2007 WO
WO-2009029631 Mar 2009 WO
WO-2009088235 Jul 2009 WO
WO-2009088236 Jul 2009 WO
WO-2009088238 Jul 2009 WO
WO-2009105495 Aug 2009 WO
WO-2010001010 Jan 2010 WO
WO-2010008803 Jan 2010 WO
WO-2010011590 Jan 2010 WO
WO-2010022272 Feb 2010 WO
WO-2010023062 Mar 2010 WO
WO-2010045537 Apr 2010 WO
WO-2010075365 Jul 2010 WO
WO-2011043955 Apr 2011 WO
WO-2011063123 May 2011 WO
WO-2011071979 Jun 2011 WO
WO-2011072235 Jun 2011 WO
WO-2011110865 Sep 2011 WO
WO-2012004580 Jan 2012 WO
WO-2012018563 Feb 2012 WO
WO-2012018564 Feb 2012 WO
WO-2012018565 Feb 2012 WO
WO-2012018566 Feb 2012 WO
WO-2012018567 Feb 2012 WO
WO-2012020460 Feb 2012 WO
WO-2012082628 Jun 2012 WO
WO-2012083280 Jun 2012 WO
WO-2012112698 Aug 2012 WO
WO-2012173706 Dec 2012 WO
WO-2013003433 Jan 2013 WO
WO-2013013094 Jan 2013 WO
WO-201 3074145 May 2013 WO
WO-2013074142 May 2013 WO
WO-2013074143 May 2013 WO
WO-2013074144 May 2013 WO
WO-2013077919 May 2013 WO
WO-2013115849 Aug 2013 WO
WO-201 3148954 Oct 2013 WO
WO-2013148960 Oct 2013 WO
WO-2017053196 Mar 2017 WO
WO-2018165442 Sep 2018 WO
WO-2018208612 Nov 2018 WO
Non-Patent Literature Citations (796)
Entry
“U.S. Appl. No. 13/087,610, Non Final Office Action dated Feb. 26, 2013”, 7 pgs.
“U.S. Appl. No. 13/087,610, Notice of Allowance dated Jun. 28, 2013”, 6 pgs.
“U.S. Appl. No. 13/087,610, Notice of Allowance dated Oct. 8, 2013”, 7 pgs.
“U.S. Appl. No. 13/087,610, Response filed May 24, 2013 to Non Final Office Action dated Feb. 26, 2013”, 15 pgs.
“U.S. Appl. No. 13/189,324, Examiner Interview Summary dated Jan. 13, 2014”, 4 pgs.
“U.S. Appl. No. 13/189,324, Final Office Action dated Jul. 16, 2013”, 19 pgs.
“U.S. Appl. No. 13/189,324, Non Final Office Action dated Dec. 11, 2012”, 19 pgs.
“U.S. Appl. No. 13/189,324, Notice of Allowance dated Feb. 20, 2014”, 8 pgs.
“U.S. Appl. No. 13/189,324, PTO Response to 312 Amendment dated May 29, 2014”, 2 pgs.
“U.S. Appl. No. 13/189,324, Response filed Jan. 15, 14 to Final Office Action dated Jul. 16, 2013”, 23 pgs.
“U.S. Appl. No. 13/189,324, Response filed Jun. 10, 2013 to Non Final Office Action dated Dec. 11, 2012”, 24 pgs.
“U.S. Appl. No. 13/189,328, Non Final Office Action dated Mar. 19, 2013”, 10 pgs.
“U.S. Appl. No. 13/189,328, Notice of Allowance dated Oct. 8, 2013”, 12 pgs.
“U.S. Appl. No. 13/189,328, PTO Response to 312 Amendment dated Dec. 13, 2013”, 2 pgs.
“U.S. Appl. No. 13/189,328, Response filed Jan. 10, 2013 to Restriction Requirement dated Dec. 10, 2012”, 9 pgs.
“U.S. Appl. No. 13/189,328, Response filed Jul. 18, 2013 to Non Final Office Action dated Mar. 19, 2013”, 16 pgs.
“U.S. Appl. No. 13/189,328, Restriction Requirement dated Dec. 10, 2012”, 6 pgs.
“U.S. Appl. No. 13/189,336, Notice of Allowance dated Sep. 13, 2013”, 30 pgs.
“U.S. Appl. No. 13/189,336, PTO Response to 312 Amendment dated Nov. 25, 2013”, 2 pgs.
“U.S. Appl. No. 13/189,336, Response filed Apr. 15, 2013 to Restriction Requirement dated Jan. 30, 2013”, 21 pgs.
“U.S. Appl. No. 13/189,336, Response filed Jul. 17, 2013 to Restriction Requirement dated Jun. 17, 2013”, 20 pgs.
“U.S. Appl. No. 13/189,336, Restriction Requirement dated Jan. 30, 2013”, 5 pgs.
“U.S. Appl. No. 13/189,336, Restriction Requirement dated Jun. 17, 2013”, 6 pgs.
“U.S. Appl. No. 13/189,338, Notice of Allowance dated Sep. 23, 2013”, 23 pgs.
“U.S. Appl. No. 13/189,338, Response filed Apr. 15, 13 to Restriction Requirement dated Feb. 14, 2013”, 18 pgs.
“U.S. Appl. No. 13/189,338, Response filed Jul. 17, 2013 to Restriction Requirement dated Jun. 17, 2013”, 16 pgs.
“U.S. Appl. No. 13/189,338, Restriction Requirement dated Feb. 14, 2013”, 5 pgs.
“U.S. Appl. No. 13/189,338, Restriction Requirement dated Jun. 17, 2013”, 6 pgs.
“U.S. Appl. No. 13/189,339, Notice of Allowance dated Sep. 20, 2013”, 16 pgs.
“U.S. Appl. No. 13/189,339, Response filed Apr. 15, 13 to Restriction Requirement dated Mar. 6, 2013”, 11 pgs.
“U.S. Appl. No. 13/189,339, Response filed Jul. 17, 2013 to Restriction Requirement dated Jun. 17, 2013”, 10 pgs.
“U.S. Appl. No. 13/189,339, Restriction Requirement dated Mar. 6, 2013”, 6 pgs.
“U.S. Appl. No. 13/189,339, Restriction Requirement dated Jun. 17, 2013”, 7 pgs.
“U.S. Appl. No. 13/229,103, Applicant Interview Summary dated Sep. 23, 2013”, 2 pgs.
“U.S. Appl. No. 13/229,103, Examiner Interview Summary dated Sep. 13, 2013”, 3 pgs.
“U.S. Appl. No. 13/229,103, Non Final Office Action dated Apr. 1, 2013”, 18 pgs.
“U.S. Appl. No. 13/229,103, Notice of Allowance dated Sep. 18, 2013”, 9 pgs.
“U.S. Appl. No. 13/229,103, Response filed Jul. 1, 2013 to Non Final Office Action dated Apr. 1, 2013”, 19 pgs.
“U.S. Appl. No. 13/229,103, Supplemental Notice of Allowability dated Oct. 18, 2013”, 2 pgs.
“U.S. Appl. No. 13/459,037, Final Office Action dated Sep. 23, 2013”, 9 pgs.
“U.S. Appl. No. 13/459,037, Non Final Office Action dated Apr. 23, 2013”, 10 pgs.
“U.S. Appl. No. 13/459,037, Notice of Allowance dated Jun. 13, 2014”, 9 pgs.
“U.S. Appl. No. 13/459,037, Preliminary Amendment filed Apr. 27, 2012”, 3 pgs.
“U.S. Appl. No. 13/459,037, Response filed Mar. 21, 2014 to Final Office Action dated Sep. 23, 2013”, 15 pgs.
“U.S. Appl. No. 13/459,037, Response filed Mar. 28, 2013 to Restriction Requirement dated Feb. 26, 2013”, 9 pgs.
“U.S. Appl. No. 13/459,037, Response filed Jul. 23, 2013 to Non Final Office Action dated Apr. 23, 2013”, 19 pgs.
“U.S. Appl. No. 13/459,037, Restriction Requirement dated Feb. 26, 2013”, 6 pgs.
“U.S. Appl. No. 13/459,041, Non Final Office Action dated Jan. 15, 2014”, 16 pgs.
“U.S. Appl. No. 13/459,041, Non Final Office Action dated Sep. 9, 2014”, 14 pgs.
“U.S. Appl. No. 13/459,041, Notice of Allowance dated Apr. 2, 2015”, 10 pgs.
“U.S. Appl. No. 13/459,041, Preliminary Amendment dated Apr. 27, 2012”, 7 pgs.
“U.S. Appl. No. 13/459,041, PTO Response to Rule 312 Communication dated Jun. 9, 2015”, 2 pgs.
“U.S. Appl. No. 13/459,041, Response filed May 15, 2014 to Non-Final Office Action dated Jan. 15, 2014”, 24 pgs.
“U.S. Appl. No. 13/459,041, Response filed Sep. 23, 2013 to Restriction Requirement dated Jul. 25, 2013”, 18 pgs.
“U.S. Appl. No. 13/459,041, Response filed Dec. 9, 2014 to Non-Final Office Action dated Sep. 9, 2014”, 23 pgs.
“U.S. Appl. No. 13/459,041, Restriction Requirement dated Jul. 25, 2013”, 9 pgs.
“U.S. Appl. No. 13/459,048, Non Final Office Action dated Jul. 11, 2013”, 6 pgs.
“U.S. Appl. No. 13/459,048, Notice of Allowance dated Nov. 26, 2013”, 10 pgs.
“U.S. Appl. No. 13/459,048, Preliminary Amendment filed Apr. 27, 2012”, 7 pgs.
“U.S. Appl. No. 13/459,048, Response filed Nov. 11, 2013 to Non-Final Office Action dated Jul. 11, 2013”, 16 pgs.
“U.S. Appl. No. 13/459,056, Examiner Interview Summary dated Dec. 26, 2013”, 3 pgs.
“U.S. Appl. No. 13/459,056, Non Final Office Action dated Jul. 25, 2013”, 11 pgs.
“U.S. Appl. No. 13/459,056, Notice of Allowance dated Feb. 20, 2014”, 5 pgs.
“U.S. Appl. No. 13/459,056, Preliminary Amendment filed Apr. 27, 2012”, 7 pgs.
“U.S. Appl. No. 13/459,056, PTO Response to Rule 312 Communication dated May 22, 2014”, 2 pgs.
“U.S. Appl. No. 13/459,056, Response filed Jan. 24, 2014 to Non-Final office Action dated Jul. 25, 2013”, 27 pgs.
“U.S. Appl. No. 13/459,056, Response filed Apr. 8, 2013 to Restriction Requirement dated Mar. 6, 2013”, 15 pgs.
“U.S. Appl. No. 13/459,056, Restriction Requirement dated Mar. 6, 2013”, 6 pgs.
“U.S. Appl. No. 13/593,339, Non Final Office Action dated Oct. 4, 2013”, 7 pgs.
“U.S. Appl. No. 13/593,339, Notice of Allowance dated Feb. 14, 2014”, 9 pgs.
“U.S. Appl. No. 13/593,339, Preliminary Amendment filed Aug. 23, 2012”, 6 pgs.
“U.S. Appl. No. 13/593,339, Response filed Jan. 31, 2014 to Non-Final Office Action dated Oct. 4, 2013”, 19 pgs.
“U.S. Appl. No. 13/593,339, Response filed Aug. 30, 2013 to Restriction Requirement dated Aug. 1, 2013”, 14 pgs.
“U.S. Appl. No. 13/593,339, Restriction Requirement dated Aug. 1, 2013”, 5 pgs.
“U.S. Appl. No. 13/593,339, Supplemental Notice of Allowability dated Mar. 31, 2014”, 2 pgs.
“U.S. Appl. No. 13/594,543, Corrected Notice of Allowance dated Mar. 16, 2016”, 2 pgs.
“U.S. Appl. No. 13/594,543, Examiner Interview Summary dated Jan. 22, 2016”, 3 pgs.
“U.S. Appl. No. 13/594,543, Final Office Action dated Jul. 17, 2014”, 12 pgs.
“U.S. Appl. No. 13/594,543, Final Office Action dated Nov. 20, 2015”, 28 pgs.
“U.S. Appl. No. 13/594,543, Non Final Office Action dated Jun. 19, 2015”, 30 pgs.
“U.S. Appl. No. 13/594,543, Non Final Office Action dated Dec. 26, 2013”, 15 pgs.
“U.S. Appl. No. 13/594,543, Non-Final Office Action dated Jan. 9, 2015”, 23 pgs.
“U.S. Appl. No. 13/594,543, Notice of Allowance dated Mar. 1, 2016”, 9 pgs.
“U.S. Appl. No. 13/594,543, Preliminary Amendment filed Aug. 24, 2012”, 4 pgs.
“U.S. Appl. No. 13/594,543, Response filed Feb. 8, 2016 to Final Office Action dated Nov. 20, 2015”, 17 pgs.
“U.S. Appl. No. 13/594,543, Response filed Apr. 7, 2015 to Non-Final Office Action dated Jan. 9, 2015”, 27 pgs.
“U.S. Appl. No. 13/594,543, Response filed May 7, 2014 to Non-Final office Action dated Dec. 26, 2013”, 17 pgs.
“U.S. Appl. No. 13/594,543, Response filed Sep. 21, 2015 to Non-Final Office Action dated Jun. 19, 2015”, 25 pgs.
“U.S. Appl. No. 13/594,543, Response filed Oct. 11, 2013 to Restriction Requirement dated Sep. 12, 2013”, 8 pgs.
“U.S. Appl. No. 13/594,543, Response filed Dec. 17, 2014 to Final Office Action dated Jul. 17, 2014”, 15 pgs.
“U.S. Appl. No. 13/594,543, Restriction Requirement dated Sep. 12, 2013”, 5 pgs.
“U.S. Appl. No. 13/819,116, Advisory Action dated Jan. 5, 2016”, 3 pgs.
“U.S. Appl. No. 13/819,116, Corrected Notice of Allowance dated Oct. 21, 2016”, 2 pgs.
“U.S. Appl. No. 13/819,116, Examiner Interview Summary dated Apr. 18, 2016”, 11 pgs.
“U.S. Appl. No. 13/819,116, Final Office Action dated Jul. 26, 2016”, 6 pgs.
“U.S. Appl. No. 13/819,116, Final Office Action dated Oct. 21, 2015”, 15 pgs.
“U.S. Appl. No. 13/819,116, Non Final Office Action dated Feb. 17, 2016”, 15 pgs.
“U.S. Appl. No. 13/819,116, Non Final Office Action dated Jun. 2, 2015”, 14 pgs.
“U.S. Appl. No. 13/819,116, Notice of Allowance dated Sep. 29, 2016”, 5 pgs.
“U.S. Appl. No. 13/819,116, Preliminary Amendment filed Feb. 26, 2013”, 8 pgs.
“U.S. Appl. No. 13/819,116, Response filed Mar. 27, 2015 to Restriction Requirement dated Feb. 12, 2015”, 11 pgs.
“U.S. Appl. No. 13/819,116, Response filed Apr. 29, 2016 to Non Final Office Action dated Feb. 17, 2016”, 17 pgs.
“U.S. Appl. No. 13/819,116, Response filed Jul. 16, 2015 to Non Final Office Action dated Jun. 2, 2015”, 22 pgs.
“U.S. Appl. No. 13/819,116, Response filed Sep. 14, 2016 Final Office Action dated Jul. 26, 2016”, 10 pgs.
“U.S. Appl. No. 13/819,116, Response filed Dec. 15, 2015 to Final Office Action dated Oct. 21, 2015”, 16 pgs.
“U.S. Appl. No. 13/819,116, Restriction Requirement dated Feb. 12, 2015”, 7 pgs.
“U.S. Appl. No. 13/836,586, Express Abandonment filed May 30, 2014”, 1 pg.
“U.S. Appl. No. 13/836,665, Examiner Interview Summary dated Jul. 17, 2014”, 4 pgs.
“U.S. Appl. No. 13/836,665, Final Office Action dated Jul. 25, 2014”, 25 pgs.
“U.S. Appl. No. 13/836,665, Non Final Office Action dated Jan. 30, 2014”, 21 pgs.
“U.S. Appl. No. 13/836,665, Notice of Allowance dated Jun. 9, 2015”, 10 pgs.
“U.S. Appl. No. 13/836,665, Response filed Jan. 23, 2015 to Final Office Action dated Jul. 25, 2014”, 25 pgs.
“U.S. Appl. No. 13/836,665, Response filed May 30, 2014 to Non-Final Office Action dated Jan. 30, 2014”, 21 pgs.
“U.S. Appl. No. 13/837,294, Final Office Action dated Apr. 25, 2016”, 7 pgs.
“U.S. Appl. No. 13/837,294, Final Office Action dated Jun. 2, 2016”, 7 pgs.
“U.S. Appl. No. 13/837,294, Non Final Office Action dated Dec. 10, 2015”, 8 pgs.
“U.S. Appl. No. 13/837,294, Notice of Allowance dated Aug. 25, 2016”, 5 pgs.
“U.S. Appl. No. 13/837,294, Response filed Mar. 4, 2016 to Non Final Office Action dated Dec. 10, 2015”, 16 pgs.
“U.S. Appl. No. 13/837,294, Response filed Aug. 3, 2016 to Final Office Action dated Jun. 2, 2016”, 7 pgs.
“U.S. Appl. No. 13/837,294, Response filed Oct. 12, 2015 to Restriction Requirement dated Aug. 24, 2015”, 9 pgs.
“U.S. Appl. No. 13/837,294, Restriction Requirement dated Aug. 24, 2015”, 6 pgs.
“U.S. Appl. No. 13/837,774, Examiner Interview Summary dated Jul. 22, 2014”, 4 pgs.
“U.S. Appl. No. 13/837,774, Final Office Action dated Mar. 17, 2016”, 14 pgs.
“U.S. Appl. No. 13/837,774, Final Office Action dated Jul. 28, 2014”, 17 pgs.
“U.S. Appl. No. 13/837,774, Non Final Office Action dated Feb. 10, 2014”, 33 pgs.
“U.S. Appl. No. 13/837,774, Non Final Office Action dated Sep. 18, 2015”, 16 pgs.
“U.S. Appl. No. 13/837,774, Response filed Jan. 28, 2015 to Final Office Action dated Jul. 28, 2014”, 16 pgs.
“U.S. Appl. No. 13/837,774, Response filed Jun. 10, 2014 to Non-Final Office Action dated Feb. 20, 2014”, 29 pgs.
“U.S. Appl. No. 13/837,774, Response filed Jul. 7, 2015 to Restriction Requirement dated May 20, 2015”, 10 pgs.
“U.S. Appl. No. 13/837,774, Response filed Dec. 16, 2015 to Non Final Office Action dated Sep. 18, 2015”, 17 pgs.
“U.S. Appl. No. 13/837,774, Restriction Requirement dated May 20, 2015”, 6 pgs.
“U.S. Appl. No. 14/034,076, Appeal Brief Filed Apr. 18, 2016”, 21 pgs.
“U.S. Appl. No. 14/034,076, Final Office Action dated Dec. 21, 2015”, 11 pgs.
“U.S. Appl. No. 14/034,076, Non Final Office Action dated Jun. 24, 2015”, 11 pgs.
“U.S. Appl. No. 14/034,076, Notice of Allowance dated Oct. 28, 2016”, 7 pgs.
“U.S. Appl. No. 14/034,076, Response filed Nov. 16, 2015 to Non Final Office Action dated Jun. 24, 2015”, 13 pgs.
“U.S. Appl. No. 14/034,937, Appeal Brief Filed Sep. 9, 2015”, 41 pgs.
“U.S. Appl. No. 14/034,937, Appeal Decision mailed May 30, 2017”, 34 pgs.
“U.S. Appl. No. 14/034,937, Final Office Action dated Jun. 5, 2015”, 22 pgs.
“U.S. Appl. No. 14/034,937, Non Final Office Action dated Jan. 2, 2015”, 21 pgs.
“U.S. Appl. No. 14/034,937, Notice of Allowance dated Aug. 30, 2017”, 14 pgs.
“U.S. Appl. No. 14/034,937, Preliminary Amendment filed Sep. 24, 2013”, 3 pgs.
“U.S. Appl. No. 14/034,937, PTO Response to Rule 312 Communication dated Oct. 10, 2017”, 2 pgs.
“U.S. Appl. No. 14/034,937, Response filed Mar. 30, 2015 to Non-Final Office Action”, 24 pgs.
“U.S. Appl. No. 14/034,937, Response filed Oct. 27, 2014 to Restriction Requirement dated Sep. 11, 2014”, 12 pgs.
“U.S. Appl. No. 14/034,937, Restriction Requirement dated Sep. 11, 2014”, 6 pgs.
“U.S. Appl. No. 14/034,937, Supplemental Preliminary Amendment filed Oct. 24, 2013”, 11 pgs.
“U.S. Appl. No. 14/034,944, Non Final Office Action dated Mar. 3, 2015”, 16 pgs.
“U.S. Appl. No. 14/034,944, Notice of Allowance dated Aug. 28, 2015”, 7 pgs.
“U.S. Appl. No. 14/034,944, Preliminary Amendment filed Sep. 24, 2013”, 3 pgs.
“U.S. Appl. No. 14/034,944, Response filed Jun. 23, 2015 to Non Final Office Action dated Mar. 3, 2015”, 15 pgs.
“U.S. Appl. No. 14/034,944, Response filed Dec. 15, 2014 to Restriction Requirement dated Oct. 14, 2014”, 12 pgs.
“U.S. Appl. No. 14/034,944, Restriction Requirement dated Oct. 14, 2014”, 6 pgs.
“U.S. Appl. No. 14/034,944, Supplemental Preliminary Amendment filed Oct. 24, 2013”, 11 pgs.
“U.S. Appl. No. 14/034,954, Advisory Action dated Aug. 25, 2015”, 3 pgs.
“U.S. Appl. No. 14/034,954, Final Office Action dated Jun. 1, 2015”, 26 pgs.
“U.S. Appl. No. 14/034,954, Non Final Office Action dated Dec. 19, 2014”, 25 pgs.
“U.S. Appl. No. 14/034,954, Notice of Allowance dated Nov. 20, 2015”, 11 pgs.
“U.S. Appl. No. 14/034,954, Preliminary Amendment filed Sep. 24, 2013”, 3 pgs.
“U.S. Appl. No. 14/034,954, Response filed Mar. 17, 2015 to Non Final Office Action dated Dec. 19, 2014”, 21 pgs.
“U.S. Appl. No. 14/034,954, Response filed Aug. 3, 2015 to Final Office Action dated Jun. 1, 2015”, 19 pgs.
“U.S. Appl. No. 14/034,954, Response filed Aug. 31, 2015 to Advisory Action dated Aug. 25, 2015”, 21 pgs.
“U.S. Appl. No. 14/034,954, Response filed Oct. 27, 2014 to Restriction Requirement dated Aug. 25, 2014”, 11 pgs.
“U.S. Appl. No. 14/034,954, Restriction Requirement dated Aug. 25, 2014”, 7 pgs.
“U.S. Appl. No. 14/034,954, Supplemental Preliminary Amendment filed Oct. 25, 2013”, 8 pgs.
“U.S. Appl. No. 14/034,963, Final Office Action dated Apr. 13, 2015”, 22 pgs.
“U.S. Appl. No. 14/034,963, Final Office Action dated Oct. 13, 2015”, 11 pgs.
“U.S. Appl. No. 14/034,963, Non Final Office Action dated Jul. 1, 2015”, 15 pgs.
“U.S. Appl. No. 14/034,963, Non Final Office Action dated Nov. 21, 2014”, 19 pgs.
“U.S. Appl. No. 14/034,963, Notice of Allowance dated Dec. 18, 2015”, 5 pgs.
“U.S. Appl. No. 14/034,963, Preliminary Amendment filed Sep. 24, 2013”, 3 pgs.
“U.S. Appl. No. 14/034,963, Response filed Mar. 20, 2015 to Non-Final Office Action dated Nov. 21, 2014”, 20 pgs.
“U.S. Appl. No. 14/034,963, Response filed Jun. 19, 2015 to Final Office Action dated Apr. 13, 2015”, 17 pgs.
“U.S. Appl. No. 14/034,963, Response filed Sep. 30, 2015 to Non Final Office Action dated Jul. 1, 2015”, 14 pgs.
“U.S. Appl. No. 14/034,963, Response filed Nov. 20, 2015 to Final Office Action dated Oct. 13, 2015”, 12 pgs.
“U.S. Appl. No. 14/063,032, Non Final Office Action dated Jun. 20, 2014”, 6 pgs.
“U.S. Appl. No. 14/063,032, Notice of Allowance dated Dec. 19, 2014”, 6 pgs.
“U.S. Appl. No. 14/063,032, Preliminary Amendment filed Oct. 25,2013”, 3 pgs.
“U.S. Appl. No. 14/063,032, Response filed Oct. 20, 2014 to Non-Final Office Action dated Jun. 20, 2014”, 9 pgs.
“U.S. Appl. No. 14/063,593, Advisory Action dated Aug. 19, 2016”, 3 pgs.
“U.S. Appl. No. 14/063,593, Final Office Action dated Jun. 9, 2016”, 10 pgs.
“U.S. Appl. No. 14/063,593, Non Final Office Action dated Jan. 25, 2016”, 9 pgs.
“U.S. Appl. No. 14/063,593, Non Final Office Action dated Nov. 30, 2016”, 12 pgs.
“U.S. Appl. No. 14/063,593, Notice of Allowance dated May 2, 2017”, 5 pgs.
“U.S. Appl. No. 14/063,593, Notice of Allowance dated May 25, 2017”, 5 pgs.
“U.S. Appl. No. 14/063,593, Preliminary Amendment filed Oct. 25, 2013”, 3 pgs.
“U.S. Appl. No. 14/063,593, Response filed Jan. 4, 2016 to Restriction Requirement dated Nov. 6, 2015”, 6 pgs.
“U.S. Appl. No. 14/063,593, Response filed Feb. 24, 2017 to Non Final Office Action dated Nov. 30, 2016”, 17 pgs.
“U.S. Appl. No. 14/063,593, Response filed Apr. 20, 2016 to Non Final Office Action dated Jan. 25, 2016”, 17 pgs.
“U.S. Appl. No. 14/063,593, Response filed Aug. 11, 2016 to Final Office Action dated Jun. 9, 2016”, 10 pgs.
“U.S. Appl. No. 14/063,593, Restriction Requirement dated Nov. 6, 2015”, 6 pgs.
“U.S. Appl. No. 14/181,033, Non Final Office Action dated May 1, 2015”, 5 pgs.
“U.S. Appl. No. 14/181,033, Notice of Allowance dated Jul. 17, 2015”, 10 pgs.
“U.S. Appl. No. 14/181,033, Response filed Jun. 22, 2015 to Non-Final Office Action dated May 1, 2015”, 11 pgs.
“U.S. Appl. No. 14/278,805, Notice of Allowance dated Dec. 1, 2015”, 8 pgs.
“U.S. Appl. No. 14/278,805, Supplemental Notice of Allowability dated Jan. 21, 2016”, 2 pgs.
“U.S. Appl. No. 14/284,028, Non Final Office Action dated Jul. 7, 2015”, 17 pgs.
“U.S. Appl. No. 14/284,028, Notice of Allowance dated Nov. 6, 2015”, 5 pgs.
“U.S. Appl. No. 14/284,028, Response filed Oct. 6, 2015 to Non Final Office Action dated Jul. 7, 2015”, 15 pgs.
“U.S. Appl. No. 14/284,028, Supplemental Notice of Allowability dated Feb. 26, 2016”, 5 pgs.
“U.S. Appl. No. 14/284,028, Supplemental Preliminary Amendment filed Jul. 8, 2014”, 13 pgs.
“U.S. Appl. No. 14/284,144, Final Office Action dated Aug. 7, 2015”, 13 pgs.
“U.S. Appl. No. 14/284,144, Non Final Office Action dated Mar. 25, 2015”, 26 pgs.
“U.S. Appl. No. 14/284,144, Notice of Allowance dated Oct. 29, 2015”, 8 pgs.
“U.S. Appl. No. 14/284,144, Preliminary Amendment filed May 21, 2014”, 3 pgs.
“U.S. Appl. No. 14/284,144, Response filed Oct. 9, 2015 to Final Office Action dated Aug. 7, 2015”, 13 pgs.
“U.S. Appl. No. 14/284,144, Response filed Jun. 23, 2015 to Non Final Office Action dated Mar. 25, 2015”, 22 pgs.
“U.S. Appl. No. 14/284,144, Supplemental Preliminary Amendment filed Jul. 3, 2014”, 10 pgs.
“U.S. Appl. No. 14/304,009, Notice of Allowance dated Nov. 16, 2016”, 7 pgs.
“U.S. Appl. No. 14/304,009, Preliminary Amendment Filed Jul. 31, 2014”, 7 pgs.
“U.S. Appl. No. 14/490,153, Final Office Action dated Apr. 15, 2015”, 18 pgs.
“U.S. Appl. No. 14/490,153, Non Final Office Action dated Nov. 12, 2014”, 9 pgs.
“U.S. Appl. No. 14/490,153, Notice of Allowance dated Aug. 14, 2015”, 10 pgs.
“U.S. Appl. No. 14/490,153, Preliminary Amendment filed Sep. 18, 2014”, 3 pgs.
“U.S. Appl. No. 14/490,153, Response filed Feb. 18, 2015 to Non-Final Office Action dated Nov. 12, 2014”, 14 pgs.
“U.S. Appl. No. 14/490,153, Response filed Jul. 7, 2015 to Final Office Action dated Apr. 15, 2015”, 14 pgs.
“U.S. Appl. No. 14/660,217, Corrected Notice of Allowance dated May 26, 2016”, 3 pgs.
“U.S. Appl. No. 14/660,217, Non Final Office Action dated Dec. 17, 2015”, 8 pgs.
“U.S. Appl. No. 14/660,217, Notice of Allowance dated Apr. 26, 2016”, 5 pgs.
“U.S. Appl. No. 14/660,217, Preliminary Amendment filed Mar. 18, 2015”, 9 pgs.
“U.S. Appl. No. 14/660,217, Response filed Mar. 23, 2016 to Non Final Office Action dated Dec. 17, 2015”, 14 pgs.
“U.S. Appl. No. 14/740,690, Non Final Office Action dated Dec. 7, 2016”, 19 pgs.
“U.S. Appl. No. 14/740,690, Notice of Allowability dated Aug. 29, 2017”, 2 pgs.
“U.S. Appl. No. 14/740,690, Notice of Allowance dated Jun. 13, 2017”, 9 pgs.
“U.S. Appl. No. 14/740,690, Response filed Mar. 3, 2017 to Non Final Office Action dated Dec. 7, 2016”, 14 pgs.
“U.S. Appl. No. 14/791,952, Corrected Notice of Allowance dated Jul. 21, 2017”, 2 pgs.
“U.S. Appl. No. 14/791,952, Final Office Action dated Mar. 31, 2017”, 8 pgs.
“U.S. Appl. No. 14/791,952, Final Office Action dated Sep. 1, 2016”, 17 pgs.
“U.S. Appl. No. 14/791,952, Non Final Office Action dated Apr. 21, 2016”, 12 pgs.
“U.S. Appl. No. 14/791,952, Non Final Office Action dated Dec. 29, 2016”, 12 pgs.
“U.S. Appl. No. 14/791,952, Notice of Allowance dated May 30, 2017”, 7 pgs.
“U.S. Appl. No. 14/791,952, Preliminary Amendment filed Jul. 7, 2015”, 7 pgs.
“U.S. Appl. No. 14/791,952, Response filed Mar. 20, 2017 to Non Final Office Action dated Dec. 29, 2016”, 12 pgs.
“U.S. Appl. No. 14/791,952, Response filed May 17, 2017—to Final Office Action dated Mar. 31, 2017”, 10 pgs.
“U.S. Appl. No. 14/791,952, Response filed Jul. 15, 2016 to Non Final Office Action dated Apr. 21, 2016”, 18 pgs.
“U.S. Appl. No. 14/791,952, Response filed Nov. 21, 2016 to Final Office Action dated Sep. 1, 2016”, 15 pgs.
“U.S. Appl. No. 14/833,385, Examiner Interview Summary dated Dec. 27, 2017”, 3 pgs.
“U.S. Appl. No. 14/833,385, Final Office Action dated Nov. 13, 2017”, 9 pgs.
“U.S. Appl. No. 14/833,385, Non Final Office Action dated Jun. 19, 2017”, 10 pgs.
“U.S. Appl. No. 14/833,385, Preliminary Amendment filed Aug. 25, 2015”, 6 pgs.
“U.S. Appl. No. 14/833,385, Response filed May 12, 2017 to Restriction Requirement dated Mar. 17, 2017”, 8 pgs.
“U.S. Appl. No. 14/833,385, Response filed Sep. 18, 2017 to Non Final Office Action dated Jun. 19, 2017”, 14 pgs.
“U.S. Appl. No. 14/833,385, Restriction Requirement dated Mar. 17, 2017”, 6 pgs.
“U.S. Appl. No. 14/918,721, Final Office Action dated Oct. 20, 2016”, 5 pgs.
“U.S. Appl. No. 14/918,721, Non Final Office Action dated Jun. 16, 2016”, 6 pgs.
“U.S. Appl. No. 14/918,721, Notice of Allowance dated Feb. 1, 2017”, 9 pgs.
“U.S. Appl. No. 14/918,721, Preliminary Amendment filed Oct. 23, 2015”, 8 pgs.
“U.S. Appl. No. 14/918,721, PTO Response to Rule 312 Communication dated Mar. 17, 2017”, 2 pgs.
“U.S. Appl. No. 14/918,721, Response filed Sep. 12, 2016 to Non Final Office Action dated Jun. 16, 2016”, 12 pgs.
“U.S. Appl. No. 14/918,721, Response filed Dec. 13, 2016 to Final Office Action dated Oct. 20, 2016”, 9 pgs.
“U.S. Appl. No. 14/926,281, Non Final Office Action dated Jun. 21, 2017”, 17 pgs.
“U.S. Appl. No. 14/926,281, Notice of Allowance dated Nov. 16, 2017”, 9 pgs.
“U.S. Appl. No. 14/926,281, Preliminary Amendment filed Oct. 30, 2015”, 8 pgs.
“U.S. Appl. No. 14/926,281, Response filed Sep. 18, 2017 to Non Final Office Action dated Jun. 21, 2017”, 11 pgs.
“U.S. Appl. No. 15/003,091, Preliminary Amendment filed Jan. 22, 2016”, 12 pgs.
“U.S. Appl. No. 15/003,091, Non Final Office Action dated Jun. 20, 2017”, 14 pgs.
“U.S. Appl. No. 15/003,091, Notice of Allowance dated Nov. 6, 2017”, 8 pgs.
“U.S. Appl. No. 15/003,091, PTO Response to Rule 312 Communication dated Jan. 23, 2018”, 2 pgs.
“U.S. Appl. No. 15/003,091, Response filed Sep. 20, 2017 to Non Final Office Action dated Jun. 20, 2017”, 17 pgs.
“U.S. Appl. No. 15/045,799, Non Final Office Action dated Nov. 1, 2016”, 8 pgs.
“U.S. Appl. No. 15/045,799, Notice of Allowance dated Mar. 10, 2017”, 10 pgs.
“U.S. Appl. No. 15/045,799, Preliminary Amendment filed Feb. 2018, 16”, 9 pgs.
“U.S. Appl. No. 15/045,799, PTO Response to Rule 312 Communication dated Apr. 18, 2017”, 2 pgs.
“U.S. Appl. No. 15/045,799, Response filed Feb. 1, 2017 to Non Final Office Action dated Nov. 1, 2016”, 15 pgs.
“U.S. Appl. No. 15/062,252, Preliminary Amendment filed Mar. 9, 2016”, 8 pgs.
“U.S. Appl. No. 15/062,262, Non Final Office Action dated Jul. 22, 2016”, 12 pgs.
“U.S. Appl. No. 15/062,262, Notice of Allowance dated Jan. 31, 2017”, 5 pgs.
“U.S. Appl. No. 15/062,262, PTO Response to Rule 312 Communication dated Mar. 7, 2017”, 2 pgs.
“U.S. Appl. No. 15/062,262, Response filed Oct. 24, 2016 to Non Final Office Action dated Jul. 22, 2016”, 13 pgs.
“U.S. Appl. No. 15/177,734, Non Final Office Action dated Feb. 10, 2017”, 21 pgs.
“U.S. Appl. No. 15/177,734, Notice of Allowance dated May 17, 2017”, 7 pgs.
“U.S. Appl. No. 15/177,734, Preliminary Amendment filed Jun. 22, 2016”, 8 pgs.
“U.S. Appl. No. 15/177,734, Response filed Apr. 19, 2017 to Non Final Office Action dated Feb. 10, 2017”, 22 pgs.
“U.S. Appl. No. 15/211,812, Non Final Office Action dated Jan. 27, 2017”, 5 pgs.
“U.S. Appl. No. 15/211,812, Notice of Allowance dated May 31, 2017”, 5 pgs.
“U.S. Appl. No. 15/211,812, Preliminary Amendment filed Sep. 8, 2016”, 8 pgs.
“U.S. Appl. No. 15/211,812, Response filed Apr. 19, 2017 to Non Final Office Action dated Jan. 27, 2017”, 9 pgs.
“U.S. Appl. No. 15/267,793, Non Final Office Action dated Jun. 14, 2018”, 12 pgs.
“U.S. Appl. No. 15/267,793, Notice of Allowability dated Jan. 17, 2019”, 2 pgs.
“U.S. Appl. No. 15/267,793, Notice of Allowance dated Dec. 21, 2018”, 5 pgs.
“U.S. Appl. No. 15/267,793, Response Filed Apr. 11, 2018 to Restriction Requirement dated Feb. 16, 2018”, 8 pgs.
“U.S. Appl. No. 15/267,793, Response filed Aug. 22, 2018 Non Final Office Action dated Jun. 14, 2018”, 16 pgs.
“U.S. Appl. No. 15/267,793, Restriction Requirement dated Feb. 16, 2018”, 7 pgs.
“U.S. Appl. No. 15/424,328, Non Final Office Action dated Jun. 23, 2017”, 5 pgs.
“U.S. Appl. No. 15/424,328, Notice of Allowance dated Oct. 16, 2017”, 6 pgs.
“U.S. Appl. No. 15/424,328, Preliminary Amendment filed Feb. 28, 2017”, 10 pgs.
“U.S. Appl. No. 15/424,328, Response filed Sep. 20, 2017 to Non Final Office Action dated Jun. 23, 2017”, 9 pgs.
“U.S. Appl. No. 15/435,620, Final Office Action dated Dec. 15, 2017”, 9 pgs.
“U.S. Appl. No. 15/435,620, Non Final Office Action dated Jul. 26, 2017”, 10 pgs.
“U.S. Appl. No. 15/435,620, Notice of Allowance dated Mar. 13, 2018”, 5 pgs.
“U.S. Appl. No. 15/435,620, Preliminary Amendment filed Mar. 20, 2017”, 7 pgs.
“U.S. Appl. No. 15/435,620, Response filed Feb. 12, 2018 to Final Office Action dated Dec. 15, 2017”, 9 pgs.
“U.S. Appl. No. 15/435,620, Response filed Oct. 25, 2017 to Non Final Office Action dated Jul. 26, 2017”, 13 pgs.
“U.S. Appl. No. 15/616,561, Non Final Office Action mailed Aug. 9, 2018”, 8 pgs.
“U.S. Appl. No. 15/616,561, Notice of Allowability dated Feb. 12, 2019”, 2 pgs.
“U.S. Appl. No. 15/616,561, Notice of Allowance dated Dec. 10, 2018”, 7 pgs.
“U.S. Appl. No. 15/616,561, Preliminary Amendment filed Jun. 8, 2017”, 7 pgs.
“U.S. Appl. No. 15/616,561, Response filed Nov. 8, 2018 to Non Final Office Action dated Aug. 9, 2018”, 11 pgs.
“U.S. Appl. No. 15/703,678, Non Final Office Action mailed Apr. 8, 2019”, 11 pgs.
“U.S. Appl. No. 15/703,678, Notice of Allowance dated Sep. 17, 2019”, 7 pgs.
“U.S. Appl. No. 15/703,678, Preliminary Amendment filed Sep. 28, 2017”, 9 pgs.
“U.S. Appl. No. 15/703,678, Response Filed Jan. 3, 2019 to Restriction Requirement dated Nov. 5, 2018”, 8 pgs.
“U.S. Appl. No. 15/703,678, Response filed Jul. 3, 2019 to Non-Final Office Action dated Apr. 8, 2019”, 20 pgs.
“U.S. Appl. No. 15/703,678, Restriction Requirement dated Nov. 5, 2018”, 6 pgs.
“U.S. Appl. No. 15/703,692, Corrected Notice of Allowability dated Jul. 8, 2019”, 2 pgs.
“U.S. Appl. No. 15/703,692, Non Final Office Action dated Jan. 14, 2019”, 11 pgs.
“U.S. Appl. No. 15/703,692, Notice of Allowance dated May 7, 2019”, 5 pgs.
“U.S. Appl. No. 15/703,692, Preliminary Amendment filed Sep. 28, 2017”, 9 pgs.
“U.S. Appl. No. 15/703,692, Response filed Apr. 4, 2019 to Non Final Office Action dated Jan. 14, 2019”, 11 pgs.
“U.S. Appl. No. 15/703,698, Corrected Notice of Allowability dated Dec. 18, 2018”, 2 pgs.
“U.S. Appl. No. 15/703,698, Non Final Office Action dated Apr. 6, 2018”, 7 pgs.
“U.S. Appl. No. 15/703,698, Notice of Allowance dated Sep. 12, 2018”, 5 pgs.
“U.S. Appl. No. 15/703,698, Preliminary Amendment filed Sep. 28, 2017”, 8 pgs.
“U.S. Appl. No. 15/703,698, Response filed Jul. 6, 2018 to Non Final Office Action dated Apr. 6, 2018”, 10 pgs.
“U.S. Appl. No. 15/703,713, Non Final Office Action dated Mar. 27, 2018”, 29 pgs.
“U.S. Appl. No. 15/703,713, Notice of Allowance dated Sep. 25, 2018”, 11 pgs.
“U.S. Appl. No. 15/703,713, Response Filed Jun. 15, 2018 to Non-Final Office Action dated Mar. 27, 2018”, 16 pgs.
“U.S. Appl. No. 15/703,713, Preliminary Amendment filed Sep. 28, 2017”, 7 pgs.
“U.S. Appl. No. 15/720,866, Non Final Office Action dated Sep. 9, 2019”, 12 pgs.
“U.S. Appl. No. 15/720,866, Response filed Jul. 10, 2019 to Restriction Requirement dated May 14, 2019”, 10 pgs.
“U.S. Appl. No. 15/720,866, Response filed Nov. 13, 2017 to Non Final Office Action dated Sep. 14, 2017”, 10 pgs.
“U.S. Appl. No. 15/720,866, Restriction Requirement dated May 14, 2019”, 7 pgs.
“U.S. Appl. No. 15/720,866, Preliminary Amendment filed Nov. 13, 2017”, 9 pgs.
“U.S. Appl. No. 15/827,654, Examiner Interview Summary dated Apr. 26, 2019”, 4 pgs.
“U.S. Appl. No. 15/827,654, Final Office Action dated Feb. 19, 2019”, 19 pgs.
“U.S. Appl. No. 15/827,654, Non Final Office Action dated Sep. 7, 2018”, 21 pgs.
“U.S. Appl. No. 15/827,654, Notice of Allowance dated Jul. 8, 2019”, 8 pgs.
“U.S. Appl. No. 15/827,654, Preliminary Amendment filed Dec. 22, 2017”, 11 pgs.
“U.S. Appl. No. 15/827,654, Response Filed May 20, 2019 to Final Office Action dated Feb. 19, 2019”, 17 pgs.
“U.S. Appl. No. 15/827,654, Response filed Jun. 6, 2018 to Restriction Requirement dated Apr. 6, 2018”, 11 pgs.
“U.S. Appl. No. 15/827,654, Response filed to Non Final Office Action dated Sep. 7, 2018”, 24 pgs.
“U.S. Appl. No. 15/827,654, Restriction Requirement dated Apr. 6, 2018”, 6 pgs.
“U.S. Appl. No. 15/915,886, Non Final Office Action dated Aug. 2, 2019”, 9 pgs.
“U.S. Appl. No. 16/530,423, Preliminary Amendment filed Aug. 28, 2019”, 7 pgs.
“Australian Application Serial No. 2011286306, First Examiner Report dated Jun. 19, 2013”, 4 pgs.
“Australian Application Serial No. 2011286306, Response filed Jun. 3, 2014 to First Examiner Report dated Jun. 19, 2013”, 16 pgs.
“Australian Application Serial No. 2011286307, First Examiner Report dated Oct. 17, 2013”, 2 pgs.
“Australian Application Serial No. 2011286307, Response filed May 21, 2014 to First Examiner Report dated Oct. 17, 2013”, 16 pgs.
“Australian Application Serial No. 2011286308, First Examiner Report dated Jun. 21, 2013”, 4 pgs.
“Australian Application Serial No. 2011286308, Response filed Jun. 6, 2014 First Examiner Report dated Jun. 21, 2013”, 19 pgs.
“Australian Application Serial No. 2011286309, First Examiner Report dated Jun. 21, 2013”, 3 pgs.
“Australian Application Serial No. 2011286309, Response filed Jun. 10, 2014 to First Examiner Report dated Jun. 21, 2013”, 4 pgs.
“Australian Application Serial No. 2011343440, First Examiner Report dated Feb. 17, 2014”, 3 pgs.
“Australian Application Serial No. 2011343440, Response filed Mar. 21, 2014 to Office Action dated Feb. 17, 2014”, 1 pg.
“Australian Application Serial No. 2012341026, First Examiner Report dated Jul. 14, 2014”, 2 pgs.
“Australian Application Serial No. 2012341026, Response filed Nov. 21, 2014 to First Examiner Report dated Jul. 14, 2014”, 1 pg.
“Australian Application Serial No. 2012341026, Statement of Proposed Amendment filed Jun. 18, 2014”, 25 pgs.
“Australian Application Serial No. 2012368262, First Examiner Report dated Nov. 2, 2016”, 4 pgs.
“Australian Application Serial No. 2012368262, Response filed Jan. 17, 2017 to Office Action dated Nov. 2, 2016”, 21 pgs.
“Australian Application Serial No. 2012368262, Response filed May 15, 2017 to Subsequent Examiners Report dated Mar. 16, 2017”, 2 pgs.
“Australian Application Serial No. 2012368262, Subsequent Examiners Report dated Mar. 16, 2017”, 3 pgs.
“Australian Application Serial No. 2013238046, First Examiner Report dated Nov. 26, 2015”, 2 pgs.
“Australian Application Serial No. 2013238046, Response filed Feb. 2, 2016 to First Examiner Report dated Nov. 26, 2015”, 1 pg.
“Australian Application Serial No. 2013238054, First Examiner Report dated Oct. 17, 2016”, 4 pgs.
“Australian Application Serial No. 2013238054, Response filed Jan. 18, 2017 to First Examiner Report dated Oct. 17, 2016”, 9 pgs.
“Australian Application Serial No. 2014250709, First Examiner Report dated Dec. 21, 2015”, 3 pgs.
“Australian Application Serial No. 2014250709, Response filed May 4, 2016 to First Examiner Report dated Dec. 21, 2015”, 12 pgs.
“Australian Application Serial No. 2014250709, Subsequent Examiners Report dated May 31, 2016”, 6 pgs.
“Australian Application Serial No. 2014250710, First Examiner Report dated Dec. 11, 2015”, 7 pgs.
“Australian Application Serial No. 2014250710, Response filed Mar. 22, 2016 to First Examiner Report dated Dec. 11, 2015”, 18 pgs.
“Australian Application Serial No. 2014250710, Response filed May 4, 2016 to Subsequent Examiners Report dated Mar. 23, 2016”, 15 pgs.
“Australian Application Serial No. 2014250710, Subsequent Examiners Report dated Mar. 23, 2016”, 3 pgs.
“Australian Application Serial No. 2014250711, First Examiner Report dated Feb. 12, 2016”, 7 pgs.
“Australian Application Serial No. 2014250711, Response filed Apr. 27, 2016 to First Examiner Report dated Feb. 12, 2016”, 32 pgs.
“Australian Application Serial No. 2015201511, First Examination Report dated Apr. 18, 2016”, 2 pgs.
“Australian Application Serial No. 2015201511, Response filed Jun. 30, 2016 to First Examiner Report dated Apr. 18, 2016”, 12 pgs.
“Australian Application Serial No. 2015238820, First Examination Report dated May 30, 2017”, 3 pgs.
“Australian Application Serial No. 2015238820, Response filed Jul. 12, 2017 to First Examination Report dated May 30, 2017”, 12 pgs.
“Australian Application Serial No. 2016225911, First Examiners Report dated Jun. 2, 2017”, 3 pgs.
“Australian Application Serial No. 2016225911, Response filed Aug. 22, 2017 to First Examiners Report dated Jun. 2, 2017”, 18 pgs.
“Australian Application Serial No. 2017235987, First Examination Report dated Nov. 1, 2018”, 4 pgs.
“Australian Application Serial No. 2017251736, First Examiners Report dated Oct. 31, 2017”, 2 pgs.
“Bi-Cruciate Stabilized Knee System”, Design Rationale, Smith & Nephew Journal, (2006), 20 pgs.
“Canadian Application Serial No. 2,806,321, Office Action dated Jan. 15, 2018”, 3 pgs.
“Canadian Application Serial No. 2,806,321, Response filed Jan. 22, 2018 to Office Action dated Jan. 15, 2018”, 7 pgs.
“Canadian Application Serial No. 2,806,321, Response filed Dec. 6, 2017 to Office Action dated Jun. 15, 2017”, 12 pgs.
“Canadian Application Serial No. 2,806,325, Office Action dated Mar. 14, 2016”, 4 pgs.
“Canadian Application Serial No. 2,806,325, Response filed Sep. 14, 2016 to Office Action dated Mar. 14, 2016”, 17 pgs.
“Canadian Application Serial No. 2,806,326, Examiner's Rule 30(2) Requisition dated Sep. 20, 2018”, 4 pgs.
“Canadian Application Serial No. 2,806,326, Office Action dated Feb. 8, 2018”, 4 pgs.
“Canadian Application Serial No. 2,806,326, Office Action dated Jun. 19, 2017”, 3 pgs.
“Canadian Application Serial No. 2,806,326, Response Filed Mar. 20, 2019 to Examiner's Rule 30(2) Requisition dated Sep. 20, 2018”, 4 pgs.
“Canadian Application Serial No. 2,806,326, Response filed Jul. 20, 2018 to Office Action dated Feb. 8, 2018”, 12 pgs.
“Canadian Application Serial No. 2,821,927, Office Action dated Jan. 25, 2018”, 6 pgs.
“Canadian Application Serial No. 2,821,927, Response filed Jul. 18, 2018 to Office Action dated Jan. 25, 2018”, 10 pgs.
“Canadian Application Serial No. 2,821,927, Voluntary Amendment dated Jun. 14, 2013”, 7 pgs.
“Canadian Application Serial No. 2,824,527, Office Action dated Mar. 17, 2014”, 2 pgs.
“Canadian Application Serial No. 2,824,527, Response filed Sep. 17, 2014 to Office Action dated Mar. 17, 2014”, 14 pgs.
“Canadian Application Serial No. 2,856,070, Preliminary Amendment filed May 25, 2015”, 27 pgs.
“Canadian Application Serial No. 2,856,571 Response filed Jan. 22, 2015 to Office Action dated Jul. 22, 2014”, 24 pgs.
“Canadian Application Serial No. 2,856,571, Office Action dated Jul. 22, 2014”, 2 pgs.
“Canadian Application Serial No. 2,863,375, Office Action dated Apr. 20, 2018”, 3 pgs.
“Canadian Application Serial No. 2,863,375, Response filed Oct. 22, 2018 Office Action dated Apr. 20, 2018”, 12 pgs.
“Canadian Application Serial No. 2,868,825, Office Action dated Dec. 27, 2018”, 3 pgs.
“Canadian Application Serial No. 2,956,119, Examiner's Rule 30(2) Requisition dated Sep. 27, 2018”, 4 pgs.
“Canadian Application Serial No. 2,956,119, Office Action dated Jan. 22, 2018”, 3 pgs.
“Canadian Application Serial No. 2,956,119, Response Filed Mar. 27, 2019 to Examiner's Rule 30(2) Requisition dated Sep. 27, 2018”, 7 pgs.
“Canadian Application Serial No. 2,989,184, Office Action dated Oct. 1, 2018”, 4 pgs.
“Canadian Application Serial No. 2,989,184, Response filed Apr. 1, 2019 to Office Action dated Oct. 1, 2018”, 10 pgs.
“Canadian Application Serial No. 2,806,321, Office Action dated Jun. 15, 2017”, 3 pgs.
“Chinese Application Serial No. 201180045673.3, Office Action dated Feb. 14, 2016”, (W/English Translation), 17 pgs.
“Chinese Application Serial No. 201180045673.3, Office Action dated Mar. 29, 2015”, (W/English Translation), 6 pgs.
“Chinese Application Serial No. 201180045673.3, Office Action dated Aug. 12, 2015”, (W/English Translation), 7 pgs.
“Chinese Application Serial No. 201180045673.3, Response filed Apr. 19, 2016 to Office Action dated Feb. 14, 2016”, No English Translation, 11 pqs.
“Chinese Application Serial No. 201180045673.3, Response filed Jun. 19, 2015 to Office Action dated Mar. 29, 2015”, (W/ English translation of claims), 11 pgs.
“Chinese Application Serial No. 201180045673.3, Response filed Oct. 27, 2015 to Office Action dated Aug. 12, 2015”, (W/ English translation of claims), 9 pgs.
“Chinese Application Serial No. 201180045681.8, Office Action dated Jan. 22, 2015”, (W/English Translation), 11 pgs.
“Chinese Application Serial No. 201180045681.8, Response filed May 14, 2015 to Office Action dated Jan. 22, 2015”, W/ English Claims, 17 pgs.
“Chinese Application Serial No. 201180045683.7, Office Action dated Mar. 9, 2015”, (W/English Translation), 6 pgs.
“Chinese Application Serial No. 201180045683.7, Response filed Jul. 14, 2015 to Office Action dated Mar. 9, 2015”, (W/ English translation of claims), 30 pgs.
“Chinese Application Serial No. 201180045689.4, Office Action dated Jan. 5, 2015”, (W/English Translation), 4 pgs.
“Chinese Application Serial No. 201180045689.4, Office Action dated Feb. 2, 2016”, w/English Translation, 11 pgs.
“Chinese Application Serial No. 201180045689.4, Office Action dated Aug. 5, 2015”, (W/English Translation), 11 pgs.
“Chinese Application Serial No. 201180045689.4, Response filed Apr. 7, 2016 to Office Action dated Feb. 2, 2016”, No English Translation, 8 pgs.
“Chinese Application Serial No. 201180045689.4, Response filed May 1, 2015 to Office Action dated Jan. 5, 2015”, W/ English Claims, 13 pgs.
“Chinese Application Serial No. 201180045689.4,Response filed Oct. 21, 2015 to Office Action dated Aug. 5, 2015”, No English Claims.
“Chinese Application Serial No. 201180067430.X, Office Action dated Aug. 28, 2014”, (W/English Translation), 8 pgs.
“Chinese Application Serial No. 201180067430.X, Response filed Jan. 4, 2015 to Office Action dated Sep. 26, 2014”, (W/ English Translation), 14 pgs.
“Chinese Application Serial No. 201180067757.7, Office Action dated Mar. 2, 2015”, (W/English Translation), 18 pgs.
“Chinese Application Serial No. 201180067757.7, Office Action dated Jun. 1, 2016”, (W/English Translation), 10 pgs.
“Chinese Application Serial No. 201180067757.7, Office Action dated Nov. 16, 2015”, (W/English Translation), 17 pgs.
“Chinese Application Serial No. 201180067757.7, Response filed Jun. 27, 2016 to Office Action dated Nov. 16, 2015”, (W/ English Translation of Claims), 12 pgs.
“Chinese Application Serial No. 201180067757.7, Response filed Jul. 10, 2015 to Office Action dated Mar. 2, 2015”, (W/ English Translation), 13 pgs.
“Chinese Application Serial No. 201180067757.7, Response filed Aug. 11, 2016 to Office Action dated Jun. 1, 2016”, (W/ English Translation Of Claims), 9 pgs.
“Chinese Application Serial No. 201180067757.7, Voluntary Amendment dated Feb. 14, 2014”, (W/ English Translation of Claims), 8 pgs.
“Chinese Application Serial No. 201280067473.2, Office Action dated Feb. 1, 2016”, (W/English Translation), 4 pgs.
“Chinese Application Serial No. 201280067473.2, Office Action dated May 20, 2015”, (W/English Translation), 15 pgs.
“Chinese Application Serial No. 201280067473.2, Office Action dated Nov. 20, 2015”, W/English Translation of Claims, 7 pgs.
“Chinese Application Serial No. 201280067473.2, Response filed Apr. 7, 2016 to Office Action dated Feb. 1, 2016”, (W/ English translation of claims), 11 pgs.
“Chinese Application Serial No. 201280067473.2, Response filed Sep. 7, 2015 to Office Action dated May 20, 2015”, (W/ English translation of claims), 12 pgs.
“Chinese Application Serial No. 201280067473.2, Response filed Dec. 4, 2015 to Office Action dated Nov. 20, 2015”, w/English Claims, 11 pgs.
“Chinese Application Serial No. 201280067481.7, Office Action dated Sep. 30, 2015”, (W/English Translation), 7 pgs.
“Chinese Application Serial No. 201280071940.9, Office Action dated Jul. 22, 2015”, (W/English Translation), 13 pgs.
“Chinese Application Serial No. 201280071940.9, Preliminary Amendment filed Mar. 23, 2015”, W/ English Claims, 11 pgs.
“Chinese Application Serial No. 201380028572.4, Office Action dated Aug. 13, 2015”, (W/English Translation), 16 pgs.
“Chinese Application Serial No. 201380028683.5, Office Action dated Jun. 27, 2016”, (W/English Translation), 8 pgs.
“Chinese Application Serial No. 201380028683.5, Office Action dated Nov. 4, 2015”, (W/English Translation), 16 pgs.
“Chinese Application Serial No. 201380028683.5, Office Action dated Dec. 30, 2016”, (W/English Translation), 4 pgs.
“Chinese Application Serial No. 201380028683.5, Response filed Feb. 8, 2017 to Office Action dated Dec. 30, 2016”, (W/ English Translation), 13 pgs.
“Chinese Application Serial No. 201380028683.5, Response filed Mar. 18, 2016 to Office Action dated Nov. 4, 2015”, (W/ English Translation of Claims), 11 pgs.
“Chinese Application Serial No. 201380028683.5, Response filed Sep. 6, 2016 to Office Action dated Jun. 27, 2016”, (W/ English Translation of Claims), 11 pgs.
“Chinese Application Serial No. 201510394094.X, Office Action dated May 24, 2017”, (W/English Translation), 11 pgs.
“Chinese Application Serial No. 201510394094.X, Office Action dated Aug. 30, 2016”, (W/English Translation), 14 pgs.
“Chinese Application Serial No. 201510394094.X, Office Action dated Nov. 3, 2017”, (W/English Translation), 10 pgs.
“Chinese Application Serial No. 201510394094.X, Response filed Jan. 16, 2017 to Office Action dated Aug. 30, 2016”, (W/ English Translation of Claims), 11 pgs.
“Chinese Application Serial No. 201510394094.X, Response filed Jan. 18, 2018 to Office Action dated Nov. 3, 2017”, (W/ English Claims), 10 pgs.
“Chinese Application Serial No. 201510394094.X, Response filed Jul. 10, 2017 to Office Action dated May 24, 2017”, (W/ English Translation), 10 pgs.
“Chinese Application Serial No. 201510640436.1, Office Action dated Sep. 28, 2016”, (W/English Translation), 13 pgs.
“Chinese Application Serial No. 201510640436.1, Response filed Feb. 16, 2017 to Office Action dated Sep. 28, 2016”, (W/ English Translation), 18 pgs.
“Chinese Application Serial No. 201610634595.5, Office Action dated Apr. 20, 2018”, (W/English Translation), 8 pgs.
“Chinese Application Serial No. 201610634595.5, Office Action dated Jun. 21, 2017”, w/English Translation, 9 pgs.
“Chinese Application Serial No. 201610634595.5, Response filed Jun. 4, 2018 to Office Action dated Apr. 20, 2018”, (W/ English Translation of Claims), 8 pgs.
“Chinese Application Serial No. 201610634595.5, Response filed Nov. 3, 2017 to Office Action dated Jun. 21, 2017”, w/English Claims, 8 pgs.
“Chinese Application Serial No. 201610685172.6, Office Action dated Apr. 10, 2017”, (W/English Translation), 11 pgs.
“Chinese Application Serial No. 201610685172.6, Office Action dated Sep. 28, 2017”, (W/English Translation), 9 pgs.
“Chinese Application Serial No. 201610685172.6, Response filed Dec. 13, 2017 to Office Action dated Sep. 28, 2017”, (W/ English Claims), 13 pgs.
“Chinese Application Serial No. 201680061268.3, Office Action dated Apr. 24, 2019”, (W/English Translation), 11 pgs.
“Chinese Application Serial No. 201680061268.3, Response filed Aug. 21, 2019 to Office Action dated Apr. 24, 2019”, (W/ English Claims), 8 pgs.
“Complete Knee Solution Surgical Technique for the CR-Flex Fixed Bearing Knee”, Zimmer Nexgen, (2003), 22 pgs.
“European Application Serial No. 11738918.9, Examination Notification Art. 94(3) dated Oct. 23, 2014”, 5 pgs.
“European Application Serial No. 11738918.9, Preliminary Amendment dated Sep. 24, 2013”, 11 pgs.
“European Application Serial No. 11738918.9, Response filed Mar. 2, 2015 to Examination Notification Art. 94(3) dated Oct. 23, 2014”, 14 pgs.
“European Application Serial No. 11738919.7, Examination Notification Art. 94(3) dated Jul. 7, 2014”, 4 pgs.
“European Application Serial No. 11738919.7, Preliminary Amendment filed Nov. 4, 2013”, 25 pgs.
“European Application Serial No. 11738919.7, Response filed Nov. 13, 2014 to Examination Notification Art. 94(3) dated Jul. 7, 2014”, 14 pgs.
“European Application Serial No. 11738920.5, Communication Pursuant to Article 94(3) EPC dated Mar. 15, 2016”, 4 pgs.
“European Application Serial No. 11738920.5, Preliminary Amendment Sep. 24, 2013”, 9 pgs.
“European Application Serial No. 11738920.5, Response filed Jul. 25, 2016 to Communication Pursuant to Article 94(3) EPC dated Mar. 15, 2016”, 6 pgs.
“European Application Serial No. 11738920.5, Response filed Sep. 24, 2013 to Communication pursuant to Rules 161(2) and 162 EPC dated Mar. 15, 2013”, 22 pgs.
“European Application Serial No. 11758060.5, Communication Pursuant to Article 94(3) EPC dated Jul. 12, 2016”, 3 pgs.
“European Application Serial No. 11758060.5, Communication Pursuant to Article 94(3) EPC dated Dec. 11, 2015”, 4 pgs.
“European Application Serial No. 11758060.5, Preliminary Amendment filed Nov. 4, 2013”, 15 pgs.
“European Application Serial No. 11758060.5, Response filed Apr. 21, 2016 to Communication Pursuant to Article 94(3) EPC dated Dec. 11, 2015”, 16 pgs.
“European Application Serial No. 11758060.5, Response filed Nov. 15, 2016 to Communication Pursuant to Article 94(3) EPC dated Jul. 12, 2016”, 23 pgs.
“European Application Serial No. 11802835.6, Communication Pursuant to Article 94(3) EPC dated Dec. 11, 2017”, 4 pgs.
“European Application Serial No. 11802835.6, Response filed Apr. 23, 2018 to Office Action dated Dec. 11, 2017”, 16 pgs.
“European Application Serial No. 11808493.8, Communication Pursuant to Article 94(3) EPC dated Dec. 7, 2015”, 4 pgs.
“European Application Serial No. 11808493.8, Examination Notification Art. 94(3) dated Feb. 20, 2015”, 6 pgs.
“European Application Serial No. 11808493.8, Response filed Feb. 26, 2014 to Communication pursuant to Rules 161(1) and 162 EPC dated Aug. 16, 2013”, 14 pgs.
“European Application Serial No. 11808493,8, Response filed Apr. 18, 2016 to Communication Pursuant to Article 94(3) EPC dated Dec. 7, 2015”, 15 pgs.
“European Application Serial No. 11808493.8, Response filed Jul. 2, 2015 to Examination Notification Art. 94(3) dated Feb. 20, 2015”, 13 pgs.
“European Application Serial No. 11815029.1, Communication Pursuant to Article 94(3) EPC dated Sep. 29, 2016”, 4 pgs.
“European Application Serial No. 11815029.1, Extended European Search Report dated Dec. 10, 2013”, 8 pgs.
“European Application Serial No. 11815029.1, Response filed Apr. 10, 2017 to Communication Pursuant to Article 94(3) EPC dated Sep. 29, 2016”, 22 pgs.
“European Application Serial No. 11815029.1, Response filed Jul. 21, 2014 Extended European Search Report dated Dec. 10, 2013”, 15 pgs.
“European Application Serial No. 12718882.9, Communication Pursuant to Article 94(3) EPC dated Dec. 1, 2015”, 11 pgs.
“European Application Serial No. 12718882.9, Response filed Feb. 10, 2015 to Communication Pursuant to Rules 161(1) and 162 EPC dated Jul. 31, 2014”, 11 pgs.
“European Application Serial No. 12718882.9, Response filed Apr. 11, 2016 to Communication Pursuant to Article 94(3) EPC dated Dec. 1, 2015”, 12 pgs.
“European Application Serial No. 12718883.7, Communication Pursuant to Article 94(3) EPC dated Dec. 2, 2015”, 4 pgs.
“European Application Serial No. 12718883.7, Communication Pursuant to Rules 161(1) and 162 EPC dated Jul. 31, 2014”, 2 pgs.
“European Application Serial No. 12718883.7, Intention to Grant dated May 20, 2016”, 5 pgs.
“European Application Serial No. 12718883.7, Response filed Feb. 10, 2015 to Communication Pursuant to Rules 161(1) and 162 EPC dated Jul. 31, 2014”, 16 pgs.
“European Application Serial No. 12718883.7, Response filed Apr. 12, 2016 to Communication Pursuant to Article 94(3) EPC dated Dec. 2, 2015”, 30 pgs.
“European Application Serial No. 12719236.7 Response filed Feb. 9, 2015 to Communication Pursuant to Rules 161(1) and 162 EPC dated Jul. 30, 2014”, 10 pgs.
“European Application Serial No. 12719236.7, Decision to Grant dated Feb. 18, 2016”, 3 pgs.
“European Application Serial No. 12719236.7, Office Action dated Aug. 27, 2015”, 7 pgs.
“European Application Serial No. 1270352.9 Response filed Feb. 9, 2015 to Communication Pursuant to Rules 161(1) and 162 EPC dated Jul. 30, 2014”, 10 pgs.
“European Application Serial No. 12756058.9, Communication Pursuant to Article 94(3) EPC dated Feb. 18, 2019”, 4 pgs.
“European Application Serial No. 12756058.9, Office Action dated Jan. 17, 2017”, 5 Pgs.
“European Application Serial No. 12756058.9, Preliminary Amendment filed Apr. 20, 2015”, 12 pgs.
“European Application Serial No. 12756058.9, Response filed May 26, 2017 to Office Action dated Jan. 17, 2017”, 16 pgs.
“European Application Serial No. 12756058.9, Response filed Jun. 28, 2019 to Communication Pursuant to Article 94(3) EPC dated Feb. 18, 2019”, 21 pgs.
“European Application Serial No. 12756869.9 Response filed Feb. 10, 2015 to Communication Pursuant to Rule 161(1) and 162 EPC dated Jul. 31, 2014”, 14 pgs.
“European Application Serial No. 12756869.9, Examination Notification Art. 94(3) dated Jul. 2, 2015”, 4 pgs.
“European Application Serial No. 12756869.9, Response filed Nov. 12, 2015 to Examination Notification Art. 94(3) dated Jul. 2, 2015”, 28 pgs.
“European Application Serial No. 13716636.9, Communication Pursuant to Article 9 4(3) EPC dated Nov. 16, 2015”, 4 pgs.
“European Application Serial No. 13716636.9, Communication Pursuant to Article 94(3) EPC dated Nov. 17, 2016”, 4 pgs.
“European Application Serial No. 13716636.9, Communication Pursuant to Article 94(3) EPC dated Jun. 6, 2016”, 5 pgs.
“European Application Serial No. 13716636.9, Communication pursuant to Rules 161(1) and 162 EPC dated Dec. 12, 2014”, 2 pgs.
“European Application Serial No. 13716636.9, Response filed Mar. 24, 2016 to Communication Pursuant to Article 94(3) EPC dated Nov. 16, 2015”, 18 pgs.
“European Application Serial No. 13716636.9, Response filed Mar. 27, 2017 to Communication Pursuant to Article 94(3) EPC dated Nov. 17, 2016”, 15 pgs.
“European Application Serial No. 13716636.9, Response filed Jun. 22, 2015 to Communication pursuant to Rules 161(1) and 162 EPC dated Dec. 12, 2014”, 10 pgs.
“European Application Serial No. 13716636.9, Response filed Oct. 17, 2016 to Communication Pursuant to Article 94(3) EPC dated Jun. 6, 2016”, 5 pgs.
“European Application Serial No. 14190180.1, Extended European Search Report dated Sep. 24, 2015”, 8 pgs.
“European Application Serial No. 15160934.4, Communication Pursuant to Article 94(3) EPC dated Apr. 26, 2018”, 5 pgs.
“European Application Serial No. 15160934.4, Extended European Search Report dated Jun. 1, 2016”, 8 pgs.
“European Application Serial No. 15160934.4, Response filed Aug. 30, 2018 to Communication Pursuant to Article 94(3) EPC dated Apr. 26, 2018”, 63 pgs.
“European Application Serial No. 15160934.4, Response filed Dec. 21, 2016 to Extended European Search Report dated Jun. 1, 2016”, 5 pgs.
“European Application Serial No. 15174394.5, Extended European Search Report dated Mar. 21, 2016”, 8 pgs.
“European Application Serial No. 15174394.5, Response filed Nov. 18, 2016 to Extended European Search Report dated Mar. 21, 2016”, 12 pgs.
“European Application Serial No. 15191781.2, Communication Pursuant to Article 94(3) EPC dated Jan. 8, 2018”, 4 pgs.
“European Application Serial No. 15191781.2, Extended European Search Report dated Mar. 1, 2017”, 8 pgs.
“European Application Serial No. 15191781.2, Response filed May 17, 2018 to Communication Pursuant to Article 94(3) EPC dated Jan. 8, 2018”, 58 pgs.
“European Application Serial No. 15191781.2, Response filed Sep. 28, 2017 to Extended European Search Report dated Mar. 1, 2017”, 14pgs.
“European Application Serial No. 16156228.5, Extended European Search Report dated May 11, 2017”, 5 pgs.
“European Application Serial No. 16183635.8, Extended European Search Report dated Jun. 30, 2017”, 9 pgs.
“European Application Serial No. 16183635.8, Response filed Mar. 27, 2018 to Extended European Search Report dated Jun. 30, 2017”, 8 pgs.
“European Application Serial No. 16189084.3, Extended European Search Report dated Oct. 9, 2017”, 9 pgs.
“European Application Serial No. 16189084.3, Response filed May 10, 2018 to Extended European Search Report dated Oct. 9, 2017”, 20 pgs.
“European Application Serial No. 16770657.1, Communication Pursuant to Article 94(3) EPC dated May 20, 2019”, 3 pgs.
“European Application Serial No. 16770657.1, Response filed Nov. 26, 18 to Office Action dated May 14, 2018”, 17 pgs.
“European Application Serial No. 17157909.7, Extended European Search Report dated Jul. 17, 2018”, 7 pgs.
“European Application Serial No. 17157909.7, Response Filed Feb. 15, 2019 to Extended European Search Report dated Jul. 17, 2018”, 37 pgs.
“European Application Serial No. 17163432.2, Extended European Search Report dated May 14, 2018”, 6 pgs.
“European Application Serial No. 17163440.5, Extended European Search Report dated Jan. 3, 2019”, 16 pgs.
“European Application Serial No. 17163440.5, Partial European Search Report dated Jul. 23, 2018”, 15 pgs.
“European Application Serial No. 17163440.5, Response filed Jul. 22, 2019 to Extended European Search Report dated Jan. 3, 2019”, 14 pgs.
“European Application Serial No. 17168095.2, Extended European Search Report dated Jun. 8, 2018”, 8 pgs.
“European Application Serial No. 17168095.2, Response Filed Jan. 17, 2019 Extended European Search Report dated Jun. 8, 2018”, 29 pgs.
“European Application Serial No. 17168308.9, Extended European Search Report dated Jun. 13, 2018”, 8 pgs.
“European Application Serial No. 17168308.9, Response Filed Jan. 17, 2019 to Extended European Search Report dated Jun. 13, 2018”, 24 pgs.
“Gender Solutions Natural Knee Flex System: Because Men and Women are Different”, Zimmer, Inc., (2007, 2009), 6 pg.
“Gender Solutions Natural Knee Flex System: Surgical Technique”, Zimmer, Inc., (2007, 2008, 2009), 36 pgs.
“Gender Solutions Natural-Knee Flex System”, Zimmer, Inc., (2007, 2009), 6 pgs.
“Indian Application Serial No. 1544/DELNP/2013, Office Action dated May 21, 2019”, (W/English Translation), 10 pgs.
“International Application Serial No. PCT/US2011/045077, International Preliminary Report on Patentability dated Jul. 5, 2012”, 23 pgs.
“International Application Serial No. PCT/US2011/045077, International Search Report and Written Opinion dated Jan. 9, 2012”, 15 pgs.
“International Application Serial No. PCT/US2011/045078, International Preliminary Report on Patentability dated Feb. 7, 2013”, 11 pgs.
“International Application Serial No. PCT/US2011/045078, International Search Report and Written Opinion dated Jan. 9, 2012”, 14 pgs.
“International Application Serial No. PCT/US2011/045080, International Preliminary Report on Patentability dated Feb. 7, 2013”, 13 pgs.
“International Application Serial No. PCT/US2011/045080, International Search Report dated Jan. 9, 2012”, 7 pgs.
“International Application Serial No. PCT/US2011/045080, Written Opinion dated Jan. 9, 2012”, 11 pgs.
“International Application Serial No. PCT/US2011/045082, International Preliminary Report on Patentability dated Feb. 7, 2013”, 11 pgs.
“International Application Serial No. PCT/US2011/045082, International Search Report dated Jan. 9, 2012”, 5 pgs.
“International Application Serial No. PCT/US2011/045082, Written Opinion dated Jan. 9, 2012”, 10 pgs.
“International Application Serial No. PCT/US2011/045083, International Preliminary Report on Patentability dated Feb. 7, 2013”, 8 pgs.
“International Application Serial No. PCT/US2011/045083, International Search Report dated Dec. 7, 2011”, 2 pgs.
“International Application Serial No. PCT/US2011/045083, Written Opinion dated Dec. 7, 2011”, 6 pgs.
“International Application Serial No. PCT/US2011/051021, International Preliminary Report on Patentability dated Mar. 21, 2013”, 8 pgs.
“International Application Serial No. PCT/US2011/051021, International Search Report dated Nov. 23, 2011”, 12 pgs.
“International Application Serial No. PCT/US2011/051021, Written Opinion dated Nov. 23, 2011”, 7 pgs.
“International Application Serial No. PCT/US2011/064435, International Preliminary Report on Patentability dated Jun. 27, 2013”, 9 pgs.
“International Application Serial No. PCT/US2011/064435, Search Report dated Jun. 21, 2012”, 5 pgs.
“International Application Serial No. PCT/US2011/064435, Written Opinion dated Jun. 21, 2012”, 7 pgs.
“International Application Serial No. PCT/US2011/065683, International Preliminary Report on Patentability dated Jun. 27, 2013”, 11 pgs.
“International Application Serial No. PCT/US2011/065683, International Search Report dated Apr. 24, 2012”, 12 pgs.
“International Application Serial No. PCT/US2011/065683, Written Opinion dated Apr. 24, 2012”, 10 pgs.
“International Application Serial No. PCT/US2012/035679, International Preliminary Report on Patentability dated May 30, 2014”, 8 pgs.
“International Application Serial No. PCT/US2012/035679, International Search Report dated Jun. 8, 2012”, 4 pgs.
“International Application Serial No. PCT/US2012/035679, Written Opinion dated Jun. 8, 2012”, 7 pgs.
“International Application Serial No. PCT/US2012/035680, International Preliminary Report on Patentability dated May 30, 2014”, 13 pgs.
“International Application Serial No. PCT/US2012/035680, Search Report dated Oct. 9, 2012”, 7 pgs.
“International Application Serial No. PCT/US2012/035680, Written Opinion dated Oct. 9, 2012”, 11 pgs.
“International Application Serial No. PCT/US2012/035683, International Preliminary Report on Patentability dated May 30, 2014”, 9 pgs.
“International Application Serial No. PCT/US2012/035683, International Search Report and Written Opinion dated Jun. 5, 2012”, 12 pgs.
“International Application Serial No. PCT/US2012/035684, International Preliminary Report on Patentability dated May 30, 2014”, 14 pgs.
“International Application Serial No. PCT/US2012/035684, International Search Report dated Aug. 8, 2012”, 9 pgs.
“International Application Serial No. PCT/US2012/035684, Written Opinion dated Jun. 8, 2012”, 12 pgs.
“International Application Serial No. PCT/US2012/052132, International Preliminary Report on Patentability dated Jun. 5, 2014”, 12 pgs.
“International Application Serial No. PCT/US2012/052132, International Search Report dated Jan. 10, 2013”, 5 pgs.
“International Application Serial No. PCT/US2012/052132, Invitation to Pay Additional Fees and Partial Search Report dated Nov. 15, 2012”, 7 pgs.
“International Application Serial No. PCT/US2012/052132, Written Opinion dated Jan. 10, 2013”, 10 pgs.
“International Application Serial No. PCT/US2012/052340, International Preliminary Report on Patentability dated Aug. 14, 2014”, 8 pgs.
“International Application Serial No. PCT/US2012/052340, Search Report dated Oct. 12, 2012”, 4 pgs.
“International Application Serial No. PCT/US2012/052340, Written Opinion dated Oct. 12, 2012”, 6 pgs.
“International Application Serial No. PCT/US2013/034286, International Preliminary Report on Patentability dated Oct. 9, 2014”, 8 pgs.
“International Application Serial No. PCT/US2013/034286, International Search Report dated Jun. 25, 2013”, 6 pgs.
“International Application Serial No. PCT/US2013/034286, Written Opinion dated Jun. 25, 2013”, 6 pgs.
“International Application Serial No. PCT/US2013/034293, International Preliminary Report on Patentability dated Oct. 9, 2014”, 9 pgs.
“International Application Serial No. PCT/US2013/034293, International Search Report dated Jun. 25, 2013”, 6 pgs.
“International Application Serial No. PCT/US2013/034293, Written Opinion dated Jun. 25, 2013”, 7 pgs.
“International Application Serial No. PCT/US2016/052163, International Preliminary Report on Patentability dated Apr. 5, 2018”, 10 pgs.
“International Application Serial No. PCT/US2016/052163, International Search Report dated Jan. 20, 2017”, 7 pgs.
“International Application Serial No. PCT/US2016/052163, Invitation to Pay Add'l Fees and Partial Search Report dated Nov. 7, 2016”, 7 pgs.
“International Application Serial No. PCT/US2016/052163, Written Opinion dated Jan. 20, 2017”, 8 pgs.
“International Application Serial No. PCT/US2018/021571, International Preliminary Report on Patentability dated Sep. 19, 2019”, 8 pgs.
“International Application Serial No. PCT/US2018/021571, International Search Report dated Jun. 7, 2018”, 6 pgs.
“International Application Serial No. PCT/US2018/021571, Written Opinion dated Jun. 7, 2018”, 6 pgs.
“Intramedullary Instrumentation Surgical Technique for the NexGen Cruciate Retaining & Legacy Posterior Stabilized Knee”, Zimmer, Inc. Nexgen Complete Knee Solution, 97-5973-102, Rev. 1, (1995, 1997, 1998), 36 pgs.
“Japanese Application Serial No. 2015-162707, Office Action dated Jun. 28, 2016”, (W/English Translation), 8 pgs.
“Japanese Application Serial No. 2013-521854, Notice of Reason for Rejection dated Sep. 16, 2014”, (W/ English Translation), 6 pgs.
“Japanese Application Serial No. 2013-521854, Response filed Dec. 16, 2014 to Notice of Reason for Rejection dated Sep. 16, 2014”, W/ English Claims, 11 pgs.
“Japanese Application Serial No. 2013-521855, Amendment filed Jul. 22, 2014”, (W/ English Translation), 20 pgs.
“Japanese Application Serial No. 2013-521855, Office Action dated Mar. 24, 2015”, W/ English Translation, 8 pgs.
“Japanese Application Serial No. 2013-521856, Notice of Allowance dated Jan. 5, 2016”, w/English Translation, 6 pgs.
“Japanese Application Serial No. 2013-521856, Office Action dated Sep. 1, 2015”, (W/ English Translation), 5 pgs.
“Japanese Application Serial No. 2013-521856, Response filed Dec. 1, 2015 to Office Action dated Sep. 1, 2015”, w/English Translation, 9 pgs.
“Japanese Application Serial No. 2013-521857, Notice of Allowance dated Feb. 9, 2016”, w/English Translation, 6 pgs.
“Japanese Application Serial No. 2013-521857, Notice of Reasons for Rejection dated Aug. 18, 2015”, (W/ English Translation), 6 pgs.
“Japanese Application Serial No. 2013-521857, Preliminary Amendment filed May 18, 2014”, (W/ English translation of claims), 9 pgs.
“Japanese Application Serial No. 2013-521857, Response filed Jan. 25, 2016 to Notice of Reasons for Rejection dated Aug. 18, 2015”, (W/ English Translation), 17 pgs.
“Japanese Application Serial No. 2013-544655, Office Action dated Mar. 8, 2016”, (W/ English Translation), 8 pgs.
“Japanese Application Serial No. 2013-544655, Office Action dated Sep. 29, 2015”, (W/ English Translation), 7 pgs.
“Japanese Application Serial No. 2013-544655, Response filed Jan. 4, 2016 to Office Action dated Sep. 29, 2015”, (English Translation of Claims), 14 pgs.
“Japanese Application Serial No. 2013-544655, Response filed Jul. 14, 2016 to Office Action dated Mar. 8, 2016”, (w/ English Translation of Claims), 13 pgs.
“Japanese Application Serial No. 2013-544858, Request for Examination filed Feb. 4, 2014”, (With English Translation), 14 pgs.
“Japanese Application Serial No. 2014-121515, Notice of Reasons for Rejection dated Jan. 5, 2016”, (W/ English Translation), 9 pgs.
“Japanese Application Serial No. 2014-121515, Office Action dated Jun. 2, 2015”, (W/ English Translation), 10 pgs.
“Japanese Application Serial No. 2014-121515, Response filed May 11, 2016 to Notice of Reasons for Rejection dated Jan. 5, 2016”, (W/ English Translation Of Claims), 11 pgs.
“Japanese Application Serial No. 2014-121515, Response filed Aug. 20, 2015 to Office Action dated Jun. 2, 2015”, (W/ English Translation Of Claims), 6 pgs.
“Japanese Application Serial No. 2014-542297, Office Action dated May 31, 2016”, (W/ English Translation Of Claims), 6 pgs.
“Japanese Application Serial No. 2014-542297, Office Action dated Jun. 30, 2015”, (W/ English Translation), 10 pgs.
“Japanese Application Serial No. 2014-542297, Office Action dated Nov. 24, 2015”, (W/ English Translation), 10 pgs.
“Japanese Application Serial No. 2014-542297, Response filed Feb. 23, 2016 to Office Action dated Nov. 24, 2015”, (W/ English Translation Of Claims), 15 pgs.
“Japanese Application Serial No. 2014-542297, Response filed Jun. 8, 2016 to Office Action dated May 31, 2016”, (W/ English Translation Of Claims), 14 pgs.
“Japanese Application Serial No. 2014-542297, Response filed Sep. 28, 2015 to Office Action dated Jun. 30, 2015”, (W/ English Translation Of Claims), 16 pgs.
“Japanese Application Serial No. 2014-542301, Office Action dated May 12, 2015”, (W/ English Translation), 6 pgs.
“Japanese Application Serial No. 2014-542301, Response filed Aug. 10, 2015 to Office Action dated May 12, 2015”, (W/ English translation of claims), 21 pgs.
“Japanese Application Serial No. 2014-554709, Office Action dated Jul. 5, 2016”, (W/ English Translation), 6 pgs.
“Japanese Application Serial No. 2014-554709, Preliminary Amendment filed Jul. 29, 2015”, (W/ English translation of claims), 8 pgs.
“Japanese Application Serial No. 2014-554709, Response filed Dec. 19, 2016 to Office Action dated Jul. 5, 2016”, (W/ English Translation of Claims), 11 pgs.
“Japanese Application Serial No. 2015-162707, Office Action dated Nov. 29, 2016”, (W/ English Translation), 3 pgs.
“Japanese Application Serial No. 2015-162707, Response filed Jan. 26, 2017 to Office Action dated Nov. 27, 2016”, (W/ English Translation), 16 pgs.
“Japanese Application Serial No. 2015-199496, Office Action dated Sep. 6, 2016”, (W/ English Translation), 5 pgs.
“Japanese Application Serial No. 2015-199496, Response filed Dec. 5, 2016 to Office Action dated Sep. 6, 2016”, (W/ English Translation of Claims), 9 pgs.
“Japanese Application Serial No. 2015-503563, Office Action dated Dec. 20, 2016”, (W/ English Translation), 10 pgs.
“Japanese Application Serial No. 2015-503563, Response Filed Mar. 13, 2017 to Office Action dated Dec. 20, 2016”, (W/ English Translation), 9 pgs.
“Japanese Application Serial No. 2016-145390, Office Action dated Apr. 25, 2017”, (W/ English Translation), 5 pgs.
“Japanese Application Serial No. 2016-145390, Response filed Jul. 3, 2017 to Office Action dated Apr. 25, 2017”, (W/ English Translation of Claims), 16 pgs.
“Japanese Application Serial No. 2017-161246, Office Action dated May 15, 2018”, (W/ English Translation), 6 pgs.
“Legacy Implant Options”, Nexgen Complete Knee Solution, (2002), 8 pgs.
“LPS-Flex Fixed Bearing Knee: Surgical Technique”, Zimmer, Inc., (2004, 2007, 2008), 16 pgs.
“Mexican Application Serial No. MX/a/2013/000988, Office Action dated Mar. 18, 2015”, w/English Claims, 17 pgs.
“Mexican Application Serial No. MX/a/2013/000988, Response filed Jun. 1, 2015 to Office Action dated Mar. 18, 2015”, (W/English Translation), 12 pgs.
“Mexican Application Serial No. MX/A/2013/000988. Office Action dated Jun. 5, 2015”, w/summary in English, 6 pgs.
“Mexican Application Serial No. MX/A/2013/000990, Final Office Action dated Feb. 4, 2016”, w/ summary in English, 4 pgs.
“Mexican Application Serial No. MX/A/2013/000990, Office Action dated Feb. 19, 2015”, (W/English Translation), 4 pgs.
“Mexican Application Serial No. MX/A/2013/000990, Response filed Apr. 29, 2015 to Office Action dated Feb. 19, 2015”, W/ English Claims, 18 pgs.
“MIS Minimally Invasive Solution, The M/G Unicompartmental Knee Minimally Invasive Surgical Technique”, Zimmer, Inc. Nexgen Complete Knee Solution, 97-5791-02, (Aug. 14, 2008), 27 pgs.
“Multi-Reference 4-in-1 Femoral Instrumentation Surgical Technique for NexGen Cruciate Retaining & NexGen Legacy Posterior Stabilized Knees”, Zimmer, Inc. Nexgen Complete Knee Solution, 97-5973-402 Rev. 1, (1998, 2000), 18 pgs.
“Natural-Knee II Primary System Surgical Technique”, Zimmer, Inc., (2005), 48 pgs.
“Nexgen Complete Knee Solution”, Extramedullary/Intramedullary Tibial Resector: Surgical Technique, Zimmer, Inc. 97-5997-002-00 Rev. 2, (2000, 2008, 2009), 28 pgs.
“Nexgen Complete Knee Solution”, Extramedullary/Intramedullary Tibial Resector: Surgical Technique, Zimmer, Inc. 97-5997-02 Rev 1, (2000), 26 pgs.
“Nexgen Complete Knee Solution for the Legacy Knee LPS-Flex Fixed Bearing Knee”, Zimmer Surgical Technique, 97-5964-102-00, (2004, 2007), 12 pgs.
“NexGen Complete Knee Solution, Intramedullary Instrumentation Surgical Technique for the NexGen Cruciate Retaining & Legacy Posterior Stabilized Knee”, Zimmer, Inc., (1995, 1997, 1998), 1-33.
“NexGen Implant Options Surgeon-Specific”, Zimmer Inc., (2000), 16 pgs.
“NexGen LPS Fixed Knee: Surgical Technique”, Zimmer Inc., (2002, 2008), 44 pgs.
“NexGen LPS-Flex Mobile and LPS-Mobile Bearing Knees”, Zimmer, Inc., (2007, 2008), 4 pgs.
“NexGen Trabecular Metal Modular Plates”, Zimmer Inc., (2007), 19 pgs.
“Persona “Medial Congruent Articular Surface” System Overview”, Zimmer, Inc., (2015), 6 pgs.
“Persona “The Personalized Knee System””, Medial Congruent Sales Training, Zimmer, Inc., (Jul. 2015), 53 pgs.
“Persona ”The Personalized Knee System“ Medial Congruent Advanced Bearings”, Zimmer, Inc., (2015), 2 pgs.
“Persona “The Personalized Knee System” Medial Congruent Articular Surface Design Rationale”, Zimmer, Inc., (2015), 20 pgs.
“Persona “The Personalized Knee System” Persona Medial Congruent”, Mar. 24-28, 2015 at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting., (Mar. 2015), 1 pg.
“Persona “The Personalized Knee System” Surgical Technique”, Zimmer, Inc., (2015), 72 pgs.
“Persona Medial Congruent Articular Surface”, Sales Training, Zimmer Biomet, (Jan. 2016), 71 pgs.
“PFC Sigma Knee System with Rotating Platform Technical/ Monograph”, Depuy PFC Sigma RP, 0611-29-050 (Rev. 3), (1999), 70 pgs.
“Primary/Revision Surgical Technique for NexGen Rotating Hinge Knee (RHK)”, Zimmer, Inc. Nexgen Complete Knee Solution, 97-5880-02, (2002), 116 pgs.
“Revision Instrumentation Surgical Technique for Legacy Knee Constrained Condylar Knee”, Zimmer, Inc. Nexgen Complete Knee Solution, 97-5994-202, (2001), 61 pgs.
“Russian Application Serial No. 2013106942, Office Action dated Apr. 16, 2015”, W/ English Translation, 5 pgs.
“Russian Application Serial No. 2013106942, Response filed Jul. 15, 2015 Office Action dated Apr. 16, 2015”, (W/ English translation of claims), 146 pgs.
“Russian Application Serial No. 2013106943, Office Action dated Jul. 1, 2015”, (W/ English Translation), 6 pgs.
“Russian Application Serial No. 2013106943, Office Action dated Dec. 28, 2015”, w/ partial English Translation, 6 pgs.
“Russian Application Serial No. 2013106943, Response filed Apr. 28, 2016 to Office Action dated Dec. 28, 2015”, (W/ English translation of claims), 19 pgs.
“Russian Application Serial No. 2013106943, Response filed Oct. 30, 2015 to Office Action dated Jul. 1, 2015”, (W/ English translation of claims), 21 pgs.
“South African Application Serial No. 2013/01327, Amendment filed Apr. 24, 2014”, W/ English Translation, 4 pgs.
“South African Application Serial No. 2013/01328, Amendment filed Apr. 24, 2014”, W/ English Translation, 4 pgs.
“Surgical Technique for Cruciate Retaining Knees and Revision Instrumentation Surgical Technique for Cruciate Retaining Augmentable Knees”, Zimmer, Inc. Nexgen Complete Knee Solution, 97-5970-202, (2002), 130 pgs.
“Surgical Technique for the CR-Flex Fixed Bearing Knee”, NexGen Complete Knee Solution, Zimmer, Inc., (2003), 22 pgs.
“Surgical Technique for the Legacy Knee LPS-Flex Fixed Bearing Knee”, Zimmer, Inc. Nexgen Complete Knee Solution, 97-5964-02, Rev. 1, (2000, 2002), 15 pgs.
“Surgical Technique for the Legacy Posterior Stabilized Knees”, Zimmer, Inc. Nexgen Complete Knee Solution, 97-5996-02, (2002), 43 pgs.
“Surgical Technique—Nexgen Complete Knee Solution for the Legacy Knee LPS—Flex Fixed Bearing Knee”, Zimmer, Inc., (2004, 2007), 12 pgs.
“The Zimmer Institute Surgical Technique MIS Quad-Sparing Surgical Technique for Total Knee Arthroplasty”, NExGen Complete Knee Solution, (2004), 55 pgs.
“Tibial Baseplate: Pocket Guide (United States Version)”, Zimmer, Inc.,, (2009), 17 pgs.
“Trabecular Metal Monoblock Tibial Components”, Zimmer, Inc., (2007), 4 pgs.
“Trabecular Metal Monoblock Tibial Components Surgical Technique Addendum”, Nexgen Zimmer, Inc., (2005, 2007), 12 pgs.
“Trabecular Metal Tibial Tray: Surgical Technique”, NexGen Zimmer, Inc., (2007, 2009), 16 pgs.
“Zimmer MIS Intramedullary Instrumentation Surgical Technique For NexGen Cruciate Retaining & NexGen Legacy Posterior Stabilized Knees”, printed 2005, 2009, Zimmer, Inc., (2009), 45 pgs.
“Zimmer Nexgen Cruciate Retaining (CR) and Legacy Knee Posterior Stabilized (LPS) Trabecular Metal Monoblock Tibias”, Zimmer, Inc Surgical Technique Addendum, 97-7253-34, Rev. 3, (2004), 11 pgs.
“Zimmer NexGen CR-Flex and LPS-Flex Knees Surgical Technique with posterior Referencing Instrumentation.”, Zimmer Inc., (2010, 2011), 48 pgs.
“Zimmer NexGen LCCK Surgical Technique for use with LCCK 4-in-1 Instrumentation”, Zimmer, Inc.; copyright 2009, 2010, 2011, (May 2011), 52 pgs.
“Zimmer NexGen MIS Modular Tibial Plate and Keel Cemented Surgical Technique”, Zimmer Inc., (2006, 2011), 26 pgs.
“Zimmer NexGen MIS Tibial Component”, Brochure-97-5950-001-00 7.5mm, (2005, 2006), 8 pgs.
“Zimmer NexGen MIS Tibial Component Cemented Surgical Technique”, Zimmer, Inc, #97-5950-002-00 Rev.1 1.5ML, (2005), 14 pgs.
“Zimmer NexGen MIS Tibial Component Cemented Surgical Technique”, Zimmer Inc., (2005, 2006, 2008, 2009, 2010), 16 pgs.
“Zimmer NexGen Trabecular Metal Augments—Abbreviated Surgical Technique”, Zimmer, Inc., (2004, 2006), 6 pgs.
“Zimmer NexGen Trabecular Metal Augments Surgical Technique for LCCK & Rotating Hing Knee Trabecular Metal Augments”, Zimmer, Inc. 97-5448-02, Rev. 1, (2004), 6 pgs.
“Zimmer NexGen Trabecular Metal Primary Patella Surgical Technique”, Zimmer. Inc., 97-7255-112-00, (2005), 10 pgs.
“Zimmer NexGen Trabecular Metal Tibial Tray”, Surgical Technique, Zimmer, Inc., (2007, 2009), 16 pgs.
“Zimmer Patient Specific Instruments”, Surgical Techniques for NexGen Complete Knee Solution Zimmer, Inc., (2010), 16 pgs.
Annayappa, Ramesh, “Tibial Prosthesis”, U.S. Appl. No. 13/189,328, filed Jul. 22, 2011, 82 pgs.
Annayappa, Ramesh, et al., “Tibial Prosthesis”, U.S. Appl. No. 13/189,324, filed Jul. 22, 2011, 50 pgs.
Ding, M., et al., “Age-related variations in the microstructure of human tibial cancellous bone”, Journal of Orthopaedic Research, 20(3), (2002), 615-621.
Ding, M., et al., “Changes in the three-dimensional microstructure of human tibial cancellous bone in early osteoarthritis”, Journal of Bone & Joint Surgery (British), 85-B(6), (Aug. 2003), 906-912.
Doyle, et al., “Comparative Analysis of Human Trabecular Bone and Polyurethane Foam”, Purdue University., 1 pg.
Dunbar, M. J., et al., “Fixation of a Trabecular Metal Knee Arthroplasty Component: A Prospective Randomized Study”, The Journal of Bone & Joint Surgery (American), vol. 91—A(7), (Jul. 2009), 1578-1586.
Edwards, Andrew, et al., “The Attachments of the Fiber Bundles of the Posterior Cruciate ligament: An Anatomic Study”, Arthroscopy: The Journal of Arthroscopic and Related Surgery, vol. 23, No. 3, (Mar. 2008), 284-290.
Freeman, M.A.R., et al., “The Movement of the Knee Studied by Magnetic Resonance Imaging”, Advanced Bearings—Clinical Orthopedics & Related Research 2003, (2003), 1 pg.
Hofmann, Aaron A, et al., “Posterior Stabilization in Total Knee Arthroplasty with Use of an Ultracongruent Polyethylene”, The Journal of Arthroplasty vol. 15, No. 5, (2000), 576-583.
Hvid, Ivan, et al., “Trabecular bone Strength Patterns at the Proximal Tibial Epiphysis”, Journal of Orthopaedic Research, vol. 3, No. 4, (1985), 464-472.
Klostermann, et al., “Distribution of bone mineral density with age and gender in the proximal tibia”, Clinical Biomechanics 19, 376-376.
Lorenz, Stephan, et al., “Radiological evaluation of the anterolateral and posteromedial bundle insertion sites of the posterior cruciate ligament”, Knee Surg Sports Traumatol Arthosc, vol. 17, (2009), 683-690.
Moorman, Claude, et al., “Tibial Insertion of the Posterior Cruciate Ligament: A Sagittal Plane Analysis Using Gross, Histologic, and Radiographic Methods”, Arthroscopy: The Journal of Arthroscopic and Related Surgery, vol. 24, No. 3, (Mar. 2008), 269-275.
Parisi, Raymond C, “Motion Facilitating Tibial Components for a Knee Prosthesis”, U.S. Appl. No. 13/229,103, filed Sep. 9, 2011, 46 pgs.
Partovi, Hamid, “Flow-Through Latch and Edge-Triggered Flip-Flop Hybrid Elements”, Proceedings of the IEEE International Solid-State Circuits Conference, Digest of Technical Papers and Slide Supplement, NexGen Inc., Milpitas, CA, (1996), 40 pgs.
Siggelkow, Eik, et al., “Impact of Tibia Bearing Surface and Femoral Component Design on Flexion Kinematics During Lunge”, Mar. 28-31, 2015 at the Orthopaedic Research Society (ORS) Annual Meeting (Poster #1645), (Mar. 2015), 1 pg.
Siggelkow, Eik, et al., “Impact of Tibia Bearing Surface Design on Deep Knee Bend Kinematics”, Mar. 24-28, 2015 at the AAOS Conference (Poster #P142), (Mar. 2015), 1 pg.
Stilling, et al., “Superior fixation of pegged trabecular metal over screw-fixed pegged porous titanium fiber mesh”, Acta Orthopaedica., (2011), 177-186.
Wentorf, Mary S. S, “Asymmetric Tibial Components for a Knee Prosthesis”, U.S. Appl. No. 13/189,338, filed Jul. 22, 2011, 58 pgs.
Wentorf, Mary S. S, “Asymmetric Tibial Components for a Knee Prosthesis”, U.S. Appl. No. 13/189,339, filed Jul. 22, 2011, 52 pgs.
Wentorf, Mary S. S, “Asymmetric Tibial Components for a Knee Prosthesis”, U.S. Appl. No. 13/189,336, filed Jul. 22, 2011, 60 pgs.
“U.S. Appl. No. 15/915,886, PTO Response to Rule 312 Communication dated May 8, 2020”, 2 pgs.
“U.S. Appl. No. 15/971,743, Notice of Allowance dated Aug. 6, 2019”, 8 pgs.
“U.S. Appl. No. 16/389,381, Non Final Office Action dated Mar. 30, 2020”, 9 pgs.
“U.S. Appl. No. 16/675,938, Preliminary Amendment filed Jan. 22, 2020”, 7 pgs.
“U.S. Appl. No. 16/715,092, Preliminary Amendment filed Mar. 19, 2020”, 10 pgs.
“U.S. Appl. No. 16/743,746, Preliminary Amendment filed Mar. 19, 2020”, 8 pgs.
“Australian Application Serial No. 2018266322, First Examination Report dated Dec. 19, 2019”, 2 pgs.
“European Application Serial No. 18711801.3, Response to Communication pursuant to Rules 161(1) and 162 EPC filed May 7, 2020”, 14 pgs.
“European Application Serial No. 19171990.5, Response filed May 13, 2020 to Extended European Search Report dated Oct. 16, 2019”, 31 pgs.
“International Application Serial No. PCT/US201 8/031177, International Preliminary Report on Patentability dated Nov. 21, 2019”, 8 pgs.
“International Application Serial No. PCT/US2018/031177, International Search Report dated Jul. 31, 2018”, 6 pgs.
“International Application Serial No. PCT/US2018/031177, Written Opinion dated Jul. 31, 2018”, 6 pgs.
“U.S. Appl. No. 15/915,886, Response filed Nov. 4, 2019 to Non-Final Office Action dated Aug. 2, 2019”, 8 pgs.
“Brazil Application Serial No. BR1120130016698, Office Action dated Aug. 27, 2019”, 8 pgs.
“Brazil Application Serial No. BR1120130016736, Office Action dated Aug. 27, 2019”, 8 pgs.
“European Application Serial No. 16770657.1, Response filed Sep. 30, 2019 to Communication Pursuant to Article 94(3) EPC dated May 20, 2019”, 26 pgs.
“European Application Serial No. 18206326.3, Extended European Search Report dated Apr. 15, 2019”, 10 pgs.
“European Application Serial No. 19171990.5, Extended European Search Report dated Oct. 16, 2019”, 8 pgs.
“Journey II XR, Bi-Cruciate Retaining Knee System”, Smith & Nephew, Surgical Technique, (2015), 40 pgs.
“Vanguard® ID Total Knee, Surgical Technique”, Zimmer Biomet; 0682.1-GLBL-en-REV0317, (2017), 36 pgs.
Bellemans, Johan, et al., “Is Neutral Mechanical Alignment Normal for All Patients?”, Clinical Orthopaedics and Related Research; DOI 10.1007/s11999-011-1936-5, (Jun. 9, 2011), 9 pgs.
Hutt, Jonathan, et al.,, “Functional joint line obliquity after kinematic total knee arthroplasty”, International Orthopaedics; DOI 10.1007/s00264-015-2733-7, (Mar. 21, 2015), 6 pgs.
Victor, Jan M. K., et al., “Constitutional Varus Does Not Affect Joint Line Orientation in the Coronal Plane”, Joint Line Orientation in the Coronal Plane; 472; DOI 10.1007/s11999-013-2898-6, (Jun. 4, 2013), pp. 98-104.
“U.S. Appl. No. 14/471,440, Notice of Allowance dated Nov. 13, 2017”, 9 pgs.
“U.S. Appl. No. 14/471,440, Response filed Aug. 16, 2017 to Restriction Requirement dated Jun. 30, 2017”, 8 pgs.
“U.S. Appl. No. 14/471,440, Restriction Requirement dated Jun. 30, 2017”, 6 pgs.
“U.S. Appl. No. 15/890,735, Notice of Allowance dated Oct. 29, 2019”, 11 pgs.
“U.S. Appl. No. 15/915,886, Notice of Allowance dated Jan. 16, 2020”, 9 pgs.
“Brazil Application Serial No. BR1120130016698, Response filed Dec. 9, 2019 to Office Action dated Aug. 27, 2019”, w/ English Claims, 22 pgs.
“Brazil Application Serial No. BR1120130016736, Response filed Dec. 9, 2019 to Office Action dated Aug. 27, 2019”, w/ English Claims, 25 pgs.
“European Application Serial No. 18206326.3, Response filed Nov. 22, 2019 to Extended European Search Report dated Apr. 15, 2019”, 15 pgs.
“Indian Application Serial No. 1544/DELNP/2013, Response filed Nov. 18, 2019 to Office Action dated May 21, 2019”, w/ English claims, 34 pgs.
“Indian Application Serial No. 1545/DELNP/2013, Office Action dated Dec. 9, 2019”, (with English translation), 8 pages.
“Turkish Application Serial No. 11808493.8, Working Requirements dated Feb. 17, 2020”, 3 pgs.
“U.S. Appl. No. 16/179,201, Examiner Interview Summary dated Feb. 8, 2021”, 3 pgs.
“U.S. Appl. No. 16/179,201, Non Final Office Action dated Nov. 2, 2020”, 15 pgs.
“U.S. Appl. No. 16/179,201, Response filed Jan. 28, 2021 to Non Final Office Action dated Nov. 2, 2020”, 16 pgs.
“U.S. Appl. No. 16/179,201, Response filed Oct. 5, 2020 to Restriction Requirement dated Aug. 7, 2020”, 9 pgs.
“U.S. Appl. No. 16/179,201, Restriction Requirement dated Aug. 7, 2020”, 10 pgs.
“U.S. Appl. No. 16/179,201, Supplemental Amendment & Response filed Feb. 19, 2021 to Non-Final Office Action Filed Nov. 2, 2020”, 17 pgs.
“U.S. Appl. No. 16/352,287, Non Final Office Action dated Dec. 10, 2020”, 12 pgs.
“U.S. Appl. No. 16/352,287, Response filed Feb. 22, 2021 to Non Final Office Action dated Dec. 10, 2020”, 14 pgs.
“U.S. Appl. No. 16/352,287, Response filed Oct. 12, 2020 to Restriction Requirement dated Aug. 17, 2020”, 8 pgs.
“U.S. Appl. No. 16/352,287, Restriction Requirement dated Aug. 17, 2020”, 6 pgs.
“U.S. Appl. No. 16/389,381, Notice of Allowance dated Jul. 16, 2020”, 5 pgs.
“U.S. Appl. No. 16/389,381, Response filed Jun. 19, 2020 to Non Final Office Action dated Mar. 30, 2020”, 9 pgs.
“U.S. Appl. No. 16/849,394, Preliminary Amendment filed Jun. 3, 2020”, 7 pgs.
“U.S. Appl. No. 17/068,435, Preliminary Amendment filed Nov. 13, 2020”, 7 pgs.
“Brazilian Application Serial No. BR1120130016736, Response filed Oct. 5, 2020 to Office Action dated Jun. 10, 2020”, (W/ English Translation of Claims), 91 pages.
“Canadian Application Serial No. 3,063,415, Office Action dated Jul. 13, 2020”, 3 pgs.
“Canadian Application Serial No. 3,063,415, Response filed Nov. 12, 2020 to Office Action dated Jul. 13, 2020”, 15 pgs.
“Chinese Application Serial No. 201880016775.4, Office Action dated Jan. 22, 2021”, (W/English Translation), 15 pgs.
“Chinese Application Serial No. 201880031319.7, Office Action dated May 15, 2020”, (W/ English Translation), 12 pgs.
“Chinese Application Serial No. 201880031319.7, Office Action dated Nov. 18, 2020”, with English translation, 9 pgs.
“Chinese Application Serial No. 201880031319.7, Response filed Jan. 18, 2021 to Office Action dated Nov. 18, 2020”, with English claims, 16 pgs.
“Chinese Application Serial No. 201880031319.7, Response filed Jul. 22, 2020 to Office Action dated May 15, 2020”, (W/ English Claims), 10 pgs.
“European Application Serial No. 18726670.5, Response to Communication pursuant to Rules 161(1) and 162 EPC filed Jul. 20, 2020”, 9 pgs.
“Indian Application Serial No. 1545/DELNP/2013, Response filed Jun. 9, 2020 to Office Action dated Dec. 9, 2019”, (W/ English Claims), 78 pgs.
“Japanese Application Serial No. 2019-562605, Notification of Reasons for Refusal dated Jun. 16, 2020”, (W/ English Translation), 7 pgs.
“Japanese Application Serial No. 2019-562605, Notification of Reasons for Refusal dated Nov. 10, 2020”, with English translation, 5 pgs.
“Japanese Application Serial No. 2019-562605, Response filed Feb. 9, 2021 to Notification of Reasons for Refusal dated Nov. 10, 2020”, w/English claims, 19 pgs.
“Japanese Application Serial No. 2019-562605, Response filed Sep. 15, 2020 to Notification of Reasons for Refusal dated Jun. 16, 2020”, (W/ English Claims), 15 pgs.
“U.S. Appl. No. 16/179,201, Advisory Action dated Jun. 25, 2021”, 3 pgs.
“U.S. Appl. No. 16/179,201, Final Office Action dated Apr. 20, 2021”, 11 pgs.
“U.S. Appl. No. 16/179,201, Response filed Jun. 18, 2021 to Final Office Action dated Apr. 20, 2021”, 16 pgs.
“U.S. Appl. No. 16/352,287, Final Office Action dated May 25, 2021”, 8 pgs.
“U.S. Appl. No. 16/352,287, Notice of Allowance dated Jun. 30, 2021”, 7 pgs.
“U.S. Appl. No. 16/352,287, Response filed Jun. 18, 2021 to Final Office Action dated May 25, 2021”, 8 pgs.
“U.S. Appl. No. 16/530,423, Non Final Office Action dated May 17, 2021”, 10 pgs.
“U.S. Appl. No. 16/715,092, Response filed Aug. 11, 2021 to Non Final Office Action dated May 17, 2021”, 15 pgs.
“U.S. Appl. No. 16/715,092, Response filed Aug. 9, 2021 to Restriction Requirement dated Jun. 25, 2021”, 7 pgs.
“U.S. Appl. No. 16/715,092, Restriction Requirement dated Jun. 25, 2021”, 6 pgs.
“Australian Application Serial No. 2020204019, First Examination Report dated Jun. 18, 2021”, 7 pgs.
“Chinese Application Serial No. 201880016775.4, Decision of Rejection dated Jul. 12, 2021”, (W/ English Translation), 13 pgs.
“European Application Serial No. 16189084.3, Communication Pursuant to Article 94(3) EPC dated Jul. 1, 2021”, 6 pgs.
Related Publications (1)
Number Date Country
20200030106 A1 Jan 2020 US
Provisional Applications (2)
Number Date Country
61381800 Sep 2010 US
61367375 Jul 2010 US
Continuations (3)
Number Date Country
Parent 15827654 Nov 2017 US
Child 16596194 US
Parent 14034937 Sep 2013 US
Child 15827654 US
Parent 13189336 Jul 2011 US
Child 14034937 US